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Abstract 
Cardiovascular disease is the leading cause of mortality. As blood pressure is one of the 
most important risk factors for cardiovascular disease, effective management of 
hypertension is critical in reducing this risk. In addition to high blood pressure, however, 
several factors have been identified as predictors of future cardiovascular events. These 
include high cholesterol, cigarette smoking, obesity and diabetes. Taken together, these 
traditional risk factors do not entirely explain the risk. Thus, many novel risk factors have 
been proposed for risk prediction of cardiovascular disease. Microalbuminuria is one such 
factor. 
Microalbuminuria is defined as excretion of albumin in the urine above the normal level 
but less than gross proteinuria. As excretion of albumin exhibits high variability due to 
many confounders (such as urinary tract infection and strenuous exercise), diagnosis of 
microalbuminuria should be ideally based on screening of multiple samples using either 
24-hour urine collection or first-morning voids. Much evidence suggests that 
microalbuminuria is a reflection of generalised endothelial dysfunction. This is supported 
by the observation that microalbuminuria is strongly associated with cardiovascular 
disease. 
My main aim was to study microalbuminuria in people with hypertension attending 
specialist clinics. Microalbuminuria has been investigated extensively in diabetes and in 
patients with renal disease. However, the available information on the association of 
microalbuminuria with hypertension has many limitations since many studies had small 
sample size, restricted population or were confounded by potential misdiagnosis of 
microalbuminuria by the use of single samples. This has led to uncertainty about the 
prevalence of microalbuminuria in hypertension, where reported prevalence ranges from 
4.7% to 58%, and probable underestimation of its clinical significance.  
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I addressed these issues by conducting a series of studies in 1059 hypertensive subjects 
attending the Glasgow Blood Pressure Clinic or the Aberdeen Hypertension Clinic. Each 
patient was invited to provide an early morning urine specimen for the assessment of 
albuminuria. Urinary tract infection was tested using urine strips and, where positive, 
samples were discarded. If the first sample showed increased albumin excretion, two 
further samples were requested. Albuminuria (microalbuminuria or gross proteinuria) was 
diagnosed when two out of the three samples showed increased albuminuria. Two 
definitions of microalbuminuria were used in the analysis, a conventional definition with 
the threshold used by most therapeutic guidelines and a new definition that accounts for 
low excretion of albumin. All patient information was obtained from case-records.  
In the first study, I showed that microalbuminuria by the conventional definition was 
present in 9.5% of non-diabetic hypertensive subjects without renal impairment. Another 
10% of this cohort had microalbuminuria by the new definition. Compared with people 
with normal urinary albumin, individuals with microalbuminuria by both definitions (n= 
786, after excluding those with diabetes or severe renal impairment) had significantly 
higher blood pressure, higher pulse pressure, increased levels of inflammatory markers, 
poorer renal function, higher triglycerides levels and used more cardiovascular drugs. 
In a second study, the association of microalbuminuria with clinical characteristics was 
investigated. Subjects with microalbuminuria had increased prevalence of risk factors / co-
morbidities such as left ventricular hypertrophy (19.2% in normoalbuminuria versus 29.7% 
and 34.8% for microalbuminuria by the new and the conventional definitions, 
respectively), ECG abnormalities and cardiovascular disease. In addition, people with 
microalbuminuria had higher risk scores for subsequent cardiovascular events using two 
risk calculators, the Framingham and the Joint British Societies equations. In a subcohort 
with controlled blood pressure and without co-morbidities or risk, microalbuminuria (by 
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combining the two definitions) was found in 14%. Compared with those with 
normoalbuminuria, subjects with microalbuminuria had higher blood pressure, poorer renal 
function, higher blood glucose and higher levels of inflammatory markers although the 
limited sample size precluded statistical significance. 
In a further study, the independent association of microalbuminuria with different risk 
factors was evaluated using multivariate testing. Systolic blood pressure, serum creatinine, 
left ventricular hypertrophy and fasting triglycerides were among factors linked with 
microalbuminuria. The risk of microalbuminuria increased in people with poorly 
controlled blood pressure. I also found that microalbuminuria was associated strongly with 
left ventricular hypertrophy [odds ratio 1.87 (95% CI, 1.12 - 3.12) for a composite of both 
definitions- the combined definition] and cardiovascular abnormalities [odds ratio 1.72 
(95% CI, 1.05 - 2.80) for the combined definition]. 
In a fourth study, the reproducibility of microalbuminuria screening was investigated. I 
discovered that a large proportion of people who had increased urinary albumin excretion 
on first sample was categorised as normoalbuminuria based on the result of multiple 
samples (48% at the Glasgow Clinic and 41% at the Aberdeen Clinic). This indicates that 
even after controlling microalbuminuria confounders, multiple testing can be 
recommended for more accurate diagnosis.  
 In the final study, I demonstrated that subjects with microalbuminuria by both definitions 
attending the Glasgow Blood Pressure Clinic had relatively high blood pressure and pulse 
pressure at first visit and subsequently. This finding indicates that subjects with 
microalbuminuria require particularly rigorous blood pressure management to achieve 
blood target blood pressure. Furthermore, individuals with microalbuminuria may be at 
risk for cardiovascular disease greater than that in those with normoalbuminuria since the 
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eventual blood pressure remained higher in these subjects. Together with the observations 
that microalbuminuria is associated with clustering of cardiovascular risk factors, my 
finding support the importance of even small increase in urine albumin excretion as an 
indicator of eventual cardiovascular disease. 
In conclusion, microalbuminuria is found in one-fifth of subjects with essential 
hypertension. Although my investigation was observational, the large sample size, the use 
of multiple samples and allowance for the effects of potential confounders enhances the 
precision of the results. Moreover, subjects involved in this study represent a real 
hypertension population with few restrictions. My findings support the value of 
microalbuminuria as a tool to identify subjects at high risk for cardiovascular disease. 
Before routine screening can be recommended, these observations require confirmation in 
clinical trials and prospective studies with long-term follow up. Linkage of the records of 
the patients who participated in this series of studies with national morbidity and mortality 
statistics offers one approach with the potential to test the clinical relevance of my 
findings. 
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1. Chapter one: Introduction  
1.1 Cardiovascular disease  
1.1.1 Epidemiology 
Cardiovascular disease is the leading cause of mortality in the world (Lloyd-Jones et al., 
2010).  Nearly 16.7 million deaths per year are attributable to this condition (WHO, 2003). 
In Europe, almost a half of all deaths are due to cardiovascular disease (Allender et al., 
2008). It has been estimated that 38% of deaths in 2003 in Scotland was attributable to 
cardiovascular system disease (Lowther et al., 2006). Even a decade ago, the United 
Kingdom (UK) expenditure on cardiovascular disease-related hospitalisation and 
disabilities was about £29.1 billion (Luengo-Fernández et al., 2006). 
Cardiovascular disease has also become a major health concern in developing countries 
(Kim and Johnston, 2011). Cardiovascular mortality in the middle-age population of such 
countries is much higher than that in developed countries (Raymond et al., 2006). These 
changes are expected to result in important economic consequences due to loss of 
productivity of working individuals.  
1.1.2 Risk factors 
There are several risk factors for cardiovascular disease. Most, such as hypertension, 
hyperlipidaemia, obesity, diabetes and cigarette smoking, are reversible and have been 
used extensively in risk stratification of cardiovascular disease. However, these classic risk 
factors do not entirely explain future cardiovascular disease (Kuulasmaa et al., 2000). As a 
result, many novel risk factors such as microalbuminuria, estimated glomerular filtration 
rate (eGFR), C-reactive protein (CRP) and homocysteine have been evaluated as potential 
predictive factors (Danesh et al., 2004, Bello et al., 2011).  
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1.1.3 Hypertension as a risk factor for cardiovascular disease 
Hypertension is one of the most challenging health problems in the world. It has been 
estimated that, globally, almost one billion individuals have hypertension (WHO, 2002). 
By 2025, that number is estimated to increase by 60%, which means that 1.56 billion 
people could be hypertensive (Kearney et al., 2005). Latest WHO statistics showed that 
hypertension is the leading cause of mortality worldwide (responsible for 13% of global 
deaths) (WHO, 2012). Hypertension is one of the most prevalent chronic disorders in the 
UK, affecting about 25% of the adult population (MacDonald and Morant, 2008). It has 
been estimated that the cost of hypertension treatment in the UK is approximately £1 
billion (National Institute for Health and Clinical Excellence, 2011). In Scotland, two 
antihypertensive agents (were among the ten most commonly prescribed drugs (National 
Health Service, 2011).  
According to the National Institute for Health and Clinical Excellence (NICE) guideline, a 
sustained systolic blood pressure (SBP) / diastolic blood pressure (DBP) of 140/90 mm Hg 
and subsequent ambulatory or home blood pressure of 135/85 mm Hg or higher is 
considered to be the threshold for diagnosis of  hypertension (National Institute for Health 
and Clinical Excellence, 2011). The BHS has classified hypertension into three categories; 
mild, moderate and severe. The society also suggests that a sustained SBP of 160 mm Hg 
or more, or a sustained DBP of 100 mm Hg or more requires initiation of pharmacological 
intervention. The threshold of treatment is reduced in high-risk patients such as those with 
diabetes or established cardiovascular diseases.  
Unmanaged hypertension predisposes the individual to serious cardiovascular and 
cerebrovascular complications, such as heart failure, stroke, myocardial infarction (MI), 
left ventricular hypertrophy (LVH), atrial fibrillation and peripheral vascular diseases as 
well as premature mortality. Several epidemiological studies have demonstrated a linear 
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relationship between blood pressure and cardiovascular risk. The Framingham Heart Study 
is of landmark importance in this field (Kannel et al., 1969). The study clearly 
demonstrated that high blood pressure is one of the most important cardiovascular disease 
risk factors.  
1.1.3.1 Hypertension as a risk factor for stroke and coronary heart diseases 
Hypertension is an independent risk factor for stroke (Rosamond et al., 2007).   A meta-
analysis of 61 observational studies involving nearly one million individuals revealed that 
mortality from stroke as well as ischemic heart diseases increases in a log-linear manner 
with an increase in SBP / DBP levels  above 115/ 75 mm Hg (Lewington  et al., 2002). 
This meta-analysis demonstrated that each 20 mm Hg increase in SBP or 10 mm Hg 
increase in DPB is associated with a twofold increase in mortality. The Framingham Heart 
Study also reported a continuous relationship between blood pressure and stroke risk 
(Seshadri et al., 2006). Moreover, in a case-control study with participants from 22 
countries, hypertension was the most important risk factor for all types of stroke 
(O'Donnell et al., 2010). These studies clearly demonstrate the importance of hypertension 
as a potentially modifiable risk factor for stroke; strict control of high blood pressure 
reduces such risk. 
High blood pressure is also an important modifiable risk factor for coronary heart diseases 
(CHD). Evidence from several epidemiological studies suggests that the risk of developing 
CHD increases with the increase of blood pressure (Eberly et al., 2004). For instance, the 
Multiple Risk Factor Intervention Trial, which involved 361,662 men, revealed a strong 
association between hypertension and CHD (Eberly et al., 2004). Among subjects with 
CHD, the prevalence of hypertension has been estimated to be 32% (Khot et al., 2003). In 
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the United States, reduction in SBP was the second most important factor (after total 
cholesterol) attributed to reduction in CHD-related mortality (Ford et al., 2007).  
The use of antihypertensive agents reduces the risk of cardiovascular disease including 
CHD and stroke. Law et al. (Law et al., 2009) analyzed 147 randomised clinical trials to 
investigate the effect of antihypertensive treatment on prevention of cardiovascular risk. 
Reductions of 10 mm Hg in SBP or 5 mm Hg in DBP are associated with 20% and 32% 
lower CHD and stroke risks, respectively; regardless of which class or agent is used as 
first-line therapy.  
1.1.3.2  Hypertension and risk of LVH and heart failure 
Chronic hypertension may lead to the development of LVH, possibly due to the increased 
workload of the heart caused by prolonged high blood pressure (Frohlich et al., 2011). 
LVH is a common finding in hypertensive subjects. A recent systematic review of 30 
studies involving treated and untreated hypertensive subjects showed that the prevalence of 
LVH using echocardiography ranged from 36% to 41%, depending on the diagnosis 
criteria (Cuspidi et al., 2012).  
High blood pressure is also an important aetiological factor for heart failure. A meta-
analysis of 23 hypertension trials conducted between 1997 and 2007 and involving 
193,424 subjects reported that the risk of developing heart failure is high in hypertensive 
subjects even under pharmacological management (Tocci et al., 2008). The authors 
reported that the rate of heart failure was 8.5 events per thousand patients per year. In a 
case-control study in the general population, hypertension was the most important risk 
factor for heart failure (Dunlay et al., 2009). Another population-based cohort study in 
elderly subjects not receiving antihypertensive agents confirmed a linear-relationship 
between SBP and heart failure (Butler et al., 2011).  
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1.1.3.3 Hypertension and kidney function 
Hypertension is closely related to kidney diseases (Bidani and Griffin, 2004). Blood 
pressure regulation through sodium and water excretion is one the important physiological 
functions of the kidneys. High blood pressure is a predisposing factor for renal 
abnormalities (Tozawa et al., 2003). Nearly 80% of patients with chronic kidney disease 
(CKD) have hypertension (Buckalew et al., 1996).  Although essential hypertension is 
considered to be strongly associated with end-stage renal disease (ESRD) in the African-
American (Klag et al., 1997), whether such finding can be extended to other population 
(e.g. Caucasian cohort) is still unclear. Using longitudinal data from the Glasgow Blood 
Pressure Clinic (GBPC), it has been found that progression to ESRD in subjects attending 
this tertiary/secondary clinic (predominantly Caucasian) is uncommon (only 1% of the 
population) (Mackinnon et al., 2008). Therefore, although high blood pressure may 
aggravate renal impairment in people with established kidney disease, progression to overt 
nephropathy and ESRD in uncomplicated hypertension is rare in the Scotland.  
1.1.4 Other traditional risk factors for cardiovascular disease 
Prolonged elevation of serum lipids may lead to atherosclerosis, which is the underlying 
pathological factor of several cardiovascular diseases such as CHD and stroke (Zhang et 
al., 2012, Woodward et al., 2007). A meta-analysis of 61 studies involving more than 
900,000 patients from Europe and Northern America showed that the total 
cholesterol/high-density lipoprotein (HDL) ratio was a powerful predictor for 
cardiovascular mortality (Prospective Studies Collaboration., 2007). The study also 
revealed that 1 mmol/L difference in total cholesterol in those between 40-49 years was 
associated with a 50% difference in CHD mortalities. Other lipid indices such as low-
density lipoprotein (LDL)-cholesterol , non–HDL-cholesterol, and apolipoprotein-B also 
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predict several cardiovascular events (such as CHD, myocardial infarction and angina) 
even in those under treatment with statins (Boekholdt et al., 2012). 
Evidence from epidemiological studies show that diabetes is a major risk factor for 
cardiovascular disease (Grundy et al., 1999, D’Agostino et al., 2008). A direct effect of 
hyperglycemia on blood vessels has been suggested (Piga et al., 2007) whereby glucose 
induces reactive oxygen species and accelerates atherosclerosis (Renard et al., 2004). The 
absolute risk for cardiovascular disease in patients with diabetes mellitus is almost double 
that in non-diabetic individuals (Fox et al., 2004).  The Nurses' Health Study reported that 
women with diabetes mellitus are at threefold increased risk for CHD mortality (Hu et al., 
2001). One of the major concerns with diabetes is that the trends for cardiovascular 
diseases attributable to diabetes have increased in the last decades (Fox et al., 2007). This 
observation reinforces the need of more extensive measurements for reduction of 
cardiovascular risk in subjects with diabetes mellitus.  
1.1.5 Evidence for cardiovascular protection using 
antihypertensive drugs 
Evidence from several trials clearly demonstrated that lowering blood pressure by 
antihypertensive drugs reduces the risk of cardiovascular morbidity (Neal et al., 2000, 
Czernichow et al., 2011). These trials showed that the cardiovascular protection of 
antihypertensive agents is evident in people with different risk profiles and in all age 
groups. The reduction of cardiovascular risk seems to be dependent mainly on the 
magnitude of blood pressure reduction regardless which antihypertensive class was used to 
achieve such reduction (Law et al., 2009).  
Management of blood pressure using a single agent is usually inadequate and may not 
reduce cardiovascular risk, especially for those with SBP/DBP above treatment goal by 
20/10 mm Hg (Weber et al., 2004, Gradman et al., 2011). The benefit from early 
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management with combination therapy over monotherapy has been suggested by the 
ACCELERATE trial (Brown et al., 2011). This trial was designed to investigate whether 
initiating combination therapy is superior to monotherapy in terms of blood pressure 
outcomes. At baseline, a group of participants were assigned to monotherapy with either 
amlodipine or aliskiren (plus placebo) while another group received a combination of both 
drugs.  After 6 months, all participants who received a combination of active treatment. 
The study revealed that those received combination therapy had better early blood pressure 
control.  Furthermore, participants who started with monotherapy never reached the blood 
pressure levels achieved by those initiated with combination therapy. Long term outcomes 
are needed to confirm the beneficial effect of initiating a combination therapy for 
management of hypertension (not quite right). A more recent observational analysis 
confirmed that combination approach is better than monotherapy for initial hypertension 
management (Egan et al., 2012).  It also showed that those started with monotherapy did 
not catch up with the blood pressure reduction achieved in those taking combination 
therapy during the first year of treatment. However, the retrospective nature of study and 
the lack of randomisation limit the interpretation of the study.  
Evidence from the ACCOMPLISH (Avoiding Cardiovascular Events through Combination 
Therapy in Patients Living with Systolic Hypertension) trial showed that a combination of 
a calcium channel blocker (CCB) plus an angiotensin converting enzyme inhibitor (ACEI) 
was better than an ACEI plus a diuretic in reducing primary endpoint (composite of 
cardiovascular mortality, myocardial infarction, CHD, stroke, angina and resuscitation 
after sudden cardiac arrest) in high-risk individuals (Jamerson et al., 2008). However, 
slightly greater blood pressure reduction (1/1 mm Hg) in the CCB combination and on-
treatment blood pressure difference could explain the better outcome.  
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In diabetes mellitus, a meta-analysis of 31 trials involving 73,913 individuals indicated that 
the greater the reduction in blood pressure the greater the reduction in stroke risk (Reboldi 
et al., 2011). Overall risk of myocardial infarction was reduced by 11%. However, when 
those with rigorous blood pressure control were compared with less-tight control, the risk 
of myocardial infarction was not reduced significantly.  
Evidence from a meta-analysis of 27 trials involving 158,709 individuals demonstrated 
equivalent cardiovascular protection of antihypertensive treatment in those with and 
without diabetes mellitus (Blood Pressure Lowering Treatment Trialists' Collaboration, 
2005). The analysis denied any difference between the classes of antihypertensive agents 
in reducing cardiovascular risk.  
For high-risk people, good control of blood pressure has been shown to protect against 
cardiovascular events (Weber et al., 2004). The Heart Outcomes Prevention Evaluation 
(HOPE ) study is a landmark study in which 9297 high risk subjects (with diabetes or 
vascular disease plus a cardiovascular risk factor) were assigned to receive an ACEI or 
placebo and followed for five years (Heart Outcomes Prevention Evaluation Study 
Investigators, 2000a). Treatment with an ACEI compared with placebo was associated 
with significant reduction in cardiovascular complications (such as cardiac arrest and heart 
failure) and cardiovascular mortality. Many recent studies have attempted to investigate 
any differential effects of antihypertensive drug classes in high-risk populations (Kasanuki 
et al., 2009, Ogihara et al., 2008). However, interpretation is difficult due to insufficiency 
of sample size and low number of events. Also, most of the added benefit can be ascribed 
to difference in blood pressure reduction between comparators.  
Cardiovascular protection mediated by antihypertensive treatment is also evident in the 
very elderly (Beckett et al., 2012).  In a cohort of 3845 subjects aged 80 years or older, 
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active treatment with diuretic ( with/without an ACEI) for a median of 1.8 years with a 
target blood pressure of less than  150/90 mm Hg significantly reduced the rate of stroke 
(fatal and non-fatal), all-cause and cause-specific mortality (Beckett et al., 2008). A sub-
analysis reported a reduction in total and cardiovascular mortality following short term 
management of blood pressure in the elderly population (Beckett et al., 2012). The results 
of these trials need careful interpretation since participants consisted of people with SBP 
greater than 160 mm Hg while those with cognitive impairment and frail subjects were 
excluded.  
1.1.6 Novel risk factor for cardiovascular disease 
In addition to conventional risk predictors, the usefulness of several novel biomarkers has 
been suggested for the prediction of future cardiovascular disease (Helfand et al., 2009). 
One of the most frequently reported novel risk factor is CRP (Pai et al., 2004). CRP is an 
acute phase protein formed by the liver following inflammatory reaction (Ridker et al., 
2000). This acute phase protein has a constant half-life and therefore, the levels of CRP are 
controlled by its rate of synthesis, which reflects the severity of the underlying cause 
(Pepys and Hirschfield, 2003). A more sensitive test for CPR (high sensitivity (hs-CRP)) is 
increasingly used as a marker for cardiovascular diseases (Nambi et al., 2009). 
Data from the Copenhagen City Heart Study demonstrated a continuous relationship 
between levels of CRP, measured once at baseline, and all-cause mortality (Zacho et al., 
2010). A meta-analysis of 54 epidemiological studies demonstrated that elevation of CRP 
concentration was associated with greater risk of CHD, stroke and cardiovascular mortality 
(Tipping  et al., 2010).  
The erythrocyte sedimentation rate (ESR) has been widely used as a screening tool in 
clinical practice to help in the detection of systemic inflammation and autoimmune 
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diseases. The ESR measures the rate of red blood cells (RBCs) precipitation out of plasma 
after 60 minutes (mm/hour). During the inflammatory process, the level of some acute-
phase proteins, including fibrinogen and globulins, increase in the plasma and as a result, 
the RBCs tend to stick leading to the formation of rouleaux (Lewi, 1954). Therefore, the 
rate of erythrocyte sedimentation increases.  
In addition to chronic inflammatory diseases, elevated ESR levels have been reported in 
coronary artery disease, heart failure and stroke (Danesh et al., 1998, Natali et al., 2003, 
Ingelsson et al., 2005, Maradit-Kremers et al., 2007). In a study involving 16,673 subjects, 
ESR was a strong and independent risk factor for CHD in both males and females 
(Andresdottir et al., 2003). ESR has been reported to be significantly higher in 
hypertensive subjects with impaired renal function (reduced eGFR and increased urinary 
albumin excretion) (Catena et al., 2000).  
Eosinophils are that play a pivotal role in the immune system (Sampson, 2000). These cells 
produce several inflammatory mediators and reactive oxygen species during infection to 
attack pathogens. Eosinphils are also involved in the pathogenesis of allergic conditions 
such as asthma (Kariyawasam and Robinson, 2007). Therefore, eosinophil count in the 
blood is frequently used in clinical practice when inflammatory disease is suspected.  
Several studies showed positive association between increased eosinophil count 
(eosinophilia) and cardiovascular mortality and morbidity. For instance, eosinophilia was 
positively correlated with cardiovascular mortality in a study involving more than 5000 
patients who had eosinophil count at baseline and followed for 30 years (Hospers et al., 
1999). Eosinophilia is also a risk predictor for CHD (Sweetnam et al., 1997) and acute 
vasospastic angina pectoris (Umemoto et al., 2000). 
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The clinical utility of the measurement of novel biomarkers of cardiovascular disease is 
controversial. For instance, while some studies suggested that CPR provides additional 
information to that provided by classic risk factors used in risk stratification equations 
(such as the Framingham equation) (Koenig et al., 2004) others showed weaker prognostic 
power (Wilson et al., 2005). In order to answer the question of whether CRP, or any novel 
risk factor, provides information additional to traditional risk factors, patients with low 
cardiovascular risk profile or even apparently healthy individuals might need to be 
followed for a prolonged period. This is because novel biomarkers may provide very early 
prognostic information, before any clinically detectable changes.  
1.2 Microalbuminuria as a marker for cardiovascular 
disease in subjects with hypertension  
1.2.1 Introduction: the renal system 
The kidney is the major excretory organ in the body. The main function is to filter the 
blood to remove any potential toxic molecules, metabolic products (such as creatinine and 
urea) and any extra fluid in order to maintain normal blood volume (Alpern et al., 2008). 
The kidney also plays an important role in reabsorbing water and some important 
molecules such as electrolytes (e.g. sodium and potassium) and proteins (Christensen and 
Gburek, 2004).  
Blood filtration occurs in the nephron, the functional unit of the kidney (Alpern et al., 
2008). Normally, each kidney has more than one million nephrons. Each nephron consists 
of tubules and glomerulus where blood filtration occurs.  The glomerulus contains a 
filtration membrane which consists of three layers: the endothelium, the epithelial 
podocyte and the basement membrane (Sherwood, 2008). The glomerular filtration 
membrane permits some blood molecules to pass through in order to reach the tubular 
system which has four parts: the proximal convoluted tubule, loop of Henle, distal 
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convoluted tubule and collecting duct (Alpern et al., 2008). In the renal tubular system, 
most of reabsorption process occurs. Nutritional molecules (such as glucose) and plasma 
proteins are usually reabsorbed in the proximal tubule (Gekle, 1998). In the loop of Henle, 
concentration of urine through water reabsorption occurs. The regulation of sodium and 
potassium ions is among the roles of distal tubules. Final ion reabsorption occurs in the 
collecting duct. 
Blood flows into the kidney through the renal artery which branches into segmental 
arteries and then to different lobular arteries (Boylu et al., 2012). These arteries further 
branch into interlobular arteries that divide to form afferent and efferent arterioles. The 
afferent arterioles are responsible for blood supply to the glomerulus while efferent 
arterioles remove blood from of the glomerulus (Boylu et al., 2012). Both afferent and 
efferent arterioles play important roles in controlling the glomerular capillary pressure by 
vasoconstriction or vasodilation.  
1.2.1.1 Protein reabsorption 
Serum proteins play major roles in the body including transporting essential molecules 
such as hormones, vitamins, lipids, minerals and exogenous substance such as drugs (Kratz 
and Elsadek, 2012). Proteins also maintain the oncotic pressure between the plasma and 
interstitial space, and are involved in the synthesis of enzymes and other substances.  
Proteins in the blood can be divided into, for example, carrier proteins such as albumin, 
immune system proteins such as immunoglobulin and acute phase proteins such as CRP 
(McClatchey, 2002). 
The most abundant serum protein is albumin, accounting for 60% of serum protein and 
with a concentration of 3.4 - 5.4 g/dL (Kadono et al., 2010). Albumin is a highly soluble 
single polypeptide which consists of 585 amino acid sequence (Carter et al., 1989). Each 
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day, 9 - 12 g of albumin is produced by the liver (Evans, 2002). More than 70% of oncotic 
colloid pressure is controlled by albumin (Kadono et al., 2010). Levels of albumin are 
affected by factors including endogenous molecules such as insulin and cortisol (Kimball 
et al., 1995). 
As mentioned earlier, kidney reabsorption of albumin and other proteins that pass the 
glomerular filtration membrane occurs in the proximal convoluted tubule. This 
reabsorption process is achieved by receptor-mediated endocytosis (Lazzara and Deen, 
2007). A receptor complex called megalin-cubilin is involved in the endocytosis process 
(Birn et al., 2000). The reabsorption process can be summarised as follow: albumin binds 
to the megalin-cubilin receptor complex in the apical plasma membrane (Amsellem et al., 
2010). After that, an adaptor molecule binds to the tail of the receptor complex to help the 
internalisation of the ligand-receptor complex (Cui et al., 1996). Once the internalisation 
process occurs, an endocytic vesicle transports the formed complex to the endosomal 
compartment where the protein complex dissociates by vesicle acidification (Birn and 
Christensen, 2006). Albumin then undergoes degradation in the lysosome to its original 
amino acids which return to the blood stream. 
1.2.2 Definition of microalbuminuria  
Normally, the kidneys reabsorb almost all the filtered albumin. A very low amount of 
albumin is present in the urine. However, certain illnesses such as diabetes, CKD and 
hypertension may mediate physiological changes that lead to excretion of larger amounts 
of albumin into the urine, albuminuria.  
Levels of albumin in the urine can be expressed as a concentration or as a ratio of albumin-
to-creatinine (table ‎1-1). Albumin in the urine at levels exceeding 300 mg/day (> 200 mg/L 
in a spot specimen or albumin-to-creatinine ratio (ACR) > 25 mg/mmol) is regarded as 
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macroalbuminuria (or gross proteinuria). This state of increased excretion of proteins in the 
urine usually reflects deterioration of kidney function. The measurement of albuminuria by 
ACR takes into consideration the differences in muscle mass between females and males, 
as males have higher muscle mass and hence higher creatinine excretion (Mattix et al., 
2002). Protein excretion in the urine can be measured in terms of albumin or total protein 
(Atkins et al., 2003). Proteinuria can be easily detected by a standard dipstick (Guy et al., 
2009). If the dipstick shows a positive result for proteinuria, quantitative measurement of 
proteins is usually advised. 
Low amounts of albumin in the urine that cannot be detected by conventional dipsticks 
(microalbuminuria) was firstly reported in 1969 by Keen et al. (Keen  et al., 1969) who 
studied the increased level of albuminuria in type 2 diabetes. A few years after that, 
Parving and colleagues (Parving et al., 1974) reported the presence of microalbuminuria in 
subjects with uncontrolled hypertension. Since then, many studies have linked 
microalbuminuria with several abnormalities. However, until recently, the vast majority of 
studies focused on the association of microalbuminuria with cardiovascular disease in 
subjects with diabetes mellitus and in patients with CKD.  
Microalbuminuria is defined as levels of albumin between 30 - 300 mg per day (equivalent 
to 20 to 200 µg/minute in a timed overnight urine collection, 20-200 mg/L on spot urine 
specimen or ACR 2.5 to 25 mg/mmol in males or 3.5 to 25 mg/mmol in females), table 
‎1-1. 
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                        Timed urine collection Spot morning urine specimen 
Albuminuria 
Level 
24-hour 
albumin 
excretion 
(mg/day) 
Overnight 
albumin 
excretion 
(µg/min) 
UAC 
(mg/L) 
Albumin-to-creatinine  ratio 
Gender mg/mmol mg/g 
Normal < 30 < 20 < 20 Male < 2.5  < 20 
Female < 3.5  < 30 
Microalbuminuria 30 - 300 20 - 200 20 - 200 Male 2.5 - 25  20 - 200 
Female 3.5 - 25  30 - 200 
Gross proteinuria >300 >200 >200 Male >25  >200 
    Female >25 >200 
Table ‎1-1: Definitions of albuminuria (Yuyun et al., 2005).  UAC: Urinary albumin 
concentration. 
 
1.2.3 Detection of microalbuminuria 
A number of dipsticks (such as Clinitek Microalbumin and Chemstrip Micral-Test ) are 
available to detect microalbuminuria (Sarafidis et al., 2007). These strips are inexpensive 
and easy to use in clinical setting but may not provide precise quantitative measurement of 
albumin level. 
Several laboratory techniques are available for the detection and quantitative measurement 
of microalbuminuria (Sviridov et al., 2006). These techniques are generally characterised 
by high specificity for detection of albumin. The most frequently utilised techniques for 
detection of microalbuminuria are immunoassays.  Non-immunological techniques for 
quantifying microalbuminuria have also been used. These tests are mainly 
chromatographic techniques such as size-exclusion high performance liquid 
chromatography (HPLC) (Sviridov et al., 2006).  
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1.2.4 Confounders of microalbuminuria screening 
Very many confounding factors may affect microalbuminuria screening and provide false-
positive results (table ‎1-2). Strenuous exercise may increase albumin level in the urine of 
healthy individuals, even above the threshold of microalbuminuria (Heathcote et al., 2009). 
The mechanism of exercise-induced temporary microalbuminuria is not completely 
established. One possibility is that this effect is caused by the increase in glomerular 
permeability due to the increase in glomerular filtration pressure mediated by strenuous 
exercise (Heathcote et al., 2009).   
Urinary tract infection (UTI) is also a possible confounder. The majority of therapeutic 
guidelines recommend the exclusion of samples that show positive evidence of UTI and 
recommend that a mid-stream specimen of urine (MSSU) should be submitted for 
bacteriology (National Kidney Foundation, 2007).  Other confounder of microalbuminuria 
screening include fever, upright position for a long time,  pregnancy and menstruation 
(Metcalf et al., 1993). The excretion of albumin in the urine may exhibit high variability in 
these conditions. Therefore, requesting additional samples after a suitable time gap is 
recommended. 
Confounders 
Upright posture Pregnancy 
Exercise Menstruation 
Fever Haematuria 
Symptomatic UTI Renal impairment 
Heavy protein diet Hyperglycemia 
Inflammation Hypertension 
Infections (e.g. hepatitis) Heart failure 
Table ‎1-2: Examples of factors associated with increased urinary albumin excretion 
(Czekalski, 1996, Airoldi and Weinstein, 2007). 
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1.2.5 Screening methods and number of samples 
There is a general consensus that 24-hour urine collection is the gold standard of 
microalbuminuria screening (Witte et al., 2009). However, complete compliance with this 
method is difficult for the individual and as a result, this approach is rarely utilised. 
Overnight albumin excretion rate is a simpler and more easily accomplished way of timed 
microalbuminuria measurement (Dyer et al., 2004). One advantage of overnight urine 
collection is that minimum movement during bedtime leads to more stable albumin 
excretion (Smulders et al., 1998). 
More commonly used methods include measuring urinary albumin concentration (UAC) or 
ACR on random samples (American Diabetes Association, 2004) or first morning voids 
(Lambers Heerspink et al., 2008). The random spot urine collection is the easiest and most 
convenient way for the patients and the practitioners. In the first morning urine sample, the 
patient is instructed to empty the bladder on retiring and to collect the first void after 
awaking up from sleep. These methods should ideally reflect the real magnitude of 
albumin excretion in the urine and are minimally affected by biological variations. 
Several studies have recently tried to identify the best method for screening of 
microalbuminuria. In a subset analysis of the PREVEND (Prevention of Renal and 
Vascular End‐stage Disease) study, the researchers compared ACR and UAC, both from 
first morning void and random sample; the outcome of interest was which test better 
replicated 24-hour urine collection (Witte et al., 2009). First morning ACR sample 
correlated with 24-hour urine collection with similar variability and prevalence. Another 
subset analysis of the PREVEND study concluded that ACR from first morning samples 
was equivalent to 24-hour urinary albumin excretion (UAE) in predicting all-cause 
mortality and cardiovascular morbidity after 7.5 years follow-up (Lambers Heerspink et 
al., 2008). Seven hundred patients with type II diabetes participating in the RENAAL 
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(Reduction of Endpoints in Non insulin Dependent Diabetes Mellitus with Angiotensin II 
Antagonist Losartan) trial were followed for 3.4 years (Lambers Heerspink et al., 2010). 
The study compared the ability of two timed collection methods (urinary protein excretion 
and UAE) and two first morning urine collection methods (UAC and ACR) in predicting 
renal outcome (doubling of creatinine or need for dialysis). The study revealed that ACR 
was the best predictor for renal outcomes. Taken together, these studies clearly 
demonstrated the reliability of ACR in detecting clinically relevant microalbuminuria. 
First morning samples measured by ACR exhibit low variability and hence better 
reliability in microalbuminuria screening. While UAC tends to be reduced when there is 
high urine volume, the ACR corrects for variability in urine excretion as the amount of 
creatinine filtered over time is relatively constant (Newman et al., 2000).  Urine from first 
morning void is usually concentrated and may reflect the real magnitude of urinary 
albumin excretion without the influence of confounding factors such as exercise. 
Several international guidelines recommend repeated samples for diagnosing 
microalbuminuria (two out of three samples should be positive) (National Collaborating 
Centre for Chronic Conditions, 2008). The repeated samples are suggested in order to 
overcome the effect of any possible confounders of microalbuminuria screening. However, 
this can be difficult to achieve in clinical setting.  As a result, the diagnosis of 
microalbuminuria in the majority of studies (especially in hypertension) has been based on 
single samples (see later). 
1.2.6 Epidemiology of microalbuminuria 
The prevalence of microalbuminuria in different populations with the same clinical 
condition varies significantly. This variability might be due to several factors such as the 
39 
 
threshold used, measurement methods, instruments or extent of co-morbidities in the study 
population (e.g. in hypertension; mild, moderate or severe) (table ‎1-2).  
1.2.6.1 Prevalence in general population 
In the UK, data from 20,911 participants in the European Prospective Investigation into 
Cancer in Norfolk (EPIC-Norfolk) showed that the prevalence of microalbuminuria in this 
British population is about 11.8% (Yuyun et al., 2004c). Earlier studies suggested that the 
prevalence of microalbuminuria in the UK ranges from 4.7% to 10.2% (Yudkin et al., 
1988, Winocour et al., 1992, Beatty et al., 1993). The prevalence of microalbuminuria in 
the US population was reported by the National Health and Nutrition Examination Surveys 
(NHANES) in two time periods; from 1988-1994 and from 1999-2004 (Coresh et al., 
2007). Microalbuminuria prevalence increased significantly between the two periods from 
7.1% to 8.2% (P =0 .01). This may be attributed to the increase in the prevalence of co-
morbidities such as obesity and metabolic disorders.  
Several studies have examined the prevalence of microalbuminuria in non-diabetic, non-
hypertensive individuals. The PREVEND study is one of the largest studies to report the 
prevalence of microalbuminuria in a Caucasian cohort (Hillege et al., 2001). 
Questionnaires and urine containers were sent to all inhabitants of the city of Groningen in 
the Netherlands. Nearly one half responded (40,856 participants). Microalbuminuria was 
present in 6.6% of non-diabetic, non-hypertensive individuals. A similar prevalence (6.2%) 
was reported recently by the Kidney Evaluation and Awareness Program in Sheffield 
(KEAPS) (Bello et al., 2010). In a subset analysis of this study, the investigators found that 
the prevalence increased to 9.5% in those who have a family history of CKD (Bello et al., 
2008).  
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The prevalence of microalbuminuria varies according to ethnicity. Microalbuminuria is 
more common in black and Asian populations compared with whites (Summerson et al., 
1995). A comparison between South Asian and white European populations living in the 
UK revealed that microalbuminuria is significantly more common in Asians (31% versus 
20%) (Dixon et al., 2006). In this study, there were no differences between the two 
populations in terms of age, sex or blood pressure levels. Another study compared UAE in 
African Caribbeans, South Asians and white Europeans (Tillin et al., 2005).  The 
prevalence of increased UAE was higher in African Caribbeans than in South Asians and 
Europeans. In a cohort of 6801 subjects from different Asian countries (China, Korea, 
Indonesia, Philippines, Singapore, Malaysia) the prevalence of microalbuminuria was 
39.8% (Weir, 2004). However, in that study, urinary albumin detection was performed by 
semi-quantitative dipsticks and more than 30% of the involved subjects had strong family 
history of cardiovascular or metabolic disease. This may partially explain the high 
prevalence of microalbuminuria. In a large epidemiological study based on diabetic 
subjects attending primary care clinics, hypertensive Hispanic subjects and non-
hypertensive Asians showed prevalence of microalbuminuria higher than that in Whites  
subjects (Young et al., 2005). 
The relation between microalbuminuria prevalence and gender is not clear. While some 
studies have shown that males have higher microalbuminuria prevalence (Pontremoli et al., 
1997), others reported no differences (Calviño et al., 1999). In subjects with type I 
diabetes, the Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) showed that UAE was associated with 
male gender and this association was explained by central obesity (measured as waist-hip 
ratio- WHR) (Sibley et al., 2006). When the prevalence was adjusted for WHR, no 
association between UAE and gender was observed.  In the EPIC-Norfolk study, the 
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prevalence of microalbuminuria was significantly higher in females (14.1% versus 8.4%, 
P<0.001) (Yuyun et al., 2004d). 
1.2.6.2 Prevalence in subjects with diabetes mellitus 
Microalbuminuria screening is recommended by the majority of clinical guidelines for the 
management of diabetes (American Diabetes Association, 2011). The prevalence of 
microalbuminuria in diabetic individuals has been addressed by many studies. The Oxford 
Regional Prospective Study recruited children aged under 16 years with type I diabetes in 
order to examine the development of microalbuminuria  (Amin et al., 2008). The study 
reported that the prevalence of microalbuminuria after 10 years and 20 years was 25.7% 
and 50.7%, respectively. Nearly 30% of adults with type I diabetes develop 
microalbuminuria in the 18 years following diagnosis (Hovind et al., 2004).  In a large, 
clinic-based study involving 24,151 patients with type II diabetes from 33 countries, ACR 
was measured randomly on single occasion and the prevalence of microalbuminuria and 
proteinuria were estimated to be  39% and 10%, respectively (Parving et al., 2006).  
The United Kingdom Prospective Diabetes Study (UKPDS 64) recruited 5097 type II 
diabetes patients (67% newly diagnosed) from different ethnic origins and followed them 
for 20 years in order to observe the progression of diabetic subjects to nephropathy (Adler 
et al., 2003). At baseline, nearly 7% of the study population had microalbuminuria and 
after 5, 10 and 15 years; the prevalence was 17%, 25% and 28%, respectively.  
Recently, Vupputuri et al. (Vupputuri et al., 2011) reported that the prevalence of 
normoalbuminuria, microalbuminuria and gross proteinuria at baseline in a population-
based analysis of people with type II diabetes in the United States (US) were 57%, 31% 
and 12%. After mean follow-up of 5.4 years, 40% of patients with normoalbuminuria 
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developed microalbuminuria and nearly 6% of microalbuminurics progressed to gross 
proteinuria. 
1.2.6.3 Prevalence of microalbuminuria in subjects with hypertension 
Although several studies have attempted to define the prevalence of microalbuminuria in 
essential hypertension, the exact figure is still unclear. The published prevalence of 
microalbuminuria in hypertensive subjects ranges from 4.7% to 58.4% (Jensen et al., 1997, 
Böhm et al., 2007).  
A longitudinal study involving 1,041 young (18-45 years) participants with mild 
hypertension (stage 1) demonstrated that microalbuminuria, detected using the 24-hour 
method,  was present in 6% of the study population, and 9% had high normoalbuminuria 
(16–29.9 mg/24 h) (Palatini et al., 2005). The low prevalence of microalbuminuria in this 
particular study may be explained by the age of the participants, as microalbuminuria tends 
to be more common in older subjects (Agrawal et al., 1996) and possibly the early stage of 
hypertension. 
In a multi-centre observational study conducted in Italy, the prevalence of 
microalbuminuria in subjects with hypertension (n=3534) was 27% (Leoncini et al., 2010). 
More than one-third of the population had diabetes and microalbuminuria was measured in 
a single sample, which may affect the precision of the estimation of microalbuminuria 
prevalence. A more recent study of hypertensive subjects without established 
cardiovascular disease or renal impairment suggested that microalbuminuria, measured on 
a  single occasion by 24-hour collection, is present in 23% of the studied population while 
less than 1% of the subjects had gross proteinuria (Cerasola et al., 2010).  
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Using urine dipsticks in the detection of microalbuminuria seems to overestimate the 
prevalence. For instance, in a large cohort of non-diabetic hypertensive subjects in 
Germany, the prevalence of microalbuminuria was 32% (Agrawal et al., 1996). In this 
study, the diagnosis of microalbuminuria was based on two positive urine dipsticks 
(Micral-Test) out of three. A highest prevalence of microalbuminuria was observed in the 
i-SEARCH global study, where 58.4% of the study population had microalbuminuria 
(Böhm et al., 2007). Almost 21,000 subjects from 26 countries participated in this clinic-
based study, making it one of the largest epidemiological studies that examine the 
prevalence of microalbuminuria in hypertensive subjects. The overall prevalence of 
microalbuminuria among participating countries was high, with rates of 53 to 71% in some 
developing countries. However, one of the limitations of this study was that the diagnosis 
of microalbuminuria was based on a single urine specimen measured using urine strips. 
Also, the majority of the study population was over 60 years of age and diabetic, which 
may contribute to the high prevalence of microalbuminuria.  
In summary, the reported prevalence of microalbuminuria has been limited by 
measurement method, under-precision caused by single screening, small sample size or too 
many restrictions on population tested. There is limited reliable information on 
microalbuminuria in hypertension and thus, the prevalence remains to be elucidated. 
1.2.7 Pathogenesis of microalbuminuria  
The pathophysiological mechanisms underlying the presence of urinary protein in 
hypertensive individuals are not completely understood. Several mechanisms have been 
proposed. These mechanisms involve alteration of renal haemodynamics and endothelial 
changes (Mattei et al., 1997). 
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As mentioned earlier, the afferent arteriole plays an important role in maintaining 
glomerular pressure. In hypertension, the afferent arteriole tends to constrict in order to 
protect the kidney from the high hydrostatic pressure caused by high blood pressure (Ito et 
al., 1992). This process is also regulated by feedback mechanism mediated by specific cells 
in the distal convoluted tubule when the volume of filtrate is high resulting in constriction 
of afferent arteriole to maintain GFR (Mountokalakis, 1997). Prolonged high blood 
pressure is thought to induce impairment of this autoregulatory process leading to 
hyperfiltration and passage of albumin into urine (Mountokalakis, 1997). This hypothesis 
is supported by the observation that in an experimental animal model, partial nephrectomy 
led to hyperfiltration in the remaining nephrons in order to maintain GFR, which in turn 
led to increase in the intra-glomerular pressure and passage of protein into the urine 
(Metcalfe, 2007).  
It has been postulated that impairment of glomerular permeability also contributes to the 
pathophysiology of microalbuminuria (Dalla Vestra et al., 2003). Alteration of glomerular 
permeability occurs as a result of changes in the structure of the glomerular filtration 
barrier. This barrier consist of three layers; endothelium covered by anionic glycoprotein 
(glycocalyx), podocyte foot processes and glomerular basement membrane, figure ‎1-1 
(Satchell and Braet, 2009). These layers are responsible for preventing some molecules 
from escaping to the lumen of Bowman capsule. The negative charge of the glycocalyx 
helps in repelling albumin as it is also negatively charged. Therefore, any structural 
changes could translate into passage of larger amount of albumin in the urine. Impairment 
of the podocytes (White et al., 2004, Toyoda et al., 2007) and glycocalyx (Nieuwdorp et 
al., 2006) have been shown in diabetic patients with microalbuminuria and subjects with 
hypertensive nephrosclerosis (Wang et al., 2009).  
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Figure ‎1-1: The glomerular filtration barrier. Consists of three layers; the endothelium, the 
glomerular basement membrane and podocyte foot processes. Each layer plays important 
role in preventing some molecules from being excreted as an ultrafiltrate. Adapted with 
permission from (Miner, 2008).  
 
Impaired function of the renin-angiotensin aldosterone system (RAAS) has also been 
implicated. Angiotensin II has been found to contribute in the sclerosis of the podocytes 
leading to excretion of large molecules including albumin (Matsusaka et al., 2010). 
Activation of angiotensin II type 1 receptors leads to an increase in the production of 
different inflammatory mediators and reactive oxygen species (ROS) which mediate 
endothelial injury locally in the kidney and systemically in the blood vessels, see figure ‎1-2 
(Warnholtz et al., 1999, Basi and Lewis, 2006). This hypothesis is supported by the 
observation that inhibition of angiotensin receptors using pharmacological approaches and 
drugs with putative anti-oxidant properties (e.g carvedilol) are associated with a significant 
reduction in microalbuminuria and several biomarkers of inflammation and oxidation 
(Persson et al., 2006, Bakris et al., 2005).  
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Figure ‎1-2: Simple illustration of mechanisms by which malfunction of RAAS could 
mediate albuminuria and atherosclerosis. Adapted with permission from (Basi and Lewis, 
2006). 
 
It has been suggested that albuminuria is associated with generalised endothelial 
dysfunction and it is widely accepted that microalbuminuria is a reflection of systemic 
vascular abnormalities that may explain the association of microalbuminuria with different 
cardiovascular diseases (Moody et al., 2012). Cottone et al. (Cottone et al., 2006) have 
shown that levels of several adhesion molecules that are involved in atherosclerosis of 
blood vessels correlated with UAE. Changes in the endothelial production of nitric oxide in 
diabetic mice lacking endothelial nitric oxide synthase is associated with higher levels of 
albuminuria compared with control mice (Mohan et al., 2008).  
All previously mentioned mechanisms could mediate microalbuminuria. Renal 
hemodynamic abnormalities as a result of increased blood pressure may increase 
glomerular permeability. In addition, increased permeability may result from endothelial 
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dysfunction due to increased oxidative stress and high levels of inflammatory markers 
caused by defects in renin-angiotensin system (RAS).  
1.2.8 Association of microalbuminuria with diseases and risk 
factors 
Over the last decade, our understanding of the importance of microalbuminuria as an 
independent risk factor for cardiovascular and metabolic morbidities has expanded 
exponentially. An increasing body of evidence suggests that microalbuminuria is a useful 
tool for predicting several diseases (Klausen et al., 2004). This is because 
microalbuminuria may reflect more complex vascular changes in the body. However, the 
awareness of the association of microalbuminuria with various diseases among clinicians is 
still poor. Haller and colleagues (Haller et al., 2010) conducted a survey among 1700 
clinicians (general practitioners, cardiologist and diabetologists) in five European countries 
to evaluate the awareness of importance of microalbuminuria in clinical practice. The vast 
majority (over 93%) of clinicians was aware of the association of microalbuminuria with 
impairment of renal function. Awareness of the association of microalbuminuria with 
abnormalities in other organs was extremely limited. For example, among participated 
clinicians in the UK, only 8%, 9%, 10%, 16% and 4% were aware of the relation between 
microalbuminuria and microvascular, cardiac, macrovascular, eyes and brain 
complications, respectively. This finding is disappointing as screening of 
microalbuminuria is easy and relatively inexpensive and the result may guide the clinician 
to identify individuals at high risk for cardiovascular complications. 
1.2.8.1 Microalbuminuria and high blood pressure 
The association of high blood pressure with increased UAE is plausible. High blood 
pressure is one of the proposed mechanisms for the presence of albumin in the urine and is 
one of the most frequently reported predictors of microalbuminuria (Moran et al., 2006).  
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In studies that aimed to characterise microalbuminuria in non-diabetic subjects with 
hypertension such as the MAGIC (Microalbuminuria: A Genoa Investigation on 
Complications) study (Pontremoli et al., 1997) and in non-diabetic subjects from general 
population such as the Gubbio Population studies (Cirillo et al., 1998), there were direct 
relationships between high blood pressure and microalbuminuria. This relation was also 
shown in a large cross-sectional study involving 4 subgroups; diabetic patients with severe 
atherosclerosis, non-diabetic with severe atherosclerosis, diabetic with mild atherosclerosis 
and non-diabetic with mild atherosclerosis (Hsu et al., 2009). In this study, high blood 
pressure, even below the threshold level for the definition of hypertension, was 
significantly associated with albuminuria in the four groups. 
The relationship between albuminuria and increased blood pressure has also been reported 
in studies using 24-hours blood pressure monitoring (Clausen et al., 1998). In a small 
group of subjects without evidence of cardiovascular or metabolic abnormalities there were  
positive correlations between UAE and 24-hour SBP, DBP and pulse pressure (Clausen et 
al., 1998). This relationship was also evident in diabetic patients (Januszewicz et al., 2011), 
hypertensive subjects with end organ damage (Wiinberg et al., 2004, Moran et al., 2006), 
resistant hypertension (Oliveras et al., 2009) and general hypertension population (Gerber 
et al., 2001). These findings are of particular importance since ambulatory blood pressure 
is now considered the gold standard for the diagnosis of hypertension and the identification 
of subjects with true refractory hypertension (National Institute for Health and Clinical 
Excellence, 2011) and therefore, may represent the most reliable data for the association 
with increased UAE. 
Increased UAE is found in those lacking the normal blood pressure reduction during 
sleeping ( non-dippers) (Bianchi et al., 1994). UAE was related to non-dipping pattern in a 
cohort of recently diagnosed hypertension (Afsar and Elsurer, 2010), in subjects with 
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untreated hypertension (Syrseloudis et al., 2010) and those with resistant hypertension 
(Oliveras et al., 2011). 
1.2.8.2 Microalbuminuria and renal function 
Microalbuminuria is best recognised for the association with deterioration in renal 
function. Microalbuminuria may be present at an early stage of kidney disease, even when 
eGFR is normal (Levey et al., 2003). Recent recommendations suggest the use of 
albuminuria in addition to eGFR for the prediction of end stage renal disease (ESRD) 
(Hallan et al., 2009, Astor et al., 2011). In a study involving almost 66,000 patients 
followed for ten years (Hallan et al., 2009) both eGFR and albuminuria were independent 
predictors for ESRD. This association was also reported recently in diabetic subjects 
followed for 10 years (Berhane et al., 2011) and in subjects with high cardiovascular risk 
(Clase et al., 2011). Combining eGFR and albuminuria screening identified hypertensive 
subjects at high risk of cardiovascular morbidities and mortalities in a prospective cohort 
study (Salles et al., 2011b). In a Canadian cohort study with a large number of patients (> 
900,000), increased albuminuria was a strong predictor for progression to ESRD 
(Hemmelgarn et al., 2010).  In a sub-analysis of the MAGIC study, 917 non-diabetic 
hypertensive subjects with normal kidney function were followed for a median of 11.8 
years (Viazzi et al., 2010). More than one-third of those who developed chronic renal 
insufficiency had microalbuminuria at baseline compared with 7% in the control group. 
The association of microalbuminuria with renal outcome was independent of eGFR or 
other confounders. Likewise, in a retrospective study of hypertensive subjects followed for 
7 years, microalbuminuria was associated with decline in creatinine clearance and 
increased cardiovascular events (Bigazzi et al., 1998). Regression or significant reduction 
of UAE (defined as reduction exceeds 50%) in non-diabetic hypertensive subjects was 
associated with better renal outcomes (Pascual et al., 2006). These finding clearly suggest 
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that microalbuminuria provides information additional to that provided by eGFR in 
prediction and identification of kidney function impairment. Therefore, routine checks for 
those at high risk for chronic disease should include albuminuria screening in order to 
prevent or delay possible progression to ESRD. 
1.2.8.3 Microalbuminuria and cerebrovascular abnormalities 
Stroke risk 
Several cross-sectional and prospective studies suggest that microalbuminuria is prevalent 
in those with recent acute stroke and may predict future stroke incidences (Lee et al., 
2010). In a prospective case-control study involving patients with recent acute stroke 
(within a week) or at high risk for developing stroke (hypertension, diabetes, transient 
ischemic attack (TIA) or ischaemic heart disease), the prevalence of microalbuminuria in 
those with stroke was significantly greater than that in the high-risk group (29% versus 
10%) (Beamer et al., 1999). During a mean follow-up period of 1.5 years, one-fifth of 
subjects with recent stroke and almost 15% of the high-risk group developed vascular 
events. New onset vascular events were more frequent in subjects with albuminuria even 
after adjusting other risk factors such as high blood pressure, diabetes and cigarette 
smoking. 
The Losartan Intervention For Endpoint reduction (LIFE) examined the association of 
microalbuminuria with cardiovascular events in 8206 hypertensive subjects with LVH 
(Wachtell et al., 2003). After follow up for a median of 4.8 years, the study revealed that 
for every 10-fold increase in UAE, the risk for stroke increased by 50%. However, this 
result has some limitations. Microalbuminuria was detected using only one specimen and 
did not include any measure to exclude those with UTI. Also, the study was performed in 
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high-risk population and whether the same pattern may be observed in patients without 
LVH is not clear.  
In the UK, data from the EPIC-Norfolk study, a general population study with a mean 
follow up of 7.2 years, revealed that stroke risk was increased by 50% in subjects with 
microalbuminuria (Yuyun et al., 2004a). A Cox multiple regression model showed that the 
hazard ratio for the association between microalbuminuria and stroke events was greater 
than that for some traditional risk factors such as total cholesterol, SBP and body mass 
index (BMI). The detection of microalbuminuria in this study was based on one random 
sample per patients which may overestimate albuminuria prevalence as discussed 
previously. 
A meta-analysis involving twelve studies with more than 48,000 patients evaluated the 
relation of microalbuminuria with stoke (Lee et al., 2010). These studies involved different 
populations with or without different co-morbidities such as prior stroke, hypertension, 
cardiovascular disease or diabetes mellitus. Microalbuminuria was strongly associated with 
stroke events. In addition, subjects with microalbuminuria had a 90% greater risk for 
developing future stroke incidents compared with individuals with normoalbuminuria.  
In the survey by Haller et al. (Haller et al., 2010), the association of microalbuminuria with 
brain abnormalities was the least recognised association, especially in the UK. This 
indicates that clinicians may miss an easy and non-invasive technique for identifying 
individuals at high risk of cerebrovascular diseases. 
Cognitive decline and cerebrovascular changes 
The largest body of evidence for the interaction between albuminuria (microalbuminuria 
and proteinuria) and cognitive function comes from the Ongoing Telmisartan Alone and in 
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Combination with Ramipril Global Endpoint Trial (ONTARGET) / the Telmisartan 
Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease 
(TRANSCEND) (Barzilay et al., 2011). More than 28,000 patients suffering from vascular 
diseases or diabetes mellitus participated in these trials. Cognitive function was assessed at 
baseline and after 5 years using a 30-point Mini–Mental State Examination (MMSE) to 
evaluate the degree of dementia. Subjects with albuminuria at baseline had lower MMSE 
scores (less than 24) and higher odds for reduced cognitive function. Similarly, those who 
developed albuminuria during the study had increased odds for cognitive impairment. One 
of the drawbacks of the study is the population studied. The conclusions cannot be 
extended to those without diabetes or vascular abnormalities as these disorders may also 
interact with cognitive decline.  
Ravera and colleagues (Ravera et al., 2002) investigated the association with subclinical 
cerebrovascular changes in a small number of untreated hypertensive subjects (11 with 
microalbuminuria and 11 with normoalbuminuria) with no clinical neurological disorders. 
Using magnetic resonance imaging, the researchers found that subjects with 
microalbuminuria had greater prevalence of cerebral lacunar infarcts. In a cohort of elderly 
subjects in Japan, cerebral small vessels disease (SVD) was correlated with 
microalbuminuria (Wada et al., 2007). In addition, ischaemic lacunar lesions and white 
matter hyperintensity were more prevalent in subjects with microalbuminuria. Another 
cross-sectional study carried out in 2316 elderly subjects showed that microalbuminuria 
was significantly related to dementia and mild cognitive impairment (Barzilay et al., 2008). 
In 285 hypertensive subjects without evidence of stroke, TIA or severely reduced renal 
function (Umemura et al., 2012), microalbuminuria was significantly related to deep or 
infratentorial cerebral microbleeds investigated by neuroimaging. Brain microbleeds were 
also strongly related to proteinuria in patients who had stroke or TIA events (Ovbiagele et 
al., 2010). 
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These findings are important for several reasons. First, cerebral SVD has been increasingly 
linked with several brain abnormalities such as cognitive decline, age-associated disorders 
and stroke (Leonardo, 2010). Second, white matter hyperintensities, possibly mediated by 
SVD-induced ischaemia, have been shown to predict stroke, cognitive decline and 
mortality (Stéphanie and Markus, 2010). Third, association between brain microbleeds and 
neurological disorders such as Alzheimer’s disease (Goos et al., 2009) and mortality 
(Henneman et al., 2009) has been suggested. 
The identification of cerebrovascular changes such as SVD, white matter lesions and 
cerebral microbleeds require time-consuming, expensive and are not routinely requested 
investigations (ultrasonography or special neuroimaging). Microalbuminuria screening 
could serve as an appropriate tool for identifying population at high risk for 
cerebrovascular complications.  
1.2.8.4 Microalbuminuria and cardiovascular abnormalities 
A growing body of evidence links microalbuminuria with abnormalities in the 
cardiovascular system. As mentioned earlier, microalbuminuria reflects generalised 
endothelial dysfunction which is a key factor for several cardiovascular diseases such as 
CHD, myocardial infarction heart failure, hyperlipidemia and atherosclerosis.  
Ischaemic heart disease risk 
The prognostic value of microalbuminuria for ischaemic heart diseases is suggested by 
evidence from a number of studies involving different population (Klausen et al., 2004). 
Subjects with untreated hypertension or high-normal blood pressure were followed for ten 
years in the Danish MONICA (Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease) project (Jensen et al., 2000). Among hypertensive subjects, 9% 
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had future ischaemic disease. The prevalence of microalbuminuria in those who developed 
ischaemic heart disease was higher than that in the control group. The relative risk for 
developing ischaemic attack associated with microalbuminuria after adjusting for known 
factors such as blood pressure, lipids, gender and BMI was 3.5. These findings were 
confirmed in a UK population-based study where microalbuminuria and gross proteinuria 
predicted future episodes of CHD with hazard ratios of 1.36 and 1.59, respectively (Yuyun 
et al., 2004d). 
The prognostic value of microalbuminuria for short and long-term outcomes following 
acute myocardial infarction has also been investigated. Berton et al. (Berton et al., 1997) 
studied albuminuria in patients hospitalised for acute myocardial infarction and compared 
findings with a control group (those hospitalised because of suspected myocardial 
infarction but who did not meet the diagnostic criteria). UAE, measured by 24-hour urine 
collection, was higher on the day of admission and after 2 days compared with the control 
group. However, participants in the control group were younger (i.e. not age-matched) and 
had fewer cardiovascular co-morbidities which may bias the comparison. Another study 
showed that more than one-third of hospitalised patients with acute myocardial infarction 
had increased UAE (Apostolovic et al., 2011). Increased UAE was a strong predictor for 
myocardial infarction complications including mortality. 
A study involving 175 non-diabetic patients with acute myocardial infarction followed for 
3 years aimed to identify factors associated with subsequent cardiovascular events or death 
(Koulouris et al., 2005). Microalbuminuria, measured by timed overnight urine collection 
on the third day after the event, was an independent predictor for both endpoints. Similar 
findings were shown in a larger non-diabetic cohort where cardiovascular complications 
following myocardial infarction episodes were higher than in those without 
microalbuminuria (Lekatsas et al., 2006). Thus, in patients with myocardial infarction, 
55 
 
increased UAE may identify those at high risk for complications. More rigorous treatment 
for these patients may lower risk for future complications. 
 Left ventricular hypertrophy and structural changes 
The LIFE study investigated the relation between increased UAE and LVH in a population 
with essential hypertension (Wachtell et al., 2002). Almost 9200 hypertensive subjects 
with evidence of LVH on electrocardiography (ECG) but without evidence of recent 
stroke, low left ventricular ejection fraction (less than 40%), myocardial infarction or 
severe kidney impairment participated. Both microalbuminuria and proteinuria were 
strongly associated with LVH even after adjusting possible confounders such as high blood 
pressure, increased age and diabetes.  
Data from the Hypertension Genetic Epidemiology Network (HyperGEN) demonstrated 
that albuminuria is associated with increased left ventricular size (on echocardiography) in 
normotensive as well as hypertensive individuals; reduced ejection fraction has seen only 
in microalbuminuric hypertensive subjects (Djoussé et al., 2008). Electrocardiological 
abnormalities such as rhythm abnormalities, intraventricular conduction defects, 
ventricular repolarisation alterations, and left-axis deviation were also associated with 
microalbuminuria (Sciarretta et al., 2009). 
It has been shown recently that in hypertensive subjects with ventricular diastolic 
impairment, microalbuminuria is associated with increased ventricular remodelling, 
stiffness and increased levels of NT-proBNP, a marker for heart wall stress (Shah et al., 
2011). In contrast, reduction in eGFR did not show an association with such changes in the 
myocardium. This means that microalbuminuria provided information additional to that 
offered by the classical marker of kidney disease. The importance of such findings is that 
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microalbuminuria could identify those with high risk for progression to heart failure and 
help to identify pharmacological agents with properties to prevent such progression. 
Congestive heart failure (CHF) 
As microalbuminuria is associated with cardiac outcomes such as CHD and myocardial 
infarction, an association with CHF is expected. This association was confirmed in  the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 
(CHARM) trial (Jackson et al., 2009). Two thousand three hundred and ten patients with 
heart failure participated in the programme. Albuminuria was found in 41% of the patients 
(30% microalbuminuria and 11% gross proteinuria). Similar prevalences were noted after 
excluding diabetes and hypertension. In this patient population, albuminuria was useful 
predictor for mortality and further deterioration in the myocardium in the studied 
population.  
The prevalence of microalbuminuria and gross proteinuria in a small cohort of subjects 
who participated in the ALiskiren Observation of heart Failure Treatment (ALOFT) study 
was 33% and 11%, respectively (Jackson et al., 2011). Albuminuria detected by dipstick in 
an Asian population was correlated with CHF with preserved left ventricular ejection 
fraction and predicted future death (Miura et al., 2012). In hypertensive subjects with LVH 
in the LIFE study, albuminuria was associated with twofold increase in risk of incident 
heart failure (Okin et al., 2008).  
In the general population, data from the Multi-Ethnic Study of Atherosclerosis (MESA) 
showed that albuminuria was the strongest predictor of new-onset CHF in 6,800 
individuals with different ethnic background (Bahrami et al., 2008). Although the follow-
up period (4 years) was too short for accelerate estimation of such an outcome, this study is 
of particular interest for several reasons. First, it described the incidence of severe cardiac 
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outcome in apparently healthy subject without clinically detectable cardiovascular disease. 
Second, the study involved subjects from four different ethnicities; Caucasians, black, 
Hispanics and Asian. Finally, the researchers showed the association between albuminuria 
and heart failure even after adjustment for traditional risk factors. This observation 
suggests that albuminuria is important in risk stratification for severe cardiac outcomes. 
Vascular diseases 
Arterial stiffness measured by pulse wave velocity (PWV) has been reported in subjects 
with microalbuminuria (Ishikawa et al., 2008). This condition is a risk factor for future 
cardiovascular events (Willum Hansen et al., 2006). Loss of arterial elasticity leads to 
increase in the force of contractions of the heart which in turn may lead to LVH and severe 
complications (Willum Hansen et al., 2006, Sutton-Tyrrell et al., 2005). 
In subjects without hypertension or diabetes, arterial stiffness was associated with 
microalbuminuria after adjusting for possible confounders (Kim et al., 2011). In small 
cohorts of untreated hypertensive subjects, the prevalence of microalbuminuria in those 
with arterial stiffness measured by carotid / femoral arteries PWV or ambulatory arterial 
stiffness index was significantly higher (Ratto et al., 2006, Mule et al., 2009). The 
association remained significant in adjusted regression models.  
Microalbuminuria has been also linked with coagulation abnormalities. A sub-analysis 
from the PREVEND study reported an increased incidence of venous thromboembolism in 
subjects with microalbuminuria (Mahmoodi et al., 2009). The incidence rate was 0.40% 
per year for those with UAE ≥ 30 -300 mg per day compared with only 0.12% per year for 
those with UAE < 15 mg per day (P<0.001). A recent post-hoc analysis of the PREVEND 
study showed that microalbuminuria was also associated with increased risk for recurrent 
venous thromboembolism (van Schouwenburg et al., 2012).  
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A direct relationship between albuminuria and atherosclerosis has been observed in many 
studies. Both conditions share a common pathological mechanism, endothelial damage. In 
a Norwegian study, a direct correlation between ACR and de novo formation and 
progression of atherosclerotic plaque in the carotid artery was reported in subjects without 
diabetes (Jørgensen et al., 2007). Moreover, microalbuminuria predicted the formation and 
the progression of early marker of atherosclerotic lesion in the carotid artery (calcification) 
in clinically health individuals participated in the MESA study (DeFilippis et al., 2010). 
Increased carotid intima-media thickness, a risk factor for atherosclerosis, was also 
observed in hypertensive subjects with microalbuminuria (Cao et al., 2006).  
1.2.8.5 Microalbuminuria and mortality 
Microalbuminuria has been shown to predict those at high risk of all-cause and 
cardiovascular mortality, especially after myocardial infarction (Berton et al., 2001). As 
mentioned earlier, microalbuminuria is a common finding in subjects with very recent 
acute myocardial infarction (Berton et al., 1997). Therefore, studies have investigated 
whether such association can help in identifying subjects with increased risk of mortality. 
A large cohort of patients (n >1200) with acute myocardial infarction were divided into 
three groups according to the result of timed-urinary albumin excretion; 
normoalbuminuria, microalbuminuria and those with gross proteinuria (Schiele et al., 
2009). The mortality rate was found to be associated with the level of albuminuria. Low 
survival rate was reported in patients with albuminuria two days after myocardial 
infarction. After one month, those with microalbuminuria had greater than twofold 
increased mortality risk compared with individuals with normoalbuminuria. 
Data from the EPIC-Norfolk study showed a continuous relationship between albumin 
level in the urine and cardiovascular mortality; adjusted hazard ratio 2.03 and all-cause 
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mortality; 1.48 (Yuyun et al., 2004b); this relationship was evident in males and females. 
However, an association with non-cardiovascular death was observed only in males.  The 
diagnosis of albuminuria was based on one random urine specimen and this is one of the 
limitations of this study. In a Norwegian study (the Nord-Trøndelag Health Study), 5369 
treated hypertensive subjects  (43% males) were followed for more than 4 years 
(Romundstad et al., 2003a). ACR showed a positive correlation with all-cause mortality 
after adjusting for common risk factors such as blood pressure, glucose, lipids, renal 
function and smoking. Men had higher probability for fatal end-point. These findings 
suggest that when using microalbuminuria for risk stratification, sex differences should be 
taken into account. 
In a meta-analysis of data from more than 100,000 individuals in the general population, 
albuminuria was shown to be significantly related to all-cause and cardiovascular mortality 
even after adjusting for all other risk factors including eGFR (Matsushita et al., 2010). 
Another meta-analysis of 13 studies showed that albuminuria is an independent predictor 
for mortality in patients with CKD (Astor et al., 2011). 
Proteinuria (>500 mg per day) has been postulated to predict cardiovascular death in 
diabetic patients (Cardoso and Salles, 2008). This was supported by finding from an 
observational study which examined the mortality rate over 10 years in type 1 diabetics 
and showed that 44% of subjects who died had proteinuria (Rossing et al., 1996) 
The association with mortality would be of particular importance if reduction in 
albuminuria level is accompanied with reductions in mortality rates. In a study involving 
more than 23,000 high risk patients followed for two years, it has been found that 
cardiovascular mortality increases by 50% for every two-fold or more increase in 
albuminuria from baseline (Schmieder et al., 2011). The study also reported that two-fold 
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or more reduction in albuminuria was associated with 15% reduction in death. This finding 
reflects the importance of microalbuminuria not only as a biomarker for cardiovascular risk 
but also a useful target for pharmacological intervention. 
1.2.9 Microalbuminuria and inflammatory markers 
It has been suggested that individuals with microalbuminuria have increased levels of 
inflammatory markers (Pedrinelli et al., 2004). Such an association might contribute to the 
involvement of microalbuminuria in the pathology of cardiovascular disease since it is 
increasingly recognised that the pathogenesis of some cardiovascular disease such as 
atherosclerosis has an inflammatory component (Libby et al., 2009). 
 The vast majority of studies that have investigated subclinical inflammatory reactions in 
subjects with microalbuminuria have utilised CRP. Data from the National Health and 
Nutrition Examination Surveys showed that in the general population, levels of CRP were 
correlated weakly with microalbuminuria (odds ratio 1.02, 95% confidence interval 1.01 to 
1.02, p = 0.0003) (Kshirsagar et al., 2008).  The Oxford Regional Prospective Study 
reported a continuous relationship between hs-CRP levels and microalbuminuria in 
subjects with type I diabetes mellitus (Marcovecchio et al., 2008). The study also reported 
that levels of hs-CRP in microalbuminuric patients were significantly higher than in those 
with normal UAE.   
A small cohort of subjects (n=91) with high-normal blood pressure (SBP: 120-139/ DBP: 
80-89 mm Hg) were compared with those with blood pressure less than 120/80 mm Hg in 
terms of UAE (measured by 24-hour urine collection following two positive early morning 
measurements) and inflammatory markers (Navarro-Gonzalez et al., 2012). Individuals 
with high-normal blood pressure had high levels of UAE and hs-CPR. In non-diabetic 
subjects with untreated hypertension, microalbuminuria was strongly correlated with level 
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of hs-CRP (Pedrinelli et al., 2004, Tsioufis et al., 2010). These findings suggest that 
microalbuminuria is closely related to a sensitive marker of inflammation which is 
considered by itself as risk factor for cardiovascular disease. 
In patients with type 2 diabetes mellitus, eosinophil count was significantly associated with 
the degree of urinary albumin excretion in men (Fukui et al., 2009). Another study showed 
a linear relationship between eosinophil count  and the severity of diabetic nephropathy 
(Chung et al., 2005).  
A relation between ESR and total urinary protein has been suggested (Liverman et al., 
1988). In type 2 diabetic patients, ESR levels showed a linear relationship with urinary 
albumin excretion (Dalla Vestra et al., 2005). This was also shown in a recent study 
involving diabetic subjects with retinopathy where ESR levels in those with albuminuria 
(both microalbuminuria and gross proteinuria) were greater than in those with normal UAE 
(Magri et al., 2012).  
1.2.10 Low-grade microalbuminuria  
A mounting body of evidence suggests that low levels of urinary albumin excretion (below 
the conventional threshold) are associated with increased cardiovascular risk (Ärnlöv et al., 
2005). The relationship between albuminuria and cardiovascular outcomes seems to 
exhibit a continuous relationship with no clear threshold for such association. The 
conventional threshold that is used currently for the definition of microalbuminuria is 
arbitrary and was chosen more than 25 years ago based on data of diabetic patients 
(Forman and Brenner, 2006).   
The PREVEND study was among first studies that reported the association between  
albuminuria at levels greater than or equal to 3.8 mg/L and mortality in subjects without 
known risk factor for cardiovascular disease (Janssen et al., 2000). An increase in the UAC 
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from 5 to 10 mg/L was associated with almost one-third increased cardiovascular death in 
the that study (Hillege et al., 2002).  In 1,568 individuals without diabetes or hypertension 
who participated in the Framingham Offspring Study, low ACR (≥ 3.9 mg/g in males and 
7.5 mg/g in females) was significantly associated with three-time greater risk for 
cardiovascular diseases and higher death incidences (Ärnlöv et al., 2005). Low-grade 
microalbuminuria has also been shown to predict increase in left ventricular mass 
(Reffelmann et al., 2010) and heart failure incidence in the general population (Blecker et 
al., 2011). 
Klausen et al. (Klausen et al., 2004) reported that a UAE rate of more than 4.8 µg per 
minute strongly predicted CHD and cardiovascular death independent of age, gender, 
diabetes, high BP, kidney function or lipid profile. Low-grade UAE was shown to be 
associated with 2-3 fold increased risk of CHD (Borch-Johnsen et al., 1999). Low 
albuminuria level was also associated with increased risk of target organ damage such as 
LVH even in healthy subjects (Lieb et al., 2006). ACR levels of 10–16 µg per mg were 
associated with greater cardiovascular mortality (Zamora and Cubeddu, 2008).  
The Framingham Heart study reported that low-grade UAE is a strong predictor for the 
progression of non-diabetic subjects from normotension to hypertension (Wang et al., 
2005). Low-grade microalbuminuria was also an independent predictor for progression to 
hypertension in females participated in the Nurses’ Health Study (Forman et al., 2008). 
However, results based on ambulatory blood pressure from the Hypertension and 
Ambulatory Recording Venetia Study (HARVEST) failed to find any predictive value of 
microalbuminuria or low-grade microalbuminuria in the development of sustained high 
blood pressure (Palatini et al., 2005). Therefore, current evidence is equivocal in support of 
the use of low-grade microalbuminuria in identifying those at high risk for developing 
hypertension. 
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The association of low-grade microalbuminuria with worse outcomes has been also shown 
in subjects with essential hypertension and those with diabetes mellitus (Wachtell et al., 
2003). In a cohort of untreated hypertensive subjects, overnight UAE (< 15 μg/minute) was 
correlated with poor renal and cardiac outcomes (Dell'Omo et al., 2002). In those with end 
organ damage participating in the LIFE study, there was a clear association between low-
grade microalbuminuria ( ≥ 2.2 mg/g) and increased risk for cardiovascular and 
cerebrovascular outcomes (Wachtell et al., 2003). Low levels of albuminuria were also 
associated with poor cardiac outcome (increased thickness of left ventricle and end-systolic 
stiffness) in hypertensive subjects with diastolic dysfunctions (Shah et al., 2010).  
Taken together, these findings emphasize the importance of examining a new definition of 
microalbuminuria, at least in patients with certain diseases or those more susceptible to 
cardiovascular complications.  
1.2.11 The use of antihypertensive drugs in microalbuminuria  
1.2.11.1 Role of blood pressure control 
It has been reported in many studies that reduction of high blood pressure reduces urinary 
albumin excretion and preserves the kidney (Bakris et al., 2000). Most studies reporting the 
benefit of blood pressure control in attenuation of albuminuria involved patients with 
diabetes (either normotensive or hypertensive), mainly because of the higher prevalence of 
renal disease in those patients (Strippoli et al., 2005). For instance, the UKPDS study 
reported that “intensive” blood pressure control (<150/85 mm Hg) by either beta blockers 
or ACEIs was associated with 29% lower microalbuminuria risk (UK Prospective Diabetes 
Study Group, 1998b).  In another study involving 386 patients with type I diabetes mellitus 
and persistent microalbuminuria, SBP lower than 115 mm Hg was among predictors for 
microalbuminuria regression along with lowering glycosylated haemoglobin and serum 
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lipids (Perkins et al., 2003). In normotensive patients with type II diabetes, blood pressure 
reduction with an ACEI or a CCB to levels below 128/75 mm Hg was associated with 
significantly fewer patients progressing to microalbuminuria or gross proteinuria compared 
with a group taking placebo (Schrier et al., 2002). 
In a trial involving a cohort of 77 patients with type II diabetes assigned to receive either 
an ACEI, a dihydropyridine CCB or placebo showed that both ACEI and CCB stabilised 
UAE over a median follow up of 5.5 years (Jerums et al., 2004). The Modification of Diet 
in Renal Disease Study also demonstrated that good blood pressure control with 
antihypertensive drugs was associated with reduction in albuminuria (Peterson et al., 
1995). The study suggested a target of < 125/75 mm Hg for patients with gross proteinuria. 
In the ADVANCE study (The BP arm of the Action in Diabetes and Vascular disease: 
preterAx and diamicroN-MR Controlled Evaluation) that involved patients with type II 
diabetes (normotensive and hypertensive) followed for 4.3 years , reduction in blood 
pressure by fixed combination of ACEI/diuretic was associated with lower incidence of 
renal complications (including microalbuminuria and gross proteinuria) (de Galan et al., 
2009).  
These findings indicate that the most crucial step in controlling albuminuria (both micro- 
and gross proteinuria) is rigorous blood pressure control. Although specific 
antihypertensive classes have been suggested to confer additional anti-proteinuric 
properties beyond blood pressure reduction (as I shall discuss later), the current evidence is 
weak. Therefore, therapeutic strategies should focus achieving blood pressure targets rather 
than relying on a specific pharmacological class.   
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1.2.11.2 Renin-angiotensin-aldosterone system blockers 
RAAS blockers are the most commonly used antihypertensive drugs for the control of 
urinary protein excretion (Mehdi et al., 2009, Menne et al., 2010). Several mechanisms by 
which RAS blockers may attenuate albumin excretion have been postulated. Reduction of 
glomerular capillary hydrostatic pressure by RAS blockers through arteriolar vasodilation 
has been suggested (Iñigo et al., 2001). Normalisation of glomerular basement membrane 
permselectivity is another postulated mechanism (Sangalli et al., 2011). 
Few studies have examined the antiproteinuric effect of RAAS blockade in patients with 
type I diabetes mellitus (Mauer et al., 2009). Treatment with an ACEI preserved the kidney 
function of patients with gross proteinuria (Lewis et al., 1993). However, whether this was 
independent of better blood pressure control or whether similar effects can been seen with 
angiotensin receptor blockers (ARBs) is unknown. In a recent trial comparing 
renoprotection of ACEI and ARBs (versus placebo), a lower incidence of 
microalbuminuria was reported with ACEI, while treatment with ARBs was associated 
with increased new onset microalbuminuria (Mauer et al., 2009). However, both groups 
did not protect the kidney over 5 years follow up. This study is limited by the exclusion of 
people with hypertension (>135/85 mm Hg), as high blood pressure plays a major role in 
nephropathy in type I diabetes (Krolewski et al., 1988) and the small number of 
participants (n=285). A meta-analysis of 12 studies showed that treatment with ACEIs was 
associated with protection against progression to gross proteinuria and regression to 
normoalbuminuria (The ACE Inhibitors in Diabetic Nephropathy Trialist Group, 2001). 
Several major trials addressed the effect of RAAS blockade in type II diabetes (Viberti et 
al., 2002, Lewis et al., 2001). In the RENAAL study,  diabetic subjects with nephropathy 
(gross proteinuria) were assigned to receive losartan or placebo plus non-RAS blocker 
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therapy (Brenner et al., 2001). It was reported that patients in losartan group had a 
reduction of albuminuria of about 35% (compared with 4% in the placebo group). In the 
HOPE study, ramipril lowered the risk of progression to diabetic nephropathy by 24% 
(Heart Outcomes Prevention Evaluation Study Investigators, 2000b). The authors 
suggested a possible role of bradykinin in regressing albuminuria as ACEIs are known to 
increase this vasodilatory substance (Gainer et al., 1998). However, other RAS blockers 
(e.g. ARBs) appeared to be equivalent to ACEIs in attenuating albuminuria do not induce 
bradykinin (McMurray, 2011, Viberti et al., 2002). One of the confounders of direct 
comparison between RAS blockers and other antihypertensive drugs is the possible better 
early blood pressure control with RAS blockers. The Irbesartan Diabetic Nephropathy 
Trial (IDNT) provided the best evidence for the superior effect of ARBs in retarding 
progression of diabetic nephropathy to ESRD in hypertensive subjects than with CCBs as 
the blood pressure was identical in the two treatment groups throughout the follow up 
period (Lewis et al., 2001).  
In a randomised trial involving 599 patients with diabetic nephropathy and hypertension, 
the addition of aliskiren to patients concomitantly receiving losartan resulted in 20% 
reduction of proteinuria (Parving et al., 2008). Blood pressure reduction in the active 
treatment group was modestly greater (2/1 mm Hg) than in the placebo group, which may 
contribute to the additional proteinuria lowering effect produced by aliskiren. However, the 
safety of the use of aliskiren with ACEIs or ARBs has been questioned recently. The 
manufacturer of aliskiren has decided to stop a clinical trial investigating the safety and 
efficacy of aliskiren in high-risk diabetic patients (Parving et al., 2009) due to increased 
incidence of hyperkalemia (predictable) and stroke (unpredicted) (Novartis, 2011). The US 
Food and Drug Administration (FDA) announced that the use of aliskiren with RAS 
blockers is contra-indicated in patients with diabetes due to increased risk of kidney 
disease, hypotension, and hyperkalemia (Food and Drug Administration, 2012).  
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Spironolactone produced a 32% reduction in proteinuria compared with placebo in a small 
study involving 20 patients with diabetes and overt nephropathy receiving other 
antihypertensive agents including RAS blockers (Schjoedt et al., 2006). Addition of 
spironolactone produced marked reduction of the blood pressure (7/5 mm Hg) compared 
with placebo. Addition of spironolactone to subjects with diabetic nephropathy under 
chronic treatment with RAS blockers resulted in further blood pressure reduction (7/3 mm 
Hg) and 40% less albuminuria (van den Meiracker et al., 2006). Moreover, in a randomised 
trial involving 81 patients with diabetes (type I or II), hypertension and gross proteinuria 
who were treated with highest dose of lisinopril (80 mg), participants were assigned to 
receive either losartan, spironolactone or placebo (Mehdi et al., 2009). Subjects receiving 
spironolactone had reduction in proteinuria greater than in those treated with losartan (34% 
versus 17%). In a study which compared the effect of spironolactone and cilazapril on 
proteinuria, spironolactone alone reduced proteinuria more than cilazapril, and 
combination therapy produced a further reduction (Rachmani et al., 2004). However, the 
publication was retracted due to uncertainty about the authenticity of the results (Diabetic 
Medicine, 2006).    
Attenuation of microalbuminuria in patients with type II diabetes has been reported  in the 
MARVAL (MicroAlbuminuria Reduction With VALsartan) study (Viberti et al., 2002). 
Valsartan reduced albuminuria more than amlodipine, although both drugs exhibited 
similar blood pressure reduction. However, the progression of renal disease is slow which 
means that follow up period in the MARVAL trial (24 weeks) may limit the validity of the 
study conclusion. Also, many studies reported beneficial effects of dihydropyridine CCBs 
on albuminuria such as in the Appropriate Blood Pressure Control in Diabetes (ABCD) 
trial (Estacio et al., 2000).  
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RAAS blockers have been shown to delay and reduce new onset microalbuminuria cases in 
several randomized controlled trial (Ruggenenti et al., 2004). The Randomized Olmesartan 
and Diabetes Microalbuminuria Prevention (ROADMAP) trial revealed that the number of 
patients who developed new onset microalbuminuria was fewer than that in placebo group 
(8.2% versus 9.8%), although renal endpoint (doubling of the serum creatinine) was the 
same in both groups (Haller et al., 2011).  The study has also shown that olmesartan 
prolonged time to the onset of microalbuminuria. Blood pressure was lower in the 
olmesartan arm and fatal cardiovascular events were statistically higher in the olmesartan 
group. The latter finding raised concerns about the safely of olmesartan as another study 
with olmesartan has reported similar finding (Imai et al., 2011). 
In non-diabetic subjects with nephropathy, treatment with ramipril (versus placebo) 
significantly reduced blood pressure, proteinuria and slowed progression of renal 
deterioration (The GISEN Group, 1997). In non-diabetic subjects with hypertension, the 
LIFE study showed that losartan was superior to atenolol in suppressing albuminuria 
excretion with minimum difference between the two treatment groups in terms of blood 
pressure reduction (Ibsen et al., 2004).  
It remains unclear whether RAAS blockers possess antiproteinuric properties beyond that 
provided by blood pressure reduction. For example, in the HOPE study, a blood pressure 
reduction of 3/2 mm Hg in the active treatment arm could explain the renoprotection 
mediated by ramipril (Heart Outcomes Prevention Evaluation Study Investigators, 2000b). 
Similarly, treatment with olmesartan was associated with greater reduction of blood 
pressure than in the placebo group (3.1/1.9 mm Hg) in the ROADMAP study (Haller et al., 
2011). Other studies were not properly designed to show an additional effect of RAAS 
blockers beyond that from blood pressure reduction. For example, in the RENAAL trial 
(Brenner et al., 2001), the design meant that losartan resulted in earlier blood pressure 
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reduction and hence, more renoprotection. Spironolactone has been shown to be effective 
in reducing blood pressure in subjects with resistant hypertension (de Souza et al., 2010). 
Therefore, it is plausible that further blood pressure reduction produced by the addition of 
spironolactone may explain most of reduction of proteinuria in the spironolactone trials. 
Moreover, most spironolactone trials were underpowered, limiting the validity of the 
conclusions (Schjoedt et al., 2006).  
The available data on whether combining drugs from different classes of RAAS blockade 
may provide better cardio-renal outcomes is unclear. The Valsartan in Combination With 
Lisinopril in Hypertensive Patients With Microalbuminuria (VALERIA) trial demonstrated 
the effect of lisinopril and valsartan in 133 hypertensive subjects with microalbuminuria 
(Menne et al., 2008). Following seven months of treatment with lisinopril, valsartan and a 
combination of lisinopril/valsartan, the ACR was reduced by 41%, 51% and 62%, 
respectively. In addition, microalbuminuria regression was achieved in 17%, 31%, and 
38% of patients receiving lisinopril, valsartan and lisinopril/valsartan, respectively. It was 
concluded that a combination of ACEI and ARB provide better outcomes. However, the 
better reduction in proteinuria with the combination could be due to the better blood 
pressure reduction achieved by the combination. It might have been better to start with the 
three treatment regimens at low doses which are then titrated to the higher doses and 
compare the reduction in proteinuria in the three groups. 
A meta-analysis of 49 studies has shown that the combination of ACEI and ARB give 
better reduction of proteinuria than monotherapy with drugs from these groups (Kunz et 
al., 2008a). However, whether such combination could be translated into better 
cardiovascular or renal outcome was not proven. In the ONTARGET study that involved 
high-risk population, combination of ramipril and telmisartan was associated with 
cardiovascular outcomes rates similar to that reported with each drug alone and was 
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associated with higher incidences of adverse drug reactions (Yusuf et al., 2008). A recent 
systematic review of 85 randomised controlled trials suggested that there is no evidence 
supporting superiority of ARB and ACEI  in combination over monotherapy from either 
group (Maione et al., 2011). The only study that reported a clear beneficial effect of a 
combination of ARB/ACEI on renal outcomes was the COOPERATE trial (Nakao et al., 
2003). However, serious concerns about the authenticity of the study were raised (Kunz et 
al., 2008b) and as a result, the paper was retracted.  
The use of combination approach of any RAAS blockers needs to be based on results from 
long-term outcomes studies. Each group of RAAS blockers may induce hyperkalemia and 
a combination approach may worsen this. Patients presenting with proteinuria are usually 
elderly, diabetic and suffer from renal insufficiency. Such conditions are usually associated 
with impaired potassium excretion and therefore, drugs induce hyperkalemia could lead to 
serious complications. Also, drug interaction is not uncommon in such patients. This could 
occur with the use of non-steroidal anti-inflammatory drugs which may lead to renal 
deterioration and agents that lead to hyperkalemia (e.g. potassium supplements and some 
frequently used anti-bacterial drugs in elderly females such as trimethoprim) (Velazquez et 
al., 1993, Harirforoosh and Jamali, 2009).  
The use of proteinuria as a surrogate marker for renal outcomes is another limitation of 
trials on RAAS blockade. For instance, the ONTARGET study showed that although 
treatment with a combination of ACEI and ARB reduced proteinuria (a surrogate marker), 
primary endpoint was increased (composite of death, need for dialysis or doubling of 
serum creatinine) (Mann et al., 2008). A meta-analysis of 70 randomised clinical trials 
concluded that there is insufficient evidence for the use of proteinuria as a surrogate 
outcome for progression of renal deterioration (Stoycheff et al., 2010). A scientific 
workshop sponsored by the American National Kidney Foundation and the US FDA 
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recommended that proteinuria can be used as a surrogate marker only in certain 
circumstances such as in nephrotic syndrome as the available evidence for the use of 
proteinuria as surrogate biomarker for  CKD is limited (Levey et al., 2009). The use of 
microalbuminuria as a surrogate endpoint for kidney outcomes is not justified by firm 
evidence. Microalbuminuria is increasingly recognised as a marker of endothelial 
dysfunction rather than renal impairment (Moody et al., 2012).  
In summary, there is some evidence of the use of ACEIs in type I diabetes mellitus for 
proteinuria but confounded by blood pressure differences. In type II diabetes mellitus, most 
of evidence is based on the use of ARBs but again most of benefit is due to blood pressure 
reduction.  Current evidence do not support the combination approach of ACEI/ARB and 
therefore; the clinical practice should be based on monotherapy with either ACEI or ARB 
depending on the tolerability with proper doses for better blood pressure control which 
would be translated into better renal outcomes. 
1.2.11.3 Calcium Channel Blockers  
The available data on the use of different classes of CCBs in patients with increased UAE 
is conflicting. It has been suggested that non-dihydropyridine CCBs  confer a better 
microalbuminuria lowering effect (Bakris et al., 2004). For instance, Smith et al. (Smith et 
al., 1998) compared the effect of diltiazem and nifedipine (a dihydropyridine CCB) on 
proteinuria in patients with type 2 diabetes mellitus. They reported that only diltiazem 
reduced proteinuria and improved glomerular permselectivity, while nifedipine did not 
produce any reduction in proteinuria. However, the magnitude of proteinuria change in 
each treatment group was imprecise mainly because of the small sample size (n=21).  
The African American Study of Kidney Disease and Hypertension (AASK) demonstrated 
that amlodipine increased proteinuria by 58% from baseline (Wright et al., 2002). 
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Nevertheless, the lack of a control group in this study makes it difficult to interpret the 
influence of amlodipine.  In contrast, some studies have shown renoprotective properties of 
dihydropyridine CCBs (Voyaki et al., 2001, Estacio et al., 2000). 
In the ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in 
Patients Living with Systolic Hypertension) trial, the renoprotection properties of 
benazepril/amlodipine versus benazepril/hydrochlorothiazide were evaluated in high-risk 
hypertension population (Bakris et al., 2010). The study showed that regression of 
microalbuminuria and gross proteinuria was greater in those who received fixed dose of 
benazepril/ hydrochlorothiazide. However, renoprotection (doubling of serum creatinine) 
with benazepril/amlodipine was superior to that with benazepril/hydrochlorothiazide. The 
study was criticised as the main endpoint was doubling of serum creatinine which could be 
a reflection of haemodynamic changes rather than preserving renal structure (Heerspink 
and de Zeeuw, 2010). A proper head to head comparison for renoprotection should be long 
enough to detect the rate of any structural changes which is translated to end stage renal 
disease, as some drugs have acute haemodynamic changes (Delles et al., 2003).   
The VVANNTT (Verapamil Versus Amlodipine in Nondiabetic Nephropathies Treated 
with Trandolapril) study showed no additive effect of combining amlodipine or verapamil 
with trandolapril compared with monotherapy with trandolapril (Boero et al., 2003). Data 
from the BENEDECT (Bergamo Nephrologic Diabetes Complications Trial) also provided 
no evidence of any effect of verapamil alone on lowering new onset microalbuminuria 
while trandolapril alone and trandolapril/ verapamil lowered the incidence of new onset 
microalbuminuria (Ruggenenti et al., 2004).  In the VVANNTT study, the follow-up 
period was relatively short (8 months). Also, limited number of subjects participated in this 
trial (69 patients).  The BENEDECT was mainly focusing on the incidence rate of new 
onset microalbuminuria in hypertensive diabetic subjects with normoalbuminuria. Thus, 
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whether verapamil helps in regressing albuminuria may not be answered in this study as 
participants were normoalbuminurics. Also, recent evidence suggests that new onset 
microalbuminuria occurred in patients under chronic treatment with RAS blockers (Cerezo 
et al., 2012).  
1.2.11.4 Beta-blockers and diuretics 
Several studies have examined the ability of beta-adrenoreceptor blocking agents in 
lowering albuminuria. For example, the GEMINI (Glycemic Effects in Diabetes Mellitus 
Carvedilol-Metoprolol Comparison in Hypertensives) trial reported that carvedilol reduced 
microalbuminuria and progression to microalbuminuria compared with metoprolol 
independently of BP reduction (Bakris et al., 2005). It has been suggested that the anti-
proteinuric effect might be explained by the putative antioxidant capability of carvedilol, 
since microalbuminuria pathogenesis involves oxidative stress. However, there is no 
evidence to support such argument. It was not clear whether in-treatment blood pressure 
was similar in the two groups. Nebivolol was also shown to have the ability to reduce 
proteinuria in a study involving 2,838 diabetic patients with hypertension and this was 
accompanied with significant blood pressure reduction (Schmidt et al., 2007).  
Early studies comparing beta blockers with ACEIs provided contradictory evidence. 
Several studies on patients with diabetic nephropathy and hypertension have shown that 
treatment with ACEIs produced reduction in albuminuria greater than with beta blockers 
(Nielsen et al., 1994, Nielsen et al., 1997). However, most of these studies involved small 
number of participants and/or short follow up. Other studies have reported comparable 
reduction of albuminuria using either beta blockers or ACEIs (Erley et al., 1993, Elving et 
al., 1994, Rudberg et al., 1999, UK Prospective Diabetes Study Group, 1998a). Again, the 
small sample sizes make these trials far from conclusive. 
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Most of the evidence of the ability of diuretics to lower proteinuria comes from studies 
where diuretics were used in combination with other antihypertensive drugs (Mogensen et 
al., 2003). Early evidence showed that treatment with metoprolol followed by addition of a 
thiazide diuretic significantly reduced UAE in patients with diabetic nephropathy 
(Christensen and Mogensen, 1987). The addition of thiazide diuretics to RAS blockers in 
patients with immunoglobulin nephropathy (Uzu et al., 2005) and in those with high 
sodium intake (Buter et al., 1998) significantly reduced blood pressure and proteinuria. 
Treatment with a combination of an ACEI and a diuretic was associated with reduction of 
new onset microalbuminuria and major cardiovascular events compared with subjects who 
received placebo (ADVANCE Collaborative Group, 2007). A recent trial showed that a 
combination of ARB and diuretic was superior to ARB plus CCB in reducing proteinuria 
after 12 weeks follow up (Matsui et al., 2011). The reduction in proteinuria was 
accompanied with reduction in nocturnal blood pressure. However, a significant reduction 
in eGFR was also reported with ARB/diuretic.  
Such finding support the need for well-designed studies with a long follow up period to 
exclude any potential temporary effect and also a more emphasis should be paid to the 
relation between blood pressure and proteinuria reduction. It seems that most of beneficial 
effect on proteinuria is driven by blood pressure change with a possible of minor additional 
changes in some classes that need to be documented properly. 
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2. Chapter two: Methodology 
2.1 Study population 
Subjects with hypertension attending either the GBPC at the Western Infirmary or the 
Aberdeen Hypertension Clinic at the Aberdeen Royal Infirmary participated in this series 
of studies. The final sample size was 1059 subjects. Out of 1059, 884 hypertensive subjects 
were attending the GBPC while the remainder (n=175) were followed at the Aberdeen 
Hypertension Clinic. Raw data from the Aberdeen Hypertension Clinic was provided by 
Professor John Webster. 
2.1.1 The Glasgow Blood Pressure Clinic 
The clinic was established in 1968 to provide consultant-led secondary/ tertiary service for 
the diagnosis and treatment of hypertensive subjects in the west of Scotland (Dunn et al., 
1990). The clinic maintains a registry containing the demographic and clinical information 
on more than 15,000 subjects. The GBPC is linked with the office of the Registrar General 
of Scotland which is responsible for recording all deaths, which means that the cause and 
date of death of the patients can be identified readily. 
Patients are usually referred to the clinic by their general practitioners or hospital 
specialist. Each patient is seen by a specialist nurse for blood pressure recording. At the 
first visit, clinical details of the patient are entered on a standardised form in order to 
facilitate their transfer to the electronic database. These details include patient’s height, 
weight, age, heart rate, family history of chronic diseases (hypertension, ischaemic heart 
disease, stroke, and diabetes) and sitting and standing systolic and diastolic blood 
pressures. In addition, the presence of co-morbidities or risk factors such as airways 
diseases, angina, cerebrovascular disease, alcohol intake, cigarette smoking, diabetes 
mellitus, heart failure, ischaemic heart disease, left ventricular hypertrophy, myocardial 
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infarction, peripheral vascular disease and renal impairment are included in the patient 
profile. The result of urine dipstick examination is also entered on the form.  
All patients undergo standardised clinical investigations such as serum biochemistry 
(including random glucose and lipid profile), haematology (complete blood count and 
ESR), spot urine specimen for blood and protein, mid stream specimen of urine for 
bacteriology, ECG and full blood count. Some patients may undergo other investigations 
when needed such as echocardiography, 24 hours ambulatory blood pressure monitoring, 
chest X-ray, retinal photography, plasma renin and aldosterone, exercise tolerance testing, 
computerised tomography and magnetic resonance imaging.  
Patients are usually followed after one month from their first visit where the results of 
clinical and laboratory investigations become available. The frequency of the subsequent 
clinic visits depends largely on the condition of each patient. New patients generally have 
more frequent visits during their first year until they reach the recommended blood 
pressure targets. 
2.1.2 The Aberdeen Hypertension Clinic 
The Aberdeen Hypertension Clinic was established in 1970 for hypertension-related 
research purposes (Webster et al., 1993). After that, the clinic started to provide a specialist 
service for the diagnosis and management of hypertension in patients living in the north-
east of Scotland.  The clinic provides a shared care system (Petrie et al., 1989). This means 
that hypertensive subjects are either followed by their general practitioners and the results 
of laboratory investigations and blood pressure records are sent to the clinic for specialist 
advice on how to manage their condition or they may attend the clinic at the Royal 
Infirmary to be seen by a specialist. Currently, more than 8,000 patients are registered in 
the shared care scheme. 
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Routinely collected data include complete blood count, lipids, glucose, height, weight, 
BMI, past medical history, urine electrolytes and drug intolerance history. 
2.2 Detection of microalbuminuria 
The detection of microalbuminuria in the two participating centres was standardised. A 
standard operating procedure form was distributed to the two clinics. This form included 
details of microalbuminuria screening and information needed from each participating 
subject. 
The protocol of detecting microalbuminuria was the same in the two study sites (the GBPC 
and the Aberdeen Hypertension Clinic) except for the method of screening for 
microalbuminuria in the first sample. At the GBPC, the detection of microalbuminuria was 
carried out using laboratory quantification while a semi-quantitative dipstick method was 
used at the Aberdeen Hypertension Clinic. Both sites used laboratory quantification of 
albuminuria in the subsequent samples. 
Laboratory detection of urinary albumin excretion was carried out using Architect c16000
®
 
analyser (Abbott Diagnostics, Maidenhead, UK) at the GBPC and an Advia 1200 
Chemistry System (Siemens Healthcare, Camberley, UK) at the Aberdeen Hypertension 
Clinic. Both machines use enzymatic assay to analyse the level of creatinine and 
turbidimetric immunoassay to analyse the level of albumin (Brook et al., 2012, Abbott 
Diagnostics, 2012). Microalbuminuria was expressed as mg/mmol.  
At the Aberdeen Hypertension Clinic, the initial detection of microalbuminuria was carried 
out using Clinitek Microalbumin 9 Reagent Strips (Siemens Medical Solutions 
Diagnostics, UK). These strips have a high sensitivity dye binding site for urinary albumin 
(Pugia et al., 1999) and another binding site for creatinine using peroxidase reaction (Pugia 
78 
 
et al., 2000). The colours yielded in the strips were further analysed using a Clinitek 50 
Urine Chemistry Analyzer (Siemens Medical Solutions Diagnostics, UK) for semi-
quantitative measurement of ACR and the results were expressed as milligrams albumin 
per gram or millimole creatinine (mg/mmol). 
2.2.1 Protocol for detecting microalbuminuria 
Each patient was invited to provide an early morning urine specimen for the assessment of 
albuminuria (in plain white topped container). Some of the patients were able to provide a 
urine sample during the clinic (9-11 A.M) while others were asked to collect urine on the 
morning of their next visits to the clinics. This sample was tested using Multistix 10 SG 
Reagent Strips (Siemens Healthcare Diagnostics, UK) for detecting leukocytes or nitrites 
as signs of urinary tract infection. If the dipstick showed positive result for leukocytes or 
nitrites, the sample was discarded and a mid-stream specimen of urine (in a red topped 
container) was sent for urine culture. When the result of urine culture showed no signs for 
urinary tract infection, the patients were requested to provide a new sample. Those with 
persisted UTI were excluded from my studies.  
The result of first urine specimen screening fell into one of four categories: 
a. Gross proteinuria: when albumin-to-creatinine ratio was greater than 25 
mg/mmol in males and females. 
b. Microalbuminuria according to the conventional (current) definition: when 
the ACR was > 2.5 mg/mmol and ≤ 25 mg/mmol in males or > 3.5 
mg/mmol and ≤ 25 mg/mmol in females (as females have skeletal muscle 
mass lower than in males). 
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c. Microalbuminuria according to a new definition (a low level of albuminuria 
which does not include the threshold level of the conventional definition): 
when ACR in males was from 1.2 to 2.5 mg/mmol or 1.7 to 3.5 mg/mmol in 
females. 
d. Normoalbuminuria: when the ACR was less than 1.2 mg/mmol in males or 
1.7 mg/mmol in females.  
The thresholds used in the new definition of microalbuminuria were selected as this is the 
current threshold used for classing patients with high normal UAE (de Jong and Curhan, 
2006). Patients from categories a, b and c (without evidence of urinary tract infection) were 
invited to provide two further first morning void (mid-stream) urine specimens for albumin 
estimation. Patients were asked to collect urine for the two samples just before their next 
visit to the clinics. 
2.3 Classifications of patients based on UAE 
Patients were considered as normoalbuminurics if the first sample showed normal UAE, 
where no further samples were requested, or when the results of two out of three samples 
showed normal UAE. Positive subjects were allocated to one of the three categories of 
albuminuria (microalbuminuria by the new definition, microalbuminuria by the 
conventional definition or gross proteinuria) based on the mean of the last two urine 
specimens. The selection of the last two samples is because laboratory quantification of 
albuminuria was used in both participating centres.  
2.4 Patient’s information included in the analysis  
Data were collected from the case-notes of the participating subjects.  Collected 
information included patient’s characteristics such as age, gender, SBP, DBP and BMI. In 
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addition, requests of laboratory tests such as serum total cholesterol level, serum HDL-
cholesterol level, eosinophil count, serum creatinine and plasma glucose (fasting specimen 
in the GBPC and random specimens at the Aberdeen Hypertension Clinic) were recorded. 
Information on risk factors and comorbidities such as type II diabetes mellitus, LVH and 
established cardiovascular disease (coronary heart diseases, stroke/transient ischaemic 
attack and peripheral vascular disease) was also collected. A complete list of all current 
cardiovascular and metabolic drugs was obtained. This included all antihypertensive agents 
(diuretics, CCBs, ACEIs, ARBs, beta-adrenoreceptor blockers, alpha-adrenoreceptor 
blockers, aldosterone antagonists and imidazoline receptor agonists), antidiabetic 
medications, lipid lowering agents (statins and others such as fibrates and ezetimibe), 
antiplatelet agents (mainly aspirin), anticoagulants and vasodilators (mainly nitrates). 
Some information was only available from patients attending the GBPC. This included 
fasting triglycerides, ESR, smoking status, evidence of ST-T changes on ECG and family 
history of type II diabetes mellitus, premature stroke or CHD.  
2.5 Laboratory and clinical measurements 
2.5.1 Blood pressure  
Both centres used the same procedure for recording blood pressure. Specialist hypertension 
nurses were responsible for measuring blood pressure readings. Prior to blood pressure 
measurement, each patient was requested to rest for 5 minutes in the supine or sitting 
position. Well-calibrated and maintained mercury sphygmomanometers ((Accoson 
Dekamet MK3, UK) at the GBPC and (Trimline Mercury Sphygmomanometer, Trimline 
Medical Products, Branchburg, New Jersey) at the Aberdeen Hypertension Clinic)) were 
used for measuring blood pressure. The arm was supported and positioned at heart level 
and any tight cloth were removed. Appropriate cuff size was selected. The cuff was 
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inflated over the brachial artery until disappearance of the pulse. This was followed by 
deflation of the cuff until the pulse re-appeared and this was recorded as estimated SBP. 
The cuff was re-inflated 30 mm Hg above the estimated SBP and a stethoscope was placed. 
After that, cuff was deflated at the rate of 2 mm Hg per second until the appearance of a 
rhythmic sound (SBP). Deflation was continued until disappearance of the sound (DBP). 
Blood pressure was measured twice and the mean was recorded. If the second 
measurement was significantly lower, a third reading was obtained and the mean of the last 
two readings was used.  
The pulse pressure was defined as the difference between the SBP and DBP (i.e. SBP 
minus DBP). The therapeutic target for blood pressure was defined as SBP < 140 mm Hg 
and DBP < 90 mm Hg.  
2.5.2 Obesity 
Obesity was defined as BMI equal to or more than 30 kg/m
2
, according to the World 
Health Organisation classification of underweight, overweight and obesity in adults 
(WHO, 2000). A BMI between 25 and 29.99 kg/m
2
 was used to define pre-obesity “over-
weight” while values between 18.5 to 24.99 was considered as optimal weight. The body 
weight was measured using calibrated weighing machines (Seca 955 chair scale at the 
GBPC and a Seca Delta Model 707 at the Aberdeen Hypertension Clinic, Brash & Sons, 
UK). Patients were instructed to remove any heavy clothes before measuring their weight. 
The height was measured by a height stick in both clinics. 
2.5.3 Diabetes mellitus 
Patients with type II diabetes were identified based on either the diagnosis by the 
responsible clinician, patient report, the use of antidiabetic agents or when the fasting 
glucose level was ≥7.0 mmol/l or the random blood glucose ≥11.1mmol/L (WHO, 2006) 
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(for those who do not have fasting result). Serum glucose was measured by enzymatic 
colorimetric technique (hexokinase assay) using an Architect c16000 analyser (Abbott 
Diagnostics, Maidenhead, UK) in Glasgow and an Advia 2400 Chemistry System 
(Siemens Healthcare, Camberley, UK) in Aberdeen. At the GBPC, fasting serum glucose 
was requested. Patients were instructed not to take any food for at least 8 hours before the 
test. Patients were advised to attend at 9.00 for performing the test. Random serum glucose 
samples were obtained for subjects attending the Aberdeen Hypertension Clinic. 
2.5.4 Renal function 
Renal function was evaluated using estimated glomerular filtration rate (eGFR). The eGFR 
was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) 
equation (Levey et al., 1999): 
eGFR= 32788 × serum creatinine ( in µmol/L) 
-1.154
 × age 
-0.203
 * (1.212 if black) × (0.742 
if female) 
Data about race was not available but it has been reported that less than 0.5% of the 
Scottish population are black/African (The Scottish Government, 2004).  Serum creatinine 
(expressed as µmol/L) was measured using the Jaffè reaction method using the Abbott 
Architect c16000 analyser in Glasgow and the Siemens Advia 2400 analyser in Aberdeen. 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI) classification was followed for defining different CKD stages (Levey et al., 
2003). An eGFR of more than or equal to 60 mL/min/1.73 m
2
 were considered as normal 
kidney function. CKD stage 3 was defined as an eGFR result between 30-59 mL/min/1.73 
m
2
 while stage 4 and 5 was defined as eGFR between 15-29 mL/min/1.73 m
2
 and < 15 
mL/min/1.73 m
2
, respectively.  
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In the main analysis, subjects with CKD stage 4 or 5 were excluded. This is because 
advanced CKD disease is usually associated with gross proteinuria. Those with stage 3 
CKD were included to allow for older participants as increased age is associated with 
progressive reduction in eGFR (Douville et al., 2009).  
2.5.5 Hyperlipidemia 
Total cholesterol and HDL were estimated using enzymatic colorimetric assay techniques 
from non-fasting samples by the Abbott Architect c16000 analyser in Glasgow and the 
Siemens Advia 2400 analyser in Aberdeen. The enzymatic colorimetric assay (by Architect 
c16000 analyser) was also used for measuring fasting triglycerides in Glasgow. Increased 
total cholesterol level was defined as values exceeded 5 mmol/L (Cooper and O’Flynn, 
2008). The normal ranges for HDL-cholesterol and fasting triglycerides are > 1.0 mmol/L 
and <2.3 mmol/l, respectively (Manninen et al., 1992). 
2.5.6 Haematological indices 
ESR was measured in subjects attending the GBPC using StaRRsed III Chemistry analyser 
(Mechatronics, Zwaag, the Netherlands). Eosinophil count was estimated using an XE-
2100 Blood Cell analyser (Sysmex, Kobe, Japan) in Glasgow and Advia 2120i 
Haematology analyser (Siemens Healthcare Diagnostics, UK) in those attending the 
Aberdeen Hypertension Clinic. 
The normal range for eosinophil count is 0.04–0.44 x 109/L (Provan, 2005). There was no 
specific threshold value for ESR. However, it has been suggested that levels between 1 to 
10 mm in one hour can be considered as normal (Hilder and Gunz, 1964).  
84 
 
2.5.7 Left ventricular hypertrophy and ECG changes 
Patients with LVH or ECG changes (ST-T wave) were identified according to the 
diagnosis of the attending clinician and their comments on the patient’s case-records. The 
criteria for diagnosing LVH on ECG were (Goldman, 1973): 
1. Standard leads: the voltage of R1 + S3 > 26 mm. 
2. Extremity leads: an R wave > 13 mm. 
3. Precordial leads: the total voltage of (SV1 + RV5) or (SV1 + RV6) is > 35 mm, or an 
R > 27mm in V5 or V6. 
Diagnosis of LVH on echocardiography was based on reports for echocardiography 
laboratory. 
2.5.8 Family history of cardiovascular / metabolic diseases, 
smoking status and cardiovascular co-morbidities 
Information regarding smoking status, co-morbidities and family history of CHD, stroke or 
diabetes mellitus was obtained from patient’s case-records. Upon their first visit, patients 
are questioned by a specialist nurse and/or the attending physician about such information 
and a copy is kept in the case-record. In addition this information is transferred to an 
electronic database. 
2.6 Inclusion/ exclusion criteria 
All patients attending the GBPC or the Aberdeen Hypertension Clinic were invited to 
participate to the study. Those with secondary hypertension, persistent UTI (n=22) or age 
less than 18 years were excluded. No patient with type I diabetes mellitus was included in 
the study. 
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2.7 The GBPC database 
Since the establishment of the GBPC, the clinical characteristics of attending patients have 
been transferred to an electronic database for audit and research purposes. The database 
nowadays stores the information of more than 15,000 patients.  
At each visit, the stored information includes the date of the visit, SBP and DBP and heart 
rate. In addition, the database contains the demographic characteristics for each patient 
(such as age, gender, BMI, smoking status and alcohol intake) and drug(s) used and their 
doses, duration of treatment and stop date, if any, and possible side effects. The results of 
baseline (first visit) dipstick for proteinuria are also entered in the database. Some of the 
patients may have more than one result for proteinuria dipstick examination.  
Other information such as type of hypertension (essential or secondary) and co-morbidities 
(such as airways disease, angina, cerebrovascular disease, diabetes, heart failure, ischaemic 
heart disease, LVH, myocardial infarction, peripheral vascular disease (PVD) and renal 
impairment) are frequently entered and updated in the electronic database. 
2.8 Cardiovascular risk estimation 
All cardiovascular risk scores were derived from the original Framingham Heart Study 
equation and the Joint British Societies (JBS) cardiovascular disease risk formula.  
2.8.1 The Framingham risk score system  
Cardiovascular disease risk calculation was based on the original Framingham formula 
(Wilson et al., 1998). Variables that are required for risk stratification are age, gender, 
smoking status, SBP, presence of diabetes mellitus, LVH, total cholesterol and HDL-
cholesterol. HDL was assumed as 1 mmol/L when actual data were missing (n=11). 
Individuals with already established CVD were excluded from the calculation. Ten-year 
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cardiovascular risk was selected as the Framingham equation can predict risk within the 
next 4 to 12 years. Ideally, the diagnosis of LVH should be based on the 
electrocardiographic criteria of the Framingham study. However, the inclusion of LVH in 
the risk prediction was based on the diagnosis of LVH by the attending clinician, mainly 
based on ECG traces. The Framingham risk score was calculated using a software written 
by Dr. Rupert Payne, University of Edinburgh (Payne, 2010) which permits risk 
calculation in large number of patients. The following outcomes were calculated from the 
Framingham heart study equation: 
1. The probability of developing any CVD over the next 10 years. 
2. The probability of developing CHD over the next 10 years (including angina 
pectoris, myocardial infarction, death from CHD and coronary insufficiency).  
3. The probability of developing stroke or transient ischaemic attack over 10 years. 
4. The probability of developing myocardial infarction over 10 years. 
5. The probability of dying from CHD over 10 years. 
6. The probability of dying from CVD over 10 years. 
Subjects were considered as high risk group when the overall CVD risk(s) was greater than 
20% over 10 years. Moderate risk group was defined as having CVD of 10% to 20% over 
than next 10 years and those who had less than 10% CVD risk were considered as low risk 
group. 
2.8.2 The JBS cardiovascular risk equation 
The JBS risk scoring system which is based on the Framingham algorithm was used to 
evaluate the cardiovascular risk in those without established CVD, diabetes or LVH as 
subjects with these diseases are considered as high risk population (British Cardiac Society 
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et al., 2005). The formula uses age, gender, SBP, smoking status and total cholesterol: 
HDL ratio. For those with missing HDL values, HDL was assumed to be 1 mmol/L. The 
cardiovascular risk score was computed using the CHD and Stroke Risk Assessor, 
University of Manchester. The JBS recommends that subjects who stopped smoking within 
the last 5 years should be considered as smokers. However, as this option was not feasible 
as direct contact with patients was not possible, “smoker” option was selected for current 
smokers only. 
The outcome measured by the JBS formula was the probability of developing any 
cardiovascular event (angina pectoris, myocardial infarction, stroke, stroke death or CHD 
death) over 10 years. Similar to the Framingham scoring system, high risk group were 
defined as having more than 20% risk while moderate and low risk groups were defined as 
having 10-20% and < 10% CVD risk, respectively.  
It should be noted that all variables used in the Framingham or the JBS equations should be 
based ideally on untreated variable. However, in this analysis, most variables were based 
on treated values which would tend to reduce risk estimation. 
2.9 Ethical approval 
The protocol for the studies was reviewed by the chairs of the ethics committees in 
Glasgow and Aberdeen. Since the project did not require patient interventions, it was 
deemed that formal ethical approval was not required. 
2.10 Statistical analysis 
2.10.1 Statistical packages used 
Statistical analysis was performed using Minitab statistical software version 16.2.1 
(Minitab Inc., State College, Pennsylvania, USA) and Statistical Package for the Social 
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Sciences (SPSS) software for Microsoft Windows version 19.0 (IBM Corporation, 
Armonk, New York, US).  
2.10.2 Summary statistics 
Quantitative variables were summarized using mean ± standard deviation or median and 
interquartile range where data were not normally distributed. Some of the data that were 
not normally distributed were transformed using the natural logarithm (the logarithm to the 
base e) and back-transformed to the original scale and represented as geometric mean with 
95% confidence interval. Categorical data were summarised as percentage of the cohort. 
The differences between any groups were considered to be significant when P value was 
less than 0.05.  
2.10.3 Comparison of two means 
For normally distributed continuous data, the difference between any two groups was 
compared using a 2 sample t test. When data were not normally distributed, the Mann-
Whitney test was used for assessing mean difference. Categorical data were compared 
using Chi-square or Fisher’s exact test for small sample size (for observations less than 5). 
2.10.4 Comparison of more than two means 
One-way analysis of variance (ANOVA) was used to compare the means of more than two 
groups when data showed normal distribution. The Kruskal–Wallis method was used when 
data were skewed. For categorical data, groups were compared using Chi-square or Fisher 
exact tests, as appropriate. Linear association in categorical data was examined using chi-
square test for trend. 
When the result of ANOVA test was significant, a post-hoc statistical analysis using 
Tukey’s method was used to identify which group was significantly different from the 
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others (within-groups comparison). The mean difference for each pairwise comparison was 
reported (95% confidence interval of mean difference).  
To allow within-groups comparisons for skewed data (e.g. ESR, eosinophil count and 
fasting triglycerides), natural logarithmic transformation was used to achieve normal 
distribution. This was followed by testing the trend using ANOVA and data were back-
transformed to the original scale and represented as geometric mean with 95% confidence 
interval. For variables with significant result with ANOVA test, multiple group 
comparison using Tukey’s method was carried out and expressed as geometric mean ratio 
with 95% confidence intervals for the ratio of the geometric mean. In categorical data, Z-
test was used for pairwise comparison when the overall P value was significant. 
2.10.5 Logistic regression 
Binary logistic regression method was performed to investigate the association of binary 
outcome with possible predictors. Predictors were added either using a stepwise backward 
elimination method or selected based on previously known possible interaction between 
the outcome and the predictors. In the stepwise backward method, all covariates are placed 
in the first model and those with no significant contribution to the model were excluded. 
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3. Chapter three: prevalence of microalbuminuria in 
hypertensive population and its association with 
cardiovascular risk factors and metabolic 
abnormalities 
3.1 Introduction 
The reported prevalence of microalbuminuria varies widely (ranging from 4.7% to 58.4%) 
(Jensen et al., 1997, Böhm et al., 2007). This variability may be due to several factors such 
as the population studied, detection method and diagnostic criteria. While international 
therapeutic guidelines recommend that the diagnosis of microalbuminuria should be based 
on repeated samples due to the high variability of albumin excretion in the urine (National 
Collaborating Centre for Chronic Conditions, 2008), the vast majority of studies of 
microalbuminuria in hypertensive subjects have been based on single measurements 
(Leoncini et al., 2010). In addition, in studies where microalbuminuria prevalence was 
high, the population studied had concomitant other risk factors. For example, in two 
studies of untreated hypertensive subjects where the prevalence of microalbuminuria was 
high (≥25%), (Pedrinelli et al., 2003, Pedrinelli et al., 2004) about three-quarters of the 
studied subjects had LVH. Most people with high blood pressure do not have end organ 
damage. Therefore, the exact prevalence of microalbuminuria prevalence in hypertensive 
subjects is still unclear.  
The current thresholds used to define microalbuminuria in spot urine samples (ACR >2.5 
mg/mmol in males and > 3.5 mg/mmol in females) is arbitrary and may underestimate the 
clinical significance of this condition. There is evidence that levels of microalbuminuria 
below the conventional cut-off levels are associated with increased cardiovascular risk in 
general population (Hillege et al., 2002). 
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The purpose of this analysis was to assess the prevalence of microalbuminuria (using two 
definitions) in a large population of hypertensive subjects attending secondary/tertiary 
referral centres.  The definitions were the conventional limits for microalbuminuria and a 
new definition with a threshold about 50% lower than that of the conventional definition. I 
also aimed to examine the association of microalbuminuria with cardiovascular, renal and 
metabolic parameters. 
3.2 Methods 
This analysis used data collected from 1059 hypertensive subjects attending the Glasgow 
Blood Pressure Clinic or the Aberdeen Hypertension Clinic. Microalbuminuria was 
defined as ACR >2.5-25 in males or >3.5-25 in females (conventional definition) or ACR 
1.2-2.5 in males or 1.7-3.5 in females (new definition) while gross proteinuria was defined 
as ACR > 25 in both genders. Each patient had urinary albumin estimation. For those with 
positive microalbuminuria, two further samples were requested. Patients with CKD stage 4 
or 5, type II diabetes mellitus or gross proteinuria were not included in the main analysis as 
they usually have increased UAE due to kidney disease.  
Demographic and clinical characteristics were compared between subjects with 
microalbuminuria and those with normal UAE. Variables studied were age, gender, blood 
pressure, BMI, serum creatinine, eGFR, serum lipids (total cholesterol, HDL-cholesterol 
and fasting triglycerides), fasting and random blood glucose and inflammatory markers 
(ESR and eosinophil count). Normally distributed data are expressed as mean ± standard 
deviation while skewed data are expressed as median (interquartile range). The groups 
were compared using a 2 sample t test or Mann-Whitney test, as appropriate. One-way 
ANOVA or Kruskal Wallis tests were used to compare more than two groups, as 
appropriate. Between-groups comparisons using Tukey’s procedure were used with 
variables that showed significant trend using ANOVA test. To allow between-groups 
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comparison for skewed data (fasting triglycerides, eosinophil cont and ESR) natural 
logarithmic transformation was used and variables were expressed as geometric mean 
(95% confidence interval). Gender differences were assessed using chi-square test. 
3.3 Results 
3.3.1 Study population: 
Figure ‎3-1 illustrates the inclusion profile. Urine was collected from 1081 individuals. 
Twenty two patients were excluded since repeated urine specimens suggested urinary tract 
infection. Of 1059 individuals who had urinary albumin estimation, 116 subjects had 
positive microalbuminuria on initial screening but failed to provide repeat samples and 
were not included in the main analysis. Among the remainder (n= 943), 125 had type II 
diabetes mellitus. Thirteen patients had gross proteinuria and 6 patients had CKD stage 4 
or 5. Missing data from 13 patients (mainly serum creatinine) precluded calculation of 
eGFR. After excluding the previously mentioned individuals, 786 patients were eligible for 
investigation of the prevalence of microalbuminuria in hypertensive subjects without 
evidence of type II diabetes or severe renal impairment (CKD stage 4 & 5 or gross 
proteinuria). 
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Figure ‎3-1: Flowchart of the study. 
 
3.3.2 Patient characteristics 
Table ‎3-1 summarises the demographic characteristics of the study population (n=1059). 
The mean age of the study population was 58 ± 14.9 years; 54% were females (detailed in 
chapter 4). More than 75% had a body mass index above 25 kg/m
2
, with an average value 
of 30.0 ± 6.1 kg/m
2
. Approximately 45% of total study population had a BMI of 30 kg/ m
2
 
or more.   
The mean SBP was 140.5 ± 19.5 mm Hg. Nearly 42% of the patients had a SBP more than 
or equal to 140 mm Hg (above the target). The mean DBP was 86.9 ± 11.4 mm Hg. About 
45% of patients had DBP of more than or equal to 90 mm Hg. 
The mean serum creatinine level in the population was 85.4 ± 25.6 µmol/L. Only 4% of the 
patients had a serum creatinine level of more than 130 µmol/L. The mean eGFR was 78.3 
±19.5 mL/min/1.73 m
2
. About 12% of the patients had stage 3 CKD. Fasting blood glucose 
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was estimated in 718 patients and the mean was 5.4 ± 1.4 mmol/L. For those who do not 
have fasting specimen, the median random glucose level was 5.4 mmol/l (interquartile 
range, 4.9 to 6.7).  
Mean total cholesterol level was 5.1 ± 1.1 mmol/L, with a mean HDL-cholesterol level of 
1.4 ± 0.47 mmol/L. More than 50% of the patients had a cholesterol measurement of ≥ 5 
mmol/L. Fasting triglycerides was estimated in nearly 67% of the population. The mean 
value for fasting triglycerides was 1.5 ± 0.90 mmol/L (median= 1.3; interquartile range, 0.9 
to 1.9).  
With regards to the inflammatory marker, ESR was estimated in nearly 61% of the total 
population. The median ESR was 8 mm in 1 hour (interquartile range, 5 to 16). Out of 650 
patients with ESR measurement, 40% had an ESR estimation of > 10 mm in 1 hour. 
Eosinophil count test were performed in 92% of the patients and the mean value was 0.19 
± 0.14 ×10
9
/L (median = 0.16, 0.1 to 0.25). The median number of cardiovascular and 
metabolic drugs used was 3 (interquartile range, 1 to 5). 
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Variable N Mean SD Median 
Interquartile range 
25% 75% 
Age (years) 1058 58.0 14.9 59.0 48.0 69.0 
BMI  (Kg/m
2
) 1029 30.0 6.1 29.1 25.8 33.1 
SBP (mm Hg) 1054 140.5 19.5 136 126.0 152.0 
DBP (mm Hg) 1054 86.9 11.4 88 80.0 94.0 
Serum creatinine (µmol/L) 1047 85.4 25.6 81.0 70.0 94.0 
eGFR (mL/min/1.73 m
2
) 1046 78.3 19.5 77.9 65.4 91.5 
Fasting glucose (mmol/L) 718 5.4 1.4 5.2 4.8 5.7 
Random glucose (mmol/L) 265 6.2 2.4 5.4 4.9 6.7 
Total cholesterol (mmol/L) 1033 5.1 1.1 5.0 4.3 5.8 
HDL-cholesterol (mmol/L) 1022 1.4 0.47 1.3 1.1 1.6 
Fasting triglycerides (mmol/L) 709 1.5 0.9 1.3 0.9 1.9 
Eosinophil count (×10
9
/L) 980 0.19 0.14 0.16 0.1 0.25 
ESR (mm in 1 hour) 650 13.7 23.9 8.0 5.0 16.0 
Number of drugs used* 1035 3.1 2.2 3.0 1.0 5.0 
Table ‎3-1 : Demographic data of the study population (n= 1059). * Cardiovascular / 
metabolic drugs. 
 
 
3.3.3 Demographic characteristics of non-diabetic hypertensive 
subjects without evidence of severe renal impairment 
Table ‎3-2 summarises the clinical characteristics of those without evidence of severe renal 
impairment (CKD stage 4 or 5) or diabetes (n=786). The mean age was 56.5 ± 14.8 years. 
Approximately 40% of the subjects were obese, with an average BMI of 29.5 ± 5.8 kg/m
2
. 
The mean SBP and DBP in this cohort were 140 ± 18.3 mm Hg and 87 ± 10.8 mm Hg, 
respectively. About 42% of the subjects had a SBP ≥ 140 mm Hg and 47% had a DBP 
record ≥ 90 mm Hg.  
The mean serum creatinine level and eGFR in this cohort were 82.6 ± 18.1 µmol/L and 
80.1 ±18.1 mL/min/1.73 m
2
, respectively. Seventy eight patients (10%) had stage 3 CKD. 
While more than 90% of the cohort had an estimation of eosinophil count, ESR was 
measured in only 60% of the subjects. The median of eosinophil count and ESR were   
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0.16 ×10
9
/L (interquartile range, 0.10 to 0.24) and 7 mm in 1 hour (interquartile range, 4 to 
15), respectively. 
The mean total cholesterol and HDL-cholesterol level in this cohort were 5.2 ± 1 mmol/L 
and 1.5 ± 0.5 mmol/L, respectively. More than half of the subjects had an estimation of 
total cholesterol of more than 5 mmol/L. The median fasting triglycerides was 1.2 
(interquartile range, 0.9 to 1.8). Fasting blood glucose was estimated in 561 patients with 
an average value of 5.2 ± 0.6 mmol/L while the mean random blood glucose in 184 
subjects was 5.5 ± 1.1 mmol/L. The median number of cardiovascular or metabolic drugs 
used in this cohort was 3.0 (interquartile range, 1.0 to 4.0). 
Variable N Mean SD Median 
Interquartile range 
25% 75% 
Age (years) 786 56.5 14.8 57.0 46.0 68.0 
BMI (Kg/m
2
) 769 29.5 5.8 28.7 25.4 32.3 
SBP (mm Hg) 784 139.8 18.3 136 126 150 
DBP(mm Hg) 784 87.3 10.8 88 80 93 
Serum creatinine (µmol/L) 786 82.6 18.1 79.0 70.0 93.0 
eGFR (mL/min/1.73 m
2
) 786 80.1 18.1 78.7 67.0 92.4 
Fasting glucose (mmol/L) 561 5.2 0.6 5.1 4.8 5.5 
Random glucose (mmol/L) 184 5.5 1.1 5.2 4.8 5.7 
Total cholesterol (mmol/L) 771 5.2 1.0 5.1 4.4 5.9 
HDL-cholesterol (mmol/L) 766 1.5 0.5 1.4 1.1 1.7 
Fasting triglycerides (mmol/L) 556 1.5 0.9 1.2 0.9 1.8 
Eosinophil count (×10
9
/L) 733 0.18 0.13 0.16 0.10 0.24 
ESR(mm in 1 hour) 480 11.9 12.7 7.0 4.0 15.0 
Number of drugs used* 766 2.7 1.9 3.0 1.0 4.0 
Table ‎3-2: Demographic characteristics of hypertensive subjects without diabetes, CKD 
(stage 4 or 5) or proteinuria (n=786). * Cardiovascular / metabolic drugs. 
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3.3.4 Demographic characteristics of non-diabetic subjects 
without severe renal impairment stratified by gender  
Table ‎3-3 represents demographic characteristics by gender in non-diabetic subjects 
without severe renal impairment (n=786). Males had mean age (53.2 ±13.8 years), lower 
than in females (59.3 ± 14.9 years) (P <0001). Both males and females had mean BMI of 
about 30 kg/m
2
. Males had mean SBP (137.8 ± 16.8 mm Hg) lower than in females (141.3 
± 19.3 mm Hg) (P<0.001). About 45% of female subjects had a SBP record of ≥ 140 mm 
Hg compared with 32% in male subjects. Males had higher mean DBP (88.3 ± 10.1 mm 
Hg in males versus 86.5 ±11.3 mm Hg in females) and the proportion of male subjects who 
had mean DBP of  ≥ 90 mm Hg was higher than in females; 51% and 45% ,respectively. 
Male subjects had mean serum creatinine higher than in females (91.1 ± 17.6 µmol/L 
versus 75.4 ± 15.1 µmol/L) (P<0.001).  Less than 3% and 1% of male and female 
respectively had serum creatinine level of more than 130 µmol/L. Although males had 
higher creatinine level, the mean eGFR in men was higher than in females; 84.4 ±18.2 and 
76.5 ± 17.2 mL/min/1.73 m
2 
(P<0.001), respectively. Fasting blood glucose was higher in 
males than in females; mean 5.2 ± 0.6 mmol/l and 5.1 ± 0.6 mmol/l (P=0.006), 
respectively. However, random serum glucose was not different. 
The mean total cholesterol level was significantly higher in females than in males (5.2 ±1.0 
mmol/L in females versus 5.0 ± 1.0 mmol/L in males, P<0.001). Likewise, HDL-
cholesterol level was higher in females than in males; 1.6 ± 0.4 mmol/L versus 1.3 ± 0.5 
mmol/L (P=0.003), respectively. Females had median triglycerides level (1.3; interquartile 
range, 0.9 to 1.7 mmol/L lower than in males (1.7; interquartile range, 1.0 to 2.1) 
(P<0.001).  
The median ESR was significantly lower in males (5 mm in 1 hour; interquartile range 2 to 
10) than in females (10 mm in 1 hour; interquartile range, 5 to 18). Only one quarter of 
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male subjects had an ESR of more than 10 mm in 1 hour. In contrast, more than 45% of 
female subjects had an ESR of more than 10 mm in 1 hour. Eosinophil count was         
lower in females than in males; mean 0.17 ± 0.13×10
9
/L and 0.20 ± 14×10
9
/L (P=0.016), 
respectively. Approximately 5% in each gender had eosinophilia. The median number of 
cardiovascular and metabolic drugs was not statistically different between males and 
females. 
 
Variable N Male  N Female P-value 
Age (years) 359 53.2 ± 13.8 427 59.3 ± 14.9 <0.001 
BMI (Kg/m
2
) 353 29.7 ± 5.1 416 29.3 ± 6.3 0.307 
SBP (mm Hg) 358 137.8 ± 16.8 426 141.3 ± 19.3 <0.001 
DBP (mm Hg) 358 88.3 ± 10.1 426 86.5 ± 11.3 <0.001 
Serum creatinine (µmol/L) 359 91.1 ± 17.6 427 75.4 ±15.1 <0.001 
eGFR (mL/min/1.73 m
2
) 359 84.4 ± 18.2 427 76.5 ± 17.2 <0.001 
Fasting glucose (mmol/L) 255 5.3 ± 0.6 306 5.1 ± 0.6 0.006 
Random glucose (mmol/L) 85 5.5 ± 1.1 99 5.5 ± 1.2 0.914 
Total cholesterol (mmol/L) 352 5.0 ± 1.0 419 5.2 ± 1.0 <0.001 
HDL-cholesterol (mmol/L) 351 1.3 ± 0.5 415 1.6 ± 0.4 0.003 
Fasting triglycerides (mmol/L) 252 1.7 (1 to 2.1) 304 1.3 (0.9 to 1.7) <0.001 
ESR (mm in 1 hour) 210 5 (2 to 10) 270 10 (5 to 18) <0.001 
Eosinophil count (×10
9
/L) 337 0.2 ± 1.4 396 0.17 ± 0.13 0.016 
Number of drugs used* 414 2.0 (1 to 4) 352 3.0 (1 to 4) 0.510 
Table ‎3-3: Demographic characteristics of non-diabetic hypertensive subjects without 
severe kidney impairment stratified by gender (n=786). Variables are expressed as mean ± 
SD or median (interquartile range), as appropriate. * Cardiovascular / metabolic drugs. 
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3.3.5 Demographic data in subjects with hypertension and type II 
diabetes mellitus: 
The demographic and clinical characteristics of diabetic patients with essential 
hypertension are listed in table ‎3-4. The genders were equally distributed in this cohort. 
The average age was 65 ± 12.2 years which is higher than mean age of non-diabetic 
subjects. Diabetic subjects were characterised by increased BMI, with a mean value of 33 
± 6.7 Kg/m
2
. The median SBP (134.0 mm Hg; interquartile range, 124.0 to 150.0) and 
mean DBP (81.4 ± 10.7 mm Hg) were slightly lower than in non-diabetic individuals. 
Diabetic subjects tended to have high serum creatinine (median 88 µmol/L; interquartile 
range, 77.0 to 104.5) and low eGFR (mean 69.8 ± 22.0 mL/min). The median fasting 
glucose level in the cohort (7.3 mmol/L; interquartile range, 5.6 to 8.8) was higher than the 
median fasting glucose level of non-diabetic individuals. Similarly, random glucose was 
higher than that in non-diabetic subjects; median 8.9 mmol/l (interquartile range, 7.1 to 
11.9). Compared with the non-diabetic cohort, the median of inflammatory markers in 
diabetic subjects were higher; 0.23 × 10
9
 /L (interquartile range, 0.15 to 0.31) for 
eosinophil and 11 mm in 1 hour for ESR (interquartile range, 5 to 28).  
The median total cholesterol level, HDL-cholesterol and fasting triglycerides were 4.3 
mmol/L (interquartile range, 3.6 to 5.1), 1.1 mmol/L (interquartile range, 1.0 to 1.4) and 
1.4 mmol/L (interquartile range, 1.1 to 2.0), respectively. While total cholesterol and HDL-
cholesterol were lower than that observed in non-diabetic subjects, fasting triglycerides 
were higher than in non-diabetics. High number of drugs was used in this cohort (median 
2.2, interquartile range, 4.0 to 7.0). 
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Variable N Mean SD Median 
Interquartile range 
25% 75% 
Age (years) 125 64.9 12.2 66.0 56.0 75.0 
BMI (Kg/m
2
) 121 33.0 6.7 32.0 28.0 36.4 
SBP (mm Hg) 123 139.3 20.7 134.0 124.0 150.0 
DBP (mm Hg) 123 81.4 10.7 82.0 75.0 88.0 
Serum creatinine (µmol/L) 125 95.5 29.3 88.0 77.0 104.5 
eGFR (mL/min/1.73 m
2
) 125 69.8 22.0 69.0 53.8 86.0 
Fasting glucose (mmol/L) 79 7.7  2.8 7.3 5.6 8.8 
Random glucose (mmol/L) 38 9.4 3.7 8.9 7.1 11.9 
Total cholesterol (mmol/L) 123 4.4 1.1 4.3 3.6 5.1 
HDL-cholesterol (mmol/L) 123 1.2 0.36 1.1 1.0 1.4 
Fasting triglycerides (mmol/L) 78 1.6 0.77 1.4 1.1 2.0 
Eosinophil count (×10
9
/L) 117 0.24 0.15 0.23 0.15 0.31 
ESR (mm in 1 hour) 78 18.7 19.5 11.0 5 28 
Number of drugs used* 125 5.4 6.0 2.2 4.0 7.0 
Table ‎3-4: Clinical characteristics of subjects with hypertension and type II diabetes 
mellitus (n=125). * Cardiovascular / metabolic drugs. 
 
 
 
3.3.6 Prevalence of microalbuminuria and gross proteinuria 
3.3.6.1 Prevalence in general hypertension population (n=943): 
According to the conventional definition, microalbuminuria was present in 104 patients 
(11%). When a lower cut-off level was used (i.e. the new definition), a further 105 patients 
(11.1%) were added, making the total prevalence according to both new and conventional 
definitions 22% (figure ‎3-2). Gross proteinuria, defined as ACR greater than 25, was found 
in only 27 patients (3%). 
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Gross proteinuria
MAU by conventional definition
MAU by new definition
Normal UAE
Categories:
75.0%
11.1%
11.0%
2.9%
 
 
 
Gross proteinuria
MAU by new & conventional def.
Normal UAE
Categories:
75.0%
22.2%
2.9%
 
Figure ‎3-2: Prevalence of microalbuminuria (MAU) in the study population (n=943). 
 
3.3.6.2 Prevalence in subjects with hypertension and type II diabetes 
mellitus (n=125): 
Microalbuminuria, according to the conventional definition, was present in 25 patients 
(20%). Another 25 patients had low ACR and met the criteria of the new definition, 
making the total prevalence to be 40%. The prevalence of gross proteinuria in this cohort 
was 9.6% (figure ‎3-3). It should be noted that nearly half of subjects with gross proteinuria 
in the overall population (n=943) were diabetics.  
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Gross proteinuria
MAU by new definition
MAU by conventional definition
Normal UAE
Categories:
50.4%
20.0%
20.0%
9.6%
 
 
Gross proteinuria
MAU by new & conventional def.
Normal UAE
Categories:
50.4%
40.0%
9.6%
 
Figure ‎3-3: Prevalence of microalbuminuria in hypertensive patients with type II diabetes. 
  
3.3.6.3 Prevalence in non-diabetic hypertensive subjects without evidence 
of severe renal impairment (n= 786): 
After excluding subjects with severely reduced renal function (stage 4 CKD), those with 
end-stage renal failure (stage 5 CKD), subjects with gross proteinuria and those with 
diabetes, the prevalence of microalbuminuria using the conventional definition was 9.5% 
(figure ‎3-4). When the new definition was used, the prevalence of microalbuminuria was 
increased by 9.9% and combining the two definitions results in a prevalence of 19.5%.  
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MAU by conventional definition
MAU by new definition
Normal UAE
Categories:
80.5%
9.9%
9.5%
 
 
 
MAU by new & conventional def.
Normal UAE
Categories:
80.5%
19.5%
 
Figure ‎3-4: Prevalence of microalbuminuria in non diabetic hypertensive subjects without 
severe renal impairment. 
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3.3.7 Demographic characteristics of non-diabetic subjects 
without severe renal impairment stratified by urinary 
albumin excretion: 
A comparison of demographic characteristics between people with normoalbuminuria and 
microalbuminuria (by the two definitions) is shown table ‎3-5. Between groups statistical 
comparisons are shown in table ‎3-6. 
3.3.7.1 General characteristics: 
The mean age of subjects with microalbuminuria according to the conventional definition 
was significantly higher than that in subjects without albuminuria, 62 ± 16.1 years versus 
55 ± 14.1 years, respectively (P=0.001). Likewise, subjects with microalbuminuria 
according to the new definition had a higher mean age compared with individuals with 
normoalbuminuria, 61 ± 16.4 years versus 55 ± 14.1 years, respectively (P=0.005).  
There were no differences between the groups in terms of body mass index where all 
groups had a mean of around 30 kg/m
2
. Males were more likely than females to have 
microalbuminuria according to both definitions. However, the comparison between the 
three groups in terms of gender failed to reach statistical significance (P=0.236).  
3.3.7.2 Blood pressure:  
There was a clear trend of stepwise increase of blood pressure with the increase of UAE. 
Subjects with microalbuminuria according to the conventional definition had the highest 
mean SBP followed by those with the new definition of microalbuminuria and 
normoalbuminuric subjects; 149.7 ± 22.5 mm Hg, 140.0 ± 18.1 mm Hg and 138.5 ±17.3 
mm Hg, respectively. The mean SBP of the conventional definition group was statistically 
higher than that in the new definition group and in normoalbuminuria, P<0.05.  Although 
there was little evidence of a difference between the three groups in terms of mean DBP, 
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the pulse pressure tended to increase with the increase of UAE; 51.0 ± 15.0 mm Hg, 55.1 ± 
17.2 mm Hg and 61 ± 21.1 mm Hg for subjects with normoalbuminuria, the new definition 
and the conventional definition of microalbuminuria, respectively (P<0.001). While the 
pulse pressure in subjects with microalbuminuria by the conventional definition was 
statistically greater than in normoalbuminuric individuals (P<0.001), the differences 
between subjects with the new definition and the two other groups did not achieve 
statistical significance. 
3.3.7.3 Blood biochemistry: 
Renal function  
The mean serum creatinine level in subjects with microalbuminuria according to the new 
and the conventional definitions was higher than in individuals with normoalbuminuria. 
Positive subjects according to the new definition had the highest mean serum creatinine; 
91.5 ± 20.9 µmol/L while the mean serum creatinine of the conventional definition group 
was 88.7 ± 25.7 µmol/L.  Individuals with normoalbuminuria had a mean serum creatinine 
of 80.7 ± 16.0 µmol/L. The differences between the microalbuminuria groups and 
normoalbuminuric individuals were significant. Nevertheless, there were no significant 
differences between the two definitions groups in the mean level of serum creatinine. 
Patients with microalbuminuria according to the new definition had the lowest mean of 
eGFR; 71.6 ± 17.9 mL/min/1.73 m
2
 and this was significantly lower than that in subjects 
normoalbuminuria; 81.5 ± 17.1 mL/min/1.73 m
2
 (P<0.001). The average eGFR in the 
conventional definition group was 77.4 ± 23.6 mL/min/1.73 m
2
 but a post-hoc analysis 
failed to reveal any difference from the other groups. 
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Metabolic indices  
Results from fasting blood glucose tests showed that patients with microalbuminuria by the 
new and the conventional definition had mean fasting blood glucose level higher than in 
the control individuals; 5.3 ± 0.5 mmol/L, 5.3 ± 0.6 mmol/L  5.1 ± 0.6 mmol/L, 
respectively, but the difference was not significant. People with the conventional definition 
of microalbuminuria had the highest random glucose level.  
Lipid profile 
All three groups had similar mean total cholesterol. Subjects with normoalbuminuria had 
mean total cholesterol of 5.2 ± 1.0 mmol/L while patients with microalbuminuria 
according to the two definitions had the same mean, 5.0 ± 1.0 mmol/L. Furthermore, the 
HDL-cholesterol levels in the three groups were not different; 1.5 ± 0.4 mmol/L for 
normoalbuminuric, 1.5 ± 0.5 mmol/L for the new definition and 1.4 ± 0.4 mmol/L for the 
conventional definition individuals. However, new definition group showed the highest 
geometric mean of fasting triglycerides (1.7 mmol/L, 95 % CI: 1.4, 2.1) compared with 
both individuals with normoalbuminuria (P=0.001) and those with microalbuminuria by 
the conventional definition (p=0.032), 1.3 mmol/L (95 % CI: 1.2, 1.3) and 1.3 mmol/L   
(95 % CI: 1.1, 1.5), respectively. 
Inflammatory markers 
Subjects with microalbuminuria by the conventional definition had the highest eosinophil 
count (P=0.012). The geometric mean in the conventional definition group was 0.18×10
9
/L 
(95% CI, 0.16 - 0.22) while those with normoalbuminuria and the new definition of 
microalbuminuria had similar geometric means 0.14×10
9
/L (95% CI, 0.13 - 0.15) 
0.14×10
9
/L (95% CI:, 0.11 - 0.16), respectively. 
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ESR was significantly higher in patients with microalbuminuria by the conventional 
definition (10.8 mm in 1 hour ; 95% CI, 7.9 - 15.1) than in individuals with normal UAE 
(7.2 mm in 1 hour; 95% CI, 6.6 - 7.9) (P =0.020).  The new definition group had an 
intermediate ESR geometric mean: 8.4 mm in 1 hour (95% CI, 6.3 - 11.4); however, the 
difference failed to reach statistical significance. 
Cardiovascular / metabolic drugs 
The median number of drugs used in individuals with normoalbuminuria was 2 
(interquartile range, 1 to 4). There was a trend of increased number of drugs used in 
microalbuminuric subjects; 3 (interquartile range, 2 to 4) for the conventional definition 
group and 4 (interquartile range, 1 to 5) for the new definition group.  
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Variable (unit) 
Normal 
UAE 
N 
New 
definition 
N 
Conventional 
definition 
N P-value 
Age (years) 55.4 ± 14.1 633 60.9 ± 16.4 78 62.0 ±16.1 75 <0.001 
BMI (Kg/m
2
) 29.4 ± 5.7 618 29.8 ± 6.0 78 29.9 ± 6.3 73 0.668 
Male (%) 44.2% 280 50.0% 39 53.3% 40 0.236 
SBP (mm Hg)  138.5 ± 17.3 631 140.0 ± 18.1 78 149.7 ± 22.5 75 <0.001 
DBP (mm Hg) 87.5 ± 10.3 631 84.9 ± 11.1 78 88.6 ± 13.7 75 0.074 
Pulse pressure 
(mm Hg) 
51.0 ± 15.0 631 55.1 ± 17.2 78 61.0 ± 21.1 75 <0.001 
Serum creatinine  
(µmol/L) 
80.7 ± 16.0 633 91.5 ± 20.9 78 88.7 ± 25.7 75 <0.001 
eGFR  
(mL/min/1.73 m
2
) 
81.5 ± 17.1 633 71.6 ± 17.9 78 77.4 ± 23.6 75 <0.001 
Fasting glucose  
(mmol/L) 
5.1 ± 0.6 463 5.3 ±  0.5 44 5.3 ± 0.6 54 0.080 
Random glucose 
(mmol/L) 
5.4 ± 1.0 139 5.4 ± 0.8 29 5.9 ± 1.7 16 0.282 
Total cholesterol 
(mmol/L) 
5.2 ± 1.0 622 5.0 ± 1.0 74 5.0 ± 1.1 75 0.099 
HDL-cholesterol  
(mmol/L) 
1.5 ± 0.4 617 1.5 ± 0.5 76 1.4 ± 0.4 73 0.741 
F. triglycerides*  
(mmol/L) 
1.3 (1.2-1.3) 459 1.7 (1.4-2.1) 43 1.3 (1.1-1.5) 54 0.001 
Eosinophil count  
(×10
9
/L) 
0.14 (0.13-0.15) 588 0.14(0.11-0.16) 75 0.18 (0.16- 0.22) 70 0.012 
ESR 
(mm in 1 hr) 
7.2 (6.6-7.9) 399 8.4(6.3-11.4) 38 10.8(7.9-15.1) 43 0.022 
No. of drugs** 2 (1 to 4) 615 4 (1 to 5) 77 3 (2 to 4) 74 <0.001 
Table ‎3-5: Comparison of patient characteristics in normoalbuminuric (n=633) and 
microalbuminuric subjects according to the new definition (n= 78) and the conventional 
definition (n=75) in non-diabetic hypertensive subjects without severe renal impairment. 
Results are summarised as mean ± standard deviation, geometric mean (95% confidence 
interval for the mean) median (interquartile range) or percentage of cohort. * F.: fasting. ** 
Cardiovascular / metabolic drugs (compared using Kruskal Wallis test). 
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Variable Categories 
Mean 
difference 
P value 
95% CI 
Lower Upper 
Age (years) 
Normoalb. versus: 
1.New def. -5.55 0.005 -9.66 -1.44 
2.Conv. def. -6.62 0.001 -10.81 -2.44 
New def. versus         Conv. def. -1.07 0.892 -6.62 4.47 
SBP (mm Hg) 
Normoalb. versus: 
1.New def. -1.48 0.772 -6.56 3.59 
2.Conv. def. -11.16 <0.001 -16.33 -6.0 
New def. versus         Conv. def. -9.68 0.003 -16.52 -2.84 
Pulse pressure 
(mm Hg) 
Normoalb. versus: 
1.New def. -4.06 0.089 -8.50 0.42 
2.Conv. def. -9.98 <0.001 -14.5 -5.40 
New def. versus          Conv. def. -5.92 0.056 -11.9 0.12 
Serum Creatinine 
(µmol/L) 
Normoalb. versus: 
1.New def. -10.78 <0.001 -15.77 -5.8 
2.Conv. def. -7.97 0.001 -13.04 -2.9 
New def. versus         Conv. def. 2.81 0.586 -3.9 9.54 
eGFR 
(mL/min/1.73 m
2
) 
Normoalb. versus: 
1.New def. 9.89 <0.001 4.85 14.94 
2.Conv. def. 4.10 0.146 -1.03 9.24 
New def. versus         Conv. def. -5.79 0.113 -12.59 1.01 
Fasting 
triglycerides*† 
(mmol/L) 
Normoalb. versus: 
1.New def. 0.74 0.001 0.62 0.90 
2.Conv. def. 0.97 0.817 0.83 1.15 
New def. versus         Conv. def. 1.31 0.032 1.03 1.66 
Eosinophil count*† 
(×10
9
/L) 
Normoalb. versus: 
1.New def. 1.02 0.963 0.83 1.30 
2.Conv. def. 0.76 0.010 0.59 0.94 
New def. versus         Conv. def. 0.73 0.043 0.54 0.99 
ESR*† 
(mm in 1 hr) 
Normoalb. versus: 
1.New def. 0.86 0.610 0.59 1.24 
2.Conv. def. 0.67 0.020 0.49 0.95 
New def. versus         Conv. def. 0.77 0.453 0.49 1.22 
 Table ‎3-6: Multiple comparisons where differences between the groups’ means (95% 
confidence interval) were statistically significant in ANOVA test. * Geometric mean ratio 
instead of mean difference.  † 95% confidence intervals for the ratio of the geometric 
mean. Normoalb.: subjects with normoalbuminuria. 
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3.3.8 Demographic and clinical characteristics of diabetic 
subjects stratified by albumin excretion 
Table ‎3-7 compares the different clinical characteristics of diabetic cohort stratified by 
albuminuria level. Overall, age, blood pressure, BMI, cholesterol, fasting triglycerides, 
ESR, serum creatinine and fasting glucose tended to increase with the increase of 
albuminuria level, although comparison between groups failed to reach statistical 
significance, except for BMI. No differences were observed in the groups when comparing 
HDL-cholesterol and eosinophil count. The eGFR tended to decline with the increase of 
albuminuria level. The use of pharmacological agents was higher in subjects with 
albuminuria (P=0.029). 
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Variable Normoalbuminuria N New definition N Conventional def. N Gross proteinuria N P value 
Age (years) 63.1 ± 12.0 63 65.4 ± 10.0 25 68.0 ± 14 25 66.7 ± 14.1  12 0.345 
BMI (kg/m
2
) 32.8 ± 6.3 61 31.3 ± 5.8 24 32.7 ± 7.3 24 38.0 ± 7.7 12 0.041 
Male (%) 44.4% 28 64.0% 16 56.0% 14 41.7% 5 0.347 
SBP (mm Hg) 132 (123 to 146) 62 134 (123 to 147) 25 142 (125 to 151) 25 142 (138 to 166) 11 0.137 
DBP (mm Hg) 81.8 ± 9.5 62 81.3 ± 10.0 25 78.7 ± 14.7 25 85.8 ± 6.8 11 0.312 
Creatinine(µmol/L) 87 ( 76 to 100) 63 90 (78.5 to 103.5) 25 83 (75 to 144.5) 25 103.5 (80.2 to 131.7) 12 0.377 
eGFR (mL/min/1.73 m
2
) 70.9 ± 18.2 63 73.2 ± 17.1 25 69.6 ± 33.4 25 57.8 ± 18.4 12 0.232 
Fasting glucose (mmol/L) 6.3 (5.2 to 8.3) 39 7.8 (5.1 to 8.5) 15 8.1 (6.1 to  10.5) 19 8.1 (7.4 to 12.7) 6 0.065 
Cholesterol (mmol/L) 4.4 (3.7 to 5.3) 62 3.8 (3.6 to 4.5) 25 4.2 (3.4 to 5.1) 24 4.8 (3.8 to 5.2) 12 0.297 
HDL-Cholesterol (mmol/L) 1.2 (1.0 to 1.4) 63 1.1 (1.0 to 1.4) 25 1.1 (0.9 to 1.3) 23 1.2 (0.9 to 1.4) 12 0.341 
F. triglycerides (mmol/L) 1.4 (1.0 to 1.9) 38 1.4 (1.1 to 2.2) 15 1.5 (0.8 to 2.0) 18 2.2 (1.3 to 2.7) 7 0.366 
Eosinophil count (×10
9
/L) 0.21 (0.15 to 0.29) 60 0.24 (0.14 to 0.33) 24 0.22 (0.14 to 0.32) 24 0.24 (0.17 to 0.33) 9 0.899 
ESR (mm in 1 hour) 9 (5.0 to 25.5) 42 7 (5.0 to 20.0) 15 20 (8.5 to 30.7) 14 38 (7.0 to 71.0) 7 0.079 
Number of drugs* 5 (3.0 to 7.0) 63 5 ( 4.5 to 6.0) 25 6 (5.0 to 7.0) 25 7 (5.2 to 8.0) 12 0.029 
Table ‎3-7: The clinical characteristics of diabetic subjects stratified by albuminuria level (n=125). Variables are expressed as mean ± SD or median 
(interquartile range), as appropriate. * Cardiovascular / metabolic drugs. Def.: definition. 
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3.4 Summary/ discussion 
The population was typical of hypertensive individuals. As well as high blood pressure, the 
subjects were relatively elderly, overweight and with multiple risk factors. 
Microalbuminuria including a new definition incorporating lower levels of albuminuria 
was present in one fifth of the study population. The distribution of the new definition and 
the conventional definition of microalbuminuria was almost equal (11%). In diabetic 
subject, the prevalence of microalbuminuria and gross proteinuria was high. Almost half of 
diabetic patients had increased levels of albumin in the urine.  
When the demographic characteristics of the non-diabetic subjects without severely 
reduced renal function was compared according to UAE classification, subjects with 
microalbuminuria had increased risk factors for poor outcomes. This was also seen with 
diabetic patients although the small number of patients precluded statistically significant 
differences.  
In summary, microalbuminuria is associated with increased levels of different risk factors 
for cardiovascular diseases. The increased levels of such factor were also evident in those 
with levels of albuminuria below the current definition of microalbuminuria. 
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4. Chapter four: association of microalbuminuria 
with co-morbidities and risk factors (categorical 
data) 
4.1 Introduction 
Microalbuminuria has been linked with several comorbidities including target organ 
damage. For instance, in the HyperGen study, the researchers found a relationship between 
albuminuria (based on a single measurement) and LVH in hypertensive subjects (Djoussé 
et al., 2008). The purpose of the analysis presented in this chapter was to further evaluate 
the association of microalbuminuria with different co-morbidities and risk factors. In 
addition, relationships with pharmacological groups and individual cardiovascular risk 
score using the Framingham and the JBS equations were investigated. 
4.2 Methods 
Categorical data were collected from patient case-notes. Information included family 
history of co-morbidities, smoking status together with co-morbidities and risk factors 
(LVH, evidence of CVD, type II diabetes and ST-T changes on ECG). The use of 
antihypertensive drugs, lipid lowering agents, antidiabetics, anticoagulants and 
vasodilators (nitrates) were also studied. Diagnosis of LVH was based on the opinion of 
the attending clinician using established criteria. The Framingham equation was used to 
calculate an individual’s cardiovascular risk. In addition, cardiovascular risk was 
calculated using the amended algorithm from the JBS. This method excludes diabetic 
subjects and those with LVH as these are considered as high risk populations. A risk score 
for any cardiovascular events in the next 10 years greater than 20% was regarded as high 
risk while a risk score between 10% - 20% or less than 10% were considered as moderate 
or low risk, respectively. Categorical variables were expressed as percentage of the cohort 
and the differences between the study’s groups were assessed using Chi-square or Fisher’s 
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exact test, as appropriate. When P value for any variable was <0.05, linear association was 
examined using chi-square test for trend. 
4.3 Results 
4.3.1 Baseline characteristics 
Clinical characteristics for categorical variables are shown in table ‎4-1. As mentioned 
earlier, the majority were females (54% of the overall population). About 10% of the study 
population were smokers and 13% had type II diabetes mellitus. Evidence of 
cardiovascular complications was relatively common with LVH in about a quarter, ST-T 
changes on ECG evident in 15% and cardiovascular diseases, including clinical evidence 
of CHD, stroke/transient ischaemic attack or peripheral vascular disease, present in about 
one fifth of the study population. Nearly 20%, 15% and 12% of the cohort had family 
history of CHD, diabetes or stroke, respectively. 
Table ‎4-1 also summarises the current therapy of the study cohort. The most commonly 
used antihypertensive agents were diuretics which were prescribed for nearly half of the 
study population. CCBs and ACEIs were also common in this cohort, each of which were 
used by more than 40% of the patients and nearly one third of the patients were treated 
with ARBs or beta blockers.  
Statins were taken by 38% of the patients but other lipid lowering drugs, such as fibrates 
and ezetimibe, were seldom used. More than quarter of the population were prescribed 
antiplatelet agents and approximately 9% of the study population were treated with 
antidiabetic drugs.  
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   Variable Total available N Percentage 
Male 1059 489 46.2% 
Family history: 
- Diabetes 747 114 15.3% 
- Stroke 795 94 11.8% 
- CHD  795 155 19.5% 
Co-morbidities/ risk:    
- Current smoker 829 76 9.2% 
- Type II diabetes 1048 137 13.1% 
- LVH 954 232 24.3% 
- ST-T changes on ECG 761 107 14.1% 
- CVD 990 174 17.6% 
Pharmacotherapy: 
- Diuretics 1040 508 48.8% 
- CCBs 1040 450 43.3% 
- ACEIs 1040 428 41.2% 
- ARBs 1040 342 32.9% 
- Beta blockers 1040 321 30.9% 
- Alpha blockers 1040 159 15.3% 
- Aldosterone antagonists 1040 95 9.1% 
- Imidazoline agonists 1040 22 2.1% 
- Statins 1040 393 37.8% 
- Other lipid lowering agents 1040 37 3.6% 
- Anti-platelet agents 1040 272 26.2% 
- Anti-diabetics 1040 88 8.5% 
- Anticoagulants 1040 28 2.7% 
- Vasodilators 1040 24 2.3% 
Table ‎4-1: Clinical characteristics (categorical variables) of the study population (n=1059).  
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4.3.2 Cardiovascular risk assessment 
Tables ‎4-2 and 4-3 present the 10 year cardiovascular risk assessment of the overall cohort 
over 10 years. Data of those with already established cardiovascular diseases including 
CHD, congestive heart failure, peripheral vascular disease and stroke (n=174) have been 
excluded. Missing information precluded the risk assessment of 29 subjects. Risk 
calculations were carried out in the remaining 856 subjects (table ‎4-2). As the age range of 
137 subjects was outside the recommended age range in the Framingham study (30 – 74 
years), risk calculations were also carried out to a subgroup of 719 individuals whose age 
met the Framingham criteria (table ‎4-3).  It should be noted that risk score calculations 
were based on values usually obtained after treatment was introduced. 
Overall, the population had moderate risk for CVD; median 14.1% (interquartile range, 
7.5% to 23.7%). In the age-restricted group, the median CVD risk was 13.1% (interquartile 
range, 7.7% to 21.3%). More than one-quarter of the individuals had high risk for CVD. 
The mean risk score using the JBS calculation (after excluding those with LVH and 
diabetes) was 11.1% (SD ± 9.4) (10.5% (SD ± 8.2) in the age-restricted group). 
The median risk of developing CHD was 9.1% (interquartile range, 4.4% to 16.1) in the 
856 subjects and 8.9% (interquartile range, 4.8% to 15.1%) in the age-restricted group. 
More than a quarter of the subjects had risk score of ≥ 15% for developing CHD over the 
next 10 years. The median risk of stroke was 2.3% (interquartile range, 1.0% to 4.8%) 
(2.1% (interquartile range, 1.0% to 3.9%) in the age-restricted group. More than 18% of 
subjects had stroke risk of 5% or more. 
The median risk score for myocardial infarction in the study cohort was 3% (interquartile 
range, 1.1 to 6.1) (2.9% (interquartile range, 1.3% to 5.8%) in the age-restricted group). 
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The risk of death from either CHD or CVD was low, with medians of 1.2% (interquartile 
range, 0.3% to 3.4%) for CHD death and 2.2% (interquartile range, 0.6% to 6.5%). About 
2% of the population had 10% risk for fatal CHD.  The risk of dying from CVD in 9.6% of 
the population was more than 10%. Almost similar risk scores were found in the age-
restricted group. 
 
Risk (%) N Mean SD Median 
Interquartile range 
25% 75% 
CVD risk 856 16.8 12.0 14.1 7.5 23.7 
CVD risk (JBS)* 607 11.1 9.4 8.8 4.7 14.6 
CHD risk 856 11.4 9.4 9.1 4.4 16.1 
Stroke risk 856 3.8 4.8 2.3 1.0 4.8 
MI risk 856 4.4 4.7 2.9 1.1 6.1 
CHD death risk 856 2.5 3.4 1.2 0.3 3.4 
CVD death risk 856 5.2 7.2 2.2 0.6 6.5 
Table ‎4-2: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in the overall population (n=1059) after excluding 
those with already established cardiovascular diseases (n=174) and those with incomplete 
infomation (n=29). * Cardiovascular risk score based on the JBS equation after excluding 
additional 249 patients with LVH or diabetes mellitus.  
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Risk (%) N Mean SD Median 
Interquartile range 
25% 75% 
CVD risk 719 15.6 10.7 13.1 7.7 21.3 
CVD risk (JBS)* 515 10.5 8.2 8.7 4.9 13.7 
CHD risk 719 11.1 8.6 8.9 4.8 15.1 
Stroke risk 719 3.0 3.4 2.1 1.0 3.9 
MI risk 719 4.2 4.2 2.9 1.3 5.8 
CHD death risk 719 2.0 2.6 1.1 0.3 2.7 
CVD death risk 719 3.7 4.8 1.9 0.6 4.7 
Table ‎4-3: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in the overall population  (n=1059) after excluding 
those with already established cardiovascular diseases (n=174), those with incomplete 
infomation (n=29) and those outside the recommended age range (n=137).  
*Cardiovascular risk score based on the JBS equation after excluding additional 204 
patients with LVH or diabetes mellitus. 
 
 
4.3.3 Clinical characteristics of hypertensive subjects without 
diabetes or severe renal impairment 
Table ‎4-4 lists clinical characteristics (categorical variables) of non-diabetic hypertensive 
subjects without severe renal impairment (stage 4, 5 CKD or gross proteinuria). Female 
subjects predominated, accounting for 55% of the cohort. The percentage of current 
smokers was 9%.  Almost 22% of the cohort had evidence of LVH and over 10% had ST-T 
changes on ECG. Fifteen percent of the cohort had evidence of established CVD such as 
CHD, stroke, transient ischaemic attack or peripheral vascular disease. Family histories of 
CHD, diabetes or stroke were found in 20%, 15% and 12%, respectively.  
The most frequently used antihypertensive drug were diuretics (44%) followed by calcium 
channel blockers (40%), ACEIs (39%), ARBs (30%) and beta blockers (28%). Lipid 
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lowering agents were used by more than 35% of the population (statins and others). About 
one fifth of the cohort used antiplatelet agents. 
Variable Total available Count Percentage 
Male 786 359 45.7% 
Family history: 
- Diabetes 555 72 13.0% 
- Stroke 590 73 12.4% 
- CHD  590 109 18.5% 
Co-morbidities/ other risk factors: 
- Current smoker 617 57 9.2% 
- LVH 727 158 21.7% 
- ST-T changes on ECG 584 79 13.5% 
- CVD 745 111 14.9% 
Pharmacotherapy: 
- Diuretics 770 341 44.3% 
- CCBs 770 306 39.7% 
- ACEIs 770 301 39.1% 
- ARBs 770 228 29.6% 
- Beta blockers 770 213 27.7% 
- Alpha blockers 770 98 12.7% 
- Aldosterone antagonists 770 55 7.1% 
- Imidazoline agonists 770 11 1.4% 
- Statins 770 256 33.2% 
- Other lipid lowering agents 770 21 2.7% 
- Anti-platelet agents 770 165 21.4% 
- Anticoagulants 770 21 2.7% 
- Vasodilators 770 13 1.7% 
Table ‎4-4: Clinical characteristics (categorical variables) of hypertensive subjects without 
diabetes mellitus or severe renal impairment (n=786). 
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4.3.4 Risk assessment for non-diabetic hypertensive subjects 
without severe renal impairment 
Cardiovascular risk assessment calculations in non-diabetic hypertensive subjects without 
severe renal impairment are shown in table ‎4-5. The cohort had a moderate overall risk for 
developing CVD of 12.2% (interquartile range, 6.5% to 21%) using the Framingham 
equation and 10.6 (SD ± 8.7) using the JBS method. About one quarter of the cohort can be 
considered as a high risk group for developing CVD based on the Framingham risk score.  
The median risk prediction for CHD was 8% (interquartile range, 4% to 14%). The 
percentage of subjects who had risk of ≥ 15% for developing CHD was more than 20%. 
The median risk score for stroke was 2% (interquartile: 0.8% to 4.1%) with 15% of the 
subjects having stroke risk estimate of 5% or more.  
The median risk score for developing MI over 10 years in this cohort was 2.4% 
(interquartile range, 1% to 4.9%). The median risk of death from CHD was 0.9% 
(interquartile range, 0.2% to 2.8%). About 2% of subjects had CHD death risk of 10% or 
more. The median 10 years risk score for CVD was 1.7% (interquartile range, 0.5% to 
5.3%) and about 8% of the cohort had CVD death risk of 10% or more. 
Table ‎4-6 summarises the risk calculation in non-diabetic subjects without severe renal 
impairment after excluding those younger than 30 years and those older than 74 years. 
There were no differences in risk scores between this subgroup and those for the whole 
population.  
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Risk (%) N Mean S.D Median 
Interquartile range 
25% 75% 
CVD risk 659 14.7 11.0 12.2 6.5 20.9 
CVD risk (JBS)* 531 10.6 8.8 8.7 4.6 14.2 
CHD risk 659 10.1 8.4 7.9 4.0 14.0 
Stroke risk 659 3.2 3.7 2.0 0.8 4.1 
MI risk 659 3.7 3.9 2.4 1.0 4.9 
CHD death risk 659 2.0 2.8 0.9 0.2 2.8 
CVD death risk 659 4.3 6.0 1.7 0.5 5.3 
Table ‎4-5: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in non-diabetic hypertensive subjects without severe 
renal impairment (n=786) after excluding 111 patients with established CVD and 16 
patients with incomplete information. * Cardiovascular risk score based on the JBS 
equation after excluding additional 128 patients with LVH. 
 
 
Risk (%) N Mean S.D Median 
Interquartile range 
25% 75% 
CVD risk 564 14.2 9.9 11.8 6.8 19.2 
CVD risk (JBS) 458 10.2 8.0 8.6 4.8 13.3 
CHD risk 564 10.1 8.0 8.0 4.3 13.4 
Stroke risk 564 2.8 3.0 1.9 0.8 3.6 
MI risk 564 3.7 3.8 2.5 1.1 4.8 
CHD death risk 564 1.8 2.4 0.8 0.2 2.4 
CVD death risk 564 3.3 4.4 1.5 0.5 4.2 
Table ‎4-6: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in non-diabetic hypertensive subjects without severe 
renal impairment (n=786) after excluding those with established cardiovascular disease 
(n=111), incomplete information (n=16) and those younger than 30 years and those older 
than 74 years (n=95). * Cardiovascular risk score based on the JBS equation after 
excluding additional 106 patients with LVH.  
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4.3.5 Clinical characteristics of hypertensive subjects without 
diabetes or severe renal impairment stratified by gender 
Table ‎4-7 lists the clinical characteristics of subjects with hypertension but without type II 
diabetes mellitus or severe renal impairment (stage 4, 5 or proteinuria) stratified by gender. 
There were no differences in terms of cardiovascular risk or co-morbidities except for 
LVH where males had double prevalence compared with females. The use of CCBs and 
ACEIs was more frequent in males while diuretics were more frequently used in females. 
Variable Female N Male N P value 
Diabetes family history 14.1% 44 11.5% 28 0.375 
Stroke family history 11.0% 36 14.1% 37 0.260 
CHD family history 16.2% 53 21.3% 56 0.135 
Current smoker  8.5% 29 10.1% 28 0.576 
LVH  14.9% 58 30.0% 99 <0.001 
ST-T changes 11.8% 38 15.7% 41 0.182 
CVD 16.8% 68 12.6% 43 0.122 
Pharmacotherapy: 
Diuretics 48.7% 203 39.1% 138 0.009 
CCBs  34.3% 143 46.2% 163 0.001 
ACEIs  35.1% 148 43.3% 153 0.027 
ARBs 28.3% 118 31.2% 110 0.428 
Beta blockers 30.2% 126 24.6% 87 0.090 
Alpha blockers 13.2% 55 12.2% 43 0.745 
Aldosterone blockers  7.0% 29 7.4% 26 0.889 
Imidazoline agonists 1.4% 6 1.4% 5 1.000 
Statins 31.7% 132 35.1% 124 0.319 
Other lipid lowering agents 2.4% 10 3.1% 11 0.658 
Anti-platelet agents 21.0% 87 22.1% 78 0.725 
Anticoagulants 2.6% 11 2.8% 10 1.000 
Vasodilators 2.2% 9 1.1% 4 0.401 
Table ‎4-7: Clinical characteristics of hypertensive subjects without diabetes or severe renal 
impairment stratified by gender (n=786). 
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4.3.6 Clinical Characteristics of diabetic hypertensive subjects 
Table ‎4-8 lists the clinical characteristics of hypertensive subjects with type II diabetes 
mellitus. The distribution of males and females in the cohort was equal. More than one 
quarter of the cohort had a family history of diabetes mellitus. Similarly, one quarter of the 
patients had a family history of CHD. One tenth of diabetic hypertensive subjects had a 
family history of stroke. Family history of diabetes, stroke and CHD in this cohort was 
higher than that observed with non-diabetic subjects. 
Overall, this cohort was characterised by high prevalence of comorbidities and risk factors. 
Nearly one third of the patients had evidence of LVH which is a higher proportion than 
that reported with non-diabetic individuals. ST-T changes on ECG were found in 23% as 
compared with 13% in non-diabetic subjects. The prevalence of CVD was twice as high in 
diabetics as in non-diabetics (34% versus 15%).  
In diabetic patients, use of cardiovascular drugs was higher than in non-diabetic 
individuals. As in the non-diabetic cohort, the most frequently prescribed antihypertensive 
drugs were diuretics. Diuretics were used by 73% of these patients compared with 44% of 
the non-diabetic subjects. CCBs, ACEIs, ARBs and beta blocker were also used frequently 
in the diabetic patients. The percentage of diabetic patients who used alpha blockers and 
aldosterone antagonists was two-fold higher than in non-diabetic individuals; (30% versus 
13%) and (14% versus 7%), respectively. Lipid lowering agents (statins and others) were 
used extensively in this cohort. More than three quarters of the diabetic patients used lipid 
lowering agents compared with 36% in hypertensive subjects without diabetes mellitus. 
Use of antiplatelet agents was also common.   
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Variable Total available N Percentage 
Male 125 63 50.4% 
Family history: 
- Diabetes 85 23 27.1% 
- Stroke 88 9 10.2% 
- CHD  87 22 25.3% 
Co-morbidities/ risk: 
- Current smoker 89 4 4.5% 
- LVH 103 32 31.1% 
- ST-T changes on ECG 77 18 23.4% 
- CVD 110 37 33.6% 
Pharmacotherapy: 
- Diuretics 125 91 72.8% 
- CCBs 125 76 60.8% 
- ACEIs 125 71 56.8% 
- ARBs 125 56 44.8% 
- Beta blockers 125 56 44.8% 
- Alpha blockers 125 38 30.4% 
- Aldosterone antagonists 125 18 14.4% 
- Imidazoline receptors agonists 125 5 4.0% 
- Statins 125 84 67.2% 
- Other lipid lowering agents 125 13 10.4% 
- Anti-platelet agents 125 67 53.6% 
- Anti-diabetics 125 76 60.8% 
- Anticoagulants 125 5 4.0% 
- Vasodilators 125 6 4.8% 
Table ‎4-8: Clinical characteristics of subjects with hypertension and type II diabetes 
mellitus (n=125). 
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4.3.7 Risk assessment in diabetic hypertensive subjects 
Table ‎4-9 shows 10 years risk assessment calculations in subjects with hypertension and 
type II diabetes. This cohort had higher probability of developing cardiovascular 
morbidities and mortalities than in non-diabetic individuals. They had high risk of 
developing general CVD; median 26.5% (interquartile range, 18.5% to 39.0%) which is 
almost double the risk score in non-diabetic subjects. More than 60% had high risk for 
CVD over the next 10 years while about one-third of diabetics were at medium risk.  
Diabetic subjects had a median probability of developing CHD over 10 years of about 17% 
(interquartile range, 10.3 to 26.9%) which is also higher than that in non-diabetic 
individuals. While only 2% of non-diabetic subjects were at risk for developing stroke, 
diabetic patients had median risk of stroke of 5.7% (interquartile range, 2.7 to 9.0). 
The median risk for MI in diabetic patients was about 8% (interquartile range, 4.0 to 12.8) 
which is higher than that in non-diabetic subjects by threefold. The median risk of dying 
from CHD or CVD in diabetic individuals were 3.9% (interquartile range, 1.8 to 7.5) and 
7.1% (interquartile range, 2.6 to 17).  
Table ‎4-10 summarises the risk scores in diabetic subjects after excluding those subjects 
outside the recommended age range. The risk scores were relatively lower than that 
reported with all diabetic subjects.  
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Risk (%) N Mean SD Median 
Interquartile range 
25% 75% 
CVD  85 30.1 14.8 26.5 18.5 39.0 
CHD 85 19.7 12.2 16.6 10.3 26.9 
Stroke 85 7.8 7.8 5.7 2.7 9.0 
MI  85 9.2 6.6 7.9 4.0 12.8 
CHD death  85 5.7 5.5 3.9 1.8 7.5 
CVD death  85 11.1 11.5 7.1 2.6 17.0 
Table ‎4-9: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in patients with hypertension and type II diabetes after 
excluding 37 patients with established CVD and 3 patients with incomplete information. 
 
 
Risk (%) N Mean SD Median 
Interquartile range 
25% 75% 
CVD  65 25.8 12.0 23.9 16.5 33.5 
CHD  65 17.5 10.6 14.5 9.9 24.6 
Stroke  65 5.4 4.5 4.6 2.3 6.4 
MI  65 8.0 5.3 7.4 3.9 10.8 
CHD death 65 3.8 3.6 2.7 1.4 5.2 
CVD death 65 6.7 6.8 4.6 1.9 8.4 
Table ‎4-10: The probability of developing different cardiovascular diseases over 10 years 
based on the Framingham equation in patients with type II diabetes and hypertension after 
exulding those with established cardiovascular disease (37), incomplete information (n=3) 
and those younger than 30 years and older than 74 years (20 patients). 
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4.3.8 A comparison of clinical characteristics according to 
albuminuria stages in non-diabetic hypertensive subjects 
without severe renal impairment 
A comparison of clinical characteristics according to microalbuminuria stages in non-
diabetic hypertensive subjects without CKD stage 4 or 5 or gross proteinuria is presented 
in table ‎4-11. The percentage of males tended to increase with the increase of ACR level 
(44% in normoalbuminuric, 50% in new definition and 53% in conventional definition 
subjects). Differences between the groups were not significant. Likewise, there were no 
significant differences in prevalence of family history, although family history of diabetes 
mellitus was more frequent in those with microalbuminuria according to the conventional 
definition. 
Prevalence of LVH, ST-T changes on ECG and clinical evidence of cardiovascular disease 
increased in a stepwise manner as albuminuria increased. Trends were statistically 
significant for all three variables although there were no statistically significant differences 
between the two definitions of microalbuminuria.  
Overall, the use of pharmacological groups tended to be high in subjects with 
microalbuminuria (by both definitions).  For individual antihypertensive drug classes, 
however, differences were statistically significant only for CCBs and beta blockers. More 
than half of subjects with microalbuminuria (according to both definitions) used CCBs 
compared with 37% in subjects with normoalbuminuria. While only a quarter of subjects 
with normoalbuminuria were treated with beta blockers, 40% of subjects with 
microalbuminuria according to the new definition used these agents. A comparison 
between subjects with and without microalbuminuria by the new definition was significant. 
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The number of microalbuminuric individuals who have been treated with lipid lowering 
agents (including statins) was higher than in subjects with normal UAE (P<0.05).  Statins 
were prescribed to half of subjects with microalbuminuria by the new definition, and the 
percentage of statins users was significantly higher than in subjects with normoalbuminuria 
and those with microalbuminuria by the conventional definition where only 31% used 
statins in each group. About 7% of individuals with microalbuminuria (according to the 
two definitions) used other lipid lowering agents compared with only 2% in individuals 
with normal UAE. 
The use of antiplatelet agents in the three groups was not statistically different, with a 
percentage of around 23% in subjects with microalbuminuria (by both definitions) and 
21% in individuals with normoalbuminuria. Only 1% of subjects with normal UAE used 
anticoagulants. On the contrary, approximately 6.5% of the new definition group and 11% 
of the conventional definition group used anticoagulants. The number of treated patients 
with anticoagulants was statistically higher in microalbuminuric subjects (by both 
definitions) than in normoalbuminuric individuals. While only 1% of normoalbuminuric 
individuals were treated with vasodilators, about 4% of subjects with microalbuminuria (by 
the two definitions groups) used anticoagulants (P=0.030). 
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Variable Normoalb. N New def. N Conv. def. N P value 
Male 44.2% 280 50.0% 39 53.3% 40 0.236 
Family history: 
Diabetes 12.4% 57 11.9% 5 19.2% 10 0.374 
Stroke 11.6% 57 17.8% 8 14.8% 8 0.389 
CHD  17.6% 87 27.9% 12 18.5% 10 0.256 
Co-morbidities/ risks: 
Current smoker  9.2% 47 10.4% 5 8.9% 5 0.924 
LVH  19.2% a 112 29.7% b 22 34.8% b 24 0.003 
ST-T changes 11.8% a 57 19.6% a, b 9 24.1% b 13 0.020 
CVD 12.7% a 76 23.7% b 18 23.6% b 17 0.004 
Pharmacotherapy 
Diuretics 43.3% 268 48.1% 37 48.6% 36 0.530 
CCBs  36.7% a 227 49.4% b 38 55.4% b 41 0.001 
ACEIs  37.6% 233 46.8% 36 43.2% 32 0.233 
ARBs 28.1% 174 35.1% 27 36.5% 27 0.178 
Beta blocker 25.5% a 158 40.3% b 31 32.4% a, b 24 0.016 
Alpha blockers 11.6% 72 18.2% 14 16.2% 12 0.167 
Aldosterone blockers  7.1% 44 7.8% 6 6.8% 5 1.000 
Imidazoline agonists 1.5% 9 1.3% 1 1.4% 1 1.000 
Statins 31.7% a 196 48.1% b 37 31.1% a 23 0.015  
Other lipid lowering 1.8% a 11 6.5% b 5 6.8% b 5 0.005 
Anti-platelet agents 21% 130 23.4% 18 23% 17 0.847 
Anticoagulants 1.3% a 8 6.5% b 5 10.8% b 8 <0.001 
Vasodilators 1.1%  a 7 3.9%  a, b 3 4.1% b 3 0.030 
Table ‎4-11: Comparison of clinical characteristics of people with normoalbuminuria 
(n=633) and subjects with microalbuminuria by the new definition (n=78) and the 
conventional definition (n=75) after excluding diabetic subjects and those with severe renal 
impairment. All values are expressed as a percentage within each group. N represents 
number of cases in each relevant variable. The result of pairwise comparison (using z-test) 
is indicated by subscript letters (a, b) where variables that share the same letter are not 
statistically different from each other.  
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4.3.9 Cardiovascular risk assessment in subjects with normal 
UAE versus microalbuminuric individuals in non-diabetic 
subjects without severe renal impairment 
Table ‎4-12 (A) shows a comparison of cardiovascular risk scores between subjects with 
normal urinary albumin excretion versus microalbuminuric subjects according to the two 
thresholds used.  The results of multiple between-group comparisons are shown in table 
‎4-12 (B). There was a trend of increased overall cardiovascular risk (figure ‎4-1) and for 
cause-specific outcomes with the increase of albuminuria level although the trends for 
CHD and MI were not statistically significant. Within group comparisons indicated that the 
conventional definition was associated with statistically significant influences. The trends 
for the new definition were similar but not significant with wide 95% confidence intervals 
except for CVD death where the new definition had a significant influence.  
Table ‎4-13 represents the same comparison but after excluding those < 30 years and those 
> 74 years. The same trends of increased risk were observed although these were not 
significant for CVD (JBS), CHD, MI and CHD death possibility because of limited 
number of subjects involved in the analysis. 
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Figure ‎4-1: The cardiovascular risk score (using the Framingham equation) stratified by 
UAE in non-diabetic subjects without severe renal impairment. Data are summarised as 
geometric mean (95%, CI). 
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A. Risk score comparisons 
Risk (%) Normoalb. N New def.  N Conv. def.  N P value 
CVD 9.6 (8.8, 10.5) 545 10.9 (7.7, 15.5) 57 14.5 (11.3, 18.7) 57 0.017 
CVD (JBS) 10.2 ± 8.4 447 11.7 ± 9.5 45 14.9 ± 11.3 39 0.005 
CHD 6.1 (5.5, 6.7) 545 6.3 (4.3, 9.3) 57 8.9 (6.5, 12.1) 57 0.087 
Stroke 1.8 (1.6, 1.9) 545 2.5(1.7, 3.5) 57 3.0 (2.2, 4.1) 57 0.001 
MI 2.0 (1.8, 2.3) 545 2.2 (1.5, 3.11) 57 2.9 (2.1, 4.0) 57 0.136 
CHD death 0.8 (0.75, 0.95) 545 1.2 (0.83, 1.8) 57 1.4 (0.97, 2.1) 57 0.008 
CVD death 1.6 (1.4, 1.8) 545 2.6 (1.8, 4.0) 57 3.2 (2.2, 4.8) 57 <0.001 
B. Tukey’s post-hoc analysis 
Risk Categories 
Mean 
ratio 
P value 
95% CI 
Lower Upper 
CVD  
Normoalb. versus: 
1.New def. 0.88 0.670 0.62 1.24 
2.Conventional def. 0.66 0.015 0.46 0.93 
New def. versus:       Conventional def. 0.75 0.319 0.47 1.19 
CVD 
(JBS)* 
Normoalb. versus: 
1.New def. -1.49 0.523 -4.72 1.73 
2.Conventional def. -4.67 0.004 -8.12 -1.22 
New def. versus:       Conventional def. -3.18 0.224 -7.7 1.33 
Stroke  
Normoalb. versus: 
1.New def. 0.73 0.094 0.51 1.03 
2.Conventional def. 0.59 0.002 0.42 0.84 
New versus:              Conventional def. 0.81 0.565 0.50 1.30 
CHD  
death 
Normoalb. versus: 
1.New def. 0.69 0.147 0.43 1.09 
2.Conventional def. 0.59 0.022 0.37 0.94 
New def. versus:       Conventional def. 0.85 0.829 0.46 1.59 
CVD  
death 
Normoalb. versus: 
1.New def. 0.62 0.038 0.39 0.98 
2.Conventional def. 0.50 0.001 0.32 0.80 
New def. versus:       Conventional def. 0.81 0.720 0.44 1.51 
Table ‎4-12: A. Comparison of cardiovascular risk assessment calculations of 
normoalbuminuric subjects and patient with microalbuminuria (by 2 definitions) in 
hypertensive subjects without severe renal impairment (n=659). Results are summarised as 
geometric mean (95% confidence interval) except CVD (JBS) where results were 
expressed as mean (±S.D). B. Post-hoc statistical analysis showing the multiple 
comparisons of the groups (95% confidence interval for the ratio of the geometric mean). * 
Mean difference (95% confidence interval for mean difference). Normoalb.: 
Normoalbuminuria 
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A. Risk score comparisons 
Risk (%) Normoalb. N New def. N Conv. def. N P-value 
CVD 10.4 (9.6, 11) 478 12.2 (9.4, 16.1) 42 14.0 (11.2,17.8) 44 0.036 
CVD (JBS) 10.1 ± 7.8 395 10.0 ± 6.3 31 13.1 ± 10.7 32 0.105 
CHD 6.8 (6.3, 7.5) 478 7.9 (5.8, 1.8) 42 9.0 (6.7, 12.2) 44 0.155 
Stroke 1.8 (1.7, 1.97) 478 2.4 (1.8, 3.3) 42 2.7 (1.9, 3.6) 44 0.006 
MI 2.6 (2.0, 2.5) 478 2.4 (1.7, 3.4) 42 2.9 (2.11,  4.0) 44 0.332 
CHD death  0.8 (0.75, 0.59) 478 1.1(0.7, 1.62) 42 1.2 (0.8, 1.8) 44 0.142 
CVD death 1.5 (1.4, 1.74) 478 2.2 ( 1.5, 3.3) 42 2.4(1.6, 3.6) 44 0.028 
B. Tukey’s post-hoc analysis 
Risk Categories 
Mean 
ratio 
P value 
95% CI 
Lower Upper 
CVD  
Normoalb. versus: 
1.New def. 0.85 0.415 0.60 0.90 
2.Conventional def. 0.74 0.050 0.54 1.00 
New def. versus:                Conventional def. 0.87 0.723 0.60 1.34 
Stroke  
Normoalb. versus: 
1.New def. 0.75 0.110 0.54 1.01 
2.Conventional def. 0.68 0.021 0.49 0.96 
New versus:                        Conventional def. 0.92 0.894 0.60 1.50 
CVD death 
Normoalb. versus: 
1.New def. 0.70 0.175 0.43 1.12 
2.Conventional def. 0.65 0.081 0.41 1.04 
New def. versus:                Conventional def. 0.94 0.969 0.49 1.77 
Table ‎4-13: A. Comparison of cardiovascular risk assessment calculations of 
normoalbuminuric subjects and patient with microalbuminuria (by 2 definitions) in non-
diabetic hypertensive subjects without CKD (stage 4 or 5) or proteinuria (n=564), after 
excluding those outside the recommended age range. Results are summarised as geometric 
mean (95% confidence interval) except CVD (JBS) where results were expressed as mean 
(±S.D). B. Post-hoc statistical analysis showing the multiple comparisons of the groups 
(95% confidence interval for the ratio of the geometric mean). 
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4.3.10 Clinical characteristics comparison in patients with 
type II diabetes and hypertension 
A comparison of clinical characteristics of diabetic subjects with normoalbuminuria, 
microalbuminuria (by both definitions) and gross proteinuria is shown in table ‎4-14. With 
the exception of ARB use, there were no statistical differences between the groups for any 
variables. However, the number of patients in each group was small. Males were 
predominant in the microalbuminuric groups while female were higher in 
normoalbuminuric and proteinuric subjects.  
Subjects with the conventional definition of microalbuminuria had the highest prevalence 
of family history of diabetes. Family history of stroke was more common in the new 
definition group than in those with normoalbuminuria or the conventional definition of 
microalbuminuria. Individuals with normal UAE had the highest prevalence of CHD 
family history. 
One fifth of subjects with microalbuminuria by the new definition were smoker compared 
with only 2% in individuals with normoalbuminuria. Subjects with the conventional 
definition of microalbuminuria and those with gross proteinuria had prevalence of LVH of 
40% compared with 35% in the new definition group and 25% in normoalbuminuric 
individuals. Patients with gross proteinuria had the highest prevalence of ST-T changes. 
Both patients with gross proteinuria and those with the new definition of microalbuminuria 
had CVD prevalence of about 42% followed by the conventional definition group (35%) 
and normoalbuminuric individuals (29%) 
Overall, the percentage of using antihypertensive medicines increased with the increase of 
ACR. Similarly, subjects with increased ACR level were taking higher percentages of 
cardiovascular medicines, except statins.  
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Variable % (n) Normal UAE N New def. N Conventional def. N Proteinuria N P value 
Male  44.4% 28 64.0% 16 56.0% 14 41.7% 5 0.353 
Family history: 
Diabetes 28.9% 13 13.3% 2 35.3% 6 25.0% 2 0.555 
Stroke  10.6% 5 13.3% 2 11.1% 2 0 0 0.951 
CHD  30.4% 14 6.7% 1 27.8% 5 25.0% 2 0.312 
Co-morbidities/ risk: 
Current smoker 2.2% 1 20.0% 3 0 0 0 0 0.056 
LVH 24.5% 13 34.8% 8 40.0% 8 42.9% 3 0.459 
ST-T changes  22.0% 9 13.3% 2 26.7% 4 50.0% 3 0.369 
CVD  28.6% 16 41.7% 10 34.8% 8 42.9% 3 0.628 
Pharmacotherapy:   
Diuretics 73.0% 46 64.0% 16 76.0% 19 83.3% 10 0.672 
CCBs 50.8% 32 64.0% 16 72.0% 18 83.3% 10 0.088 
ACEIs 50.8% 32 56.0% 14 68.0% 17 66.7% 8 0.455 
ARBs 41.3% 26 40.0% 10 40.0% 10 83.3% 10 0.046 
Beta blocker 39.7% 25 44.0% 11 52.0% 13 58.3% 7 0.560 
Alpha blockers 30.2% 19 32.0% 8 32.0% 8 25.0% 3 1.000 
Aldosterone blockers 12.7% 8 12.0% 3 28.0% 7 0 0 0.135 
Imidazoline  agonists 3.2% 2 8.0% 2 4.0% 1 0 0 0.767 
Statins 84.0% 39 72.0% 21 50.0% 18 84.0% 6 0.111 
Other lipid lowering 11.1% 7 12.0% 3 0 0 25.0% 3 0.085 
Anti-platelet agents 46.0% 29 48.0% 12 60.0% 15 75.0% 9 0.238 
Anti-diabetics 55.6% 35 52.0% 13 72.0% 18 83.3% 10 0.150 
Anticoagulants 3.2% 2 4.0% 1 8.0% 2 0 0 0.767 
Vasodilators 4.8% 3 0 0 8.0% 2 8.3% 1 0.390 
Table ‎4-14: Comparison of clinical characteristics of hypertensive patients with diabetes [normoalbuminuria (n=63), microalbuminuria by the new 
definition (n=25), the conventional definition (n=25) and gross proteinuria (n=12)].  All values are expressed as a percentage within each group.  
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4.3.11 Cardiovascular risk assessment comparison between 
normoalbuminuric and microalbuminuric diabetic 
hypertensive subjects 
Table ‎4-15 shows a comparison of risk assessment scores in diabetic subject stratified by 
ACR level. The cardiovascular risk calculations were based on data of 85 diabetic patients 
after excluding those with established CVD. Although the Kruskal–Wallis test did not 
reveal any significant differences between the groups, there were trends for stepwise 
increase of risk with the increase of ACR level. The lack of statistical significance may be 
due to the small sample sizes in each group. A similar trend can be seen in the even smaller 
group of subjects who met the age range criteria of the Framingham study (table ‎4-16). 
Risk factor  
(%) 
Normal UAE 
(n=45) 
New definition 
(n=15) 
Conventional 
def. (n=17) 
Proteinuria 
(n=8) 
P value 
CVD 
24.2 
( 17.1 to 34.4) 
25.9 
(20.4 to 41.6) 
38.4 
(22.4 to 46.6) 
34.9 
(19.7 to 45.4) 
0.123 
CHD 
14.7 
(9.7 to 23.0) 
14.5 
(11.1 to 24.6) 
23.6 
(12.2 to 33.6) 
22.6 
(9.92 to 31.5) 
0.263 
Stroke 
4.7 
(2.3 to 6.9) 
6.1 
(3.6 to 9.2) 
8.3 
(3.5 to 13.0) 
7.55 
(5.0 to 12.5) 
0.152 
MI 
7.1 
(3.3 to 10.6) 
7.9 
(4.1 to 10.5) 
10.8 
(5.9 to 14.9) 
10.8 
(4.2 to 13.8) 
0.148 
CHD death 
3.6 
(1.6 to 6.2) 
3.3 
(1.6 to 8.8) 
6.3 
(2.4 to 11.2) 
5.5 
(2.1 to 13.2) 
0.160 
CVD death 
4.9 
(1.8 to 10.9) 
5.7 
(2.7 to 21.9) 
16.7 
(5.1 to 21.2) 
7.9 
(3.6 to 29.7) 
0.114 
Table ‎4-15: A comparison of the risk scores in subjects with hypertension and diabetes 
(n=85) stratified by ACR after excluding 37 patients with established CVD and 2 patients 
with incomplete information.  Data are summarised as median (interquartile range). The 
medians of the groups were compared using the Kruskal–Wallis test. Def.: definition. 
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Risk factor  
(%) 
Normal UAE 
(n=38) 
New definition 
(n=11) 
Conventional 
def. (n=10) 
Proteinuria 
(n=6) 
P value 
CVD 
21.9 
(16.0 to 32.2) 
23.3 
( 19.8 to 28.4) 
29.0 
( 17.0 to 40.0) 
32.7 
( 15.0 to 36.4) 
0.612 
CHD 
14.6 
(9.7 to 21.9) 
12.9 
(11.1 to 17.9) 
18.4 
( 11.1 to 33.2) 
20.2 
(6.2 to 26.4) 
0.680 
Stroke 
4.2 
(1.9 to 6.2) 
3.9 
(3.2 to 6.5) 
4.9 
( 1.9 to 9.65) 
6.3 
( 4.3 to 7.9) 
0.395 
MI 
6.5 
(3.3 to 10.5) 
6.6 
(3.9 to 9.6) 
8.0 
(5.9 to 14.30) 
10.8 
(2.8 to 13.8) 
0.435 
CHD death 
2.5 
( 1.3 to 4.9) 
2.6 
(1.5 to 3.4) 
4.2 
(1.7 to 6.5) 
5.0 
(1.0 to 6.3) 
0.676 
CVD death 
4.5 
(1.7 to 8.2) 
3.8 
(2.6 to 6.3) 
8.5 
(2.0 to 17.2) 
6.2 
(2.6 to 8.5) 
0.642 
Table ‎4-16: A comparison of the risk scores in subjects with hypertension and diabetes 
(n=65) stratified by ACR.  Patients <30 or >74 years were excluded. Data are expressed as 
median (interquartile range). The medians of the groups were compared using the Kruskal–
Wallis test. 
 
4.3.12 Prevalence in patients with and without different 
cardiovascular and metabolic abnormalities  
Figure ‎4-2 A illustrates the prevalence of microalbuminuria in patients with type II 
diabetes (without gross proteinuria), CKD, CVD, LVH and strain (LVH and ECG 
changes), LVH and ST-T changes on ECG. The highest prevalence of albuminuria was 
found in diabetic subjects and those with CKD (stages 3, 4 or 5). About 37% of those with 
established CVD had microalbuminuria by the combined definition (i.e. the new definition 
plus the conventional definition). Similarly, those with LVH and strain had 
microalbuminuria prevalence of 37%. Microalbuminuria by the combined definition was 
found in about one-third of those with LVH or ST-T changes on ECG. In subjects with 
poor blood pressure control (defined as SBP ≥ 155 mm Hg and/or DBP ≥ 95 mm Hg which 
represented the top quartile of the cohort) but without evidence of previously mentioned 
diseases and risk factors, microalbuminuria was present in 18.5% of subjects (figure ‎4-2 
138 
 
B). When the data of those with poor blood pressure control were removed in addition to 
other co-morbidities and risk factors (no established risks), microalbuminuria was still 
present in 14% of the subjects. 
A) 
 
 
 
 
B)  
 
 
Figure ‎4-2: A) Prevalence of microalbuminuria in subjects without gross proteinuria but 
with several diseases/ risk factors. B) Prevalence of microalbuminuria in those with poor 
blood pressure control (defined as SBP ≥155 mm Hg and\or DBP ≥ 95 mm Hg) and those 
without recognised cardiovascular risk factors.  
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4.3.13 A comparison of demographic characteristics of those 
without established CVD / risk factors stratified by UAE 
Table ‎4-17 shows comparisons of microalbuminuric (by the combined definition) and 
normoalbuminuric subjects in a subcohort of the hypertensive subjects with relatively well-
controlled blood pressure ( <155/95 mm Hg) and without evidence of established 
cardiovascular diseases or risk factors (CVD, LVH, ST-T changes on ECG, all stages of 
CKD, gross proteinuria and type II diabetes mellitus). There was a trend for increased 
blood pressure and some biochemical parameters although this was not supported by 
statistical significance, except for DBP and serum creatinine.  
Variable (unit) Normal UAE N Microalbuminuria N P-Value 
Age (years)  53.2 ± 14.2 299 56.0 ± 17.4 47 0.216 
BMI (Kg/m
2
) 29.4 ± 5.8 293 29.6 ± 7.3 47 0.854 
SBP (mm Hg) 131.1 ± 10.3 298 133.7 ± 9.5 47 0.108 
DBP (mm Hg) 84.5 ± 7.5 298 86.7 ± 6.5 47 0.054 
Serum creatinine (µmol/L)  78.0 ± 13.6 298 83.2 ± 17.3 48 0.050 
eGFR (mL/min/1.73 m
2
) 84.8 ± 16.2 298 82.0 ± 17.1 47 0.264 
Fasting glucose (mmol/L) 5.1 ± 0.6 220 5.1 ± 0.5 33 0.902 
Random glucose (mmol/L) 5.2 (4.8 to 5.8) 59 5.3 (5.1 to 5.8) 14 0.293 
Total cholesterol (mmol/L) 5.2 ± 1.0 293 5.2 ± 1.1 46 0.997 
HDL-cholesterol (mmol/L)   1.5 ± 0.4 289 1.5 ± 0.6 46 0.502 
Fasting  triglycerides (mmol/L)  1.2 (0.9 to 1.7) 217 1.3 (0.8 to 1.9) 33 0.385 
Eosinophil count  (×10
9
/L)  0.15 (0.1 to 0.2) 272 0.17 (0.1 to 0.3) 46 0.201 
ESR  (mm in 1 hr)  7.0 (4.0 to 12.5) 178 7.0 (4.0 to 16.0) 23 0.585 
Number of drugs * 2.0 (1.0 to 3.0) 288 2.0 (1.0 to 3.0) 47 0.820 
Table ‎4-17: Data of subjects without established cardiovascular diseases or risks stratified 
by level of albuminuria (normoalbuminuria (n=299) versus microalbuminuria by the 
combined definition (n=48)). Variables are expressed as mean (±SD) or median 
(interquartile range), as appropriate. * Cardiovascular / metabolic drugs. 
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4.3.14 A comparison of clinical characteristics and risk 
scores of those without established CVD / risk factors 
stratified by UAE 
Tables ‎4-18 and ‎4-19 show comparisons of clinical characteristics / risk scores for those 
without co-morbidities, CVD or risk factors (CVD, LVH, ST-T changes on ECG, all stages 
of CKD, gross proteinuria and type II diabetes mellitus). Trends for increased risk scores 
with the increase of UAE were observed (even after excluding those outside the 
recommended age range, table ‎4-20) although this was not supported by statistical 
significance possibly because of the small sample size. Likewise, the use of some 
antihypertensive agents (such as CCBs, ARBs, beta blockers and aldosterone antagonists) 
tended to be higher in microalbuminuric subjects although the magnitude of differences 
was slight. 
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Variable (%) Normoalbuminuria N Microalbuminuria N P-Value 
Male 44.1% 132 52.1% 25 0.350 
Diabetes family history 10.6% 24 21.4% 6 0.115 
Stroke family history 12.2% 29 10% 3 1.000 
CHD family history 17.2% 41 17.2% 5 1.000 
Smoker 10.9% 27 5.9% 2 0.549 
Diuretics 39.8% 115 29.8% 14 0.201 
CCBs 34.6% 100 48.9% 23 0.072 
ACEIs 34.3% 99 36.2% 17 0.869 
ARBs 27.7% 80 31.9% 15 0.601 
Beta blockers 20.8% 60 29.8% 14 0.185 
Alpha blockers 9.3% 27 8.5% 4 1.000 
Aldosterone antagonists 3.8% 11 10.6% 5 0.057 
Imidazoline agonists 0.7% 2 0 0 1.000 
Antiplatelet agents 18.3% 53 10.6% 5 0.296 
Statins 27.3% 79 19.1% 9 0.285 
lipid lowering agents 0.7% 2 0 0 1.000 
Vasodilators 0.7% 2 0 0 1.000 
Anticoagulants 0 0 2.1% 1 0.140 
Table ‎4-18: Clinical characteristics of subjects without established cardiovascular diseases 
or risks stratified by the level of albuminuria (normoalbuminuria (n=299) versus 
microalbuminuria by the combined definition (n=48)). Variables are expressed as 
percentage of cohort. N represents total number of cases of relevant variables. 
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Risk (%) Normoalbuminuria N Microalbuminuria N P-value 
CVD 9.0 (4.8 to 14.8) 292 10.6 (6.4 to 17.0) 45 0.264 
CVD (JBS) 7.5 (3.9 to 11.6) 292 8.5 (5.1 to 12.8) 45 0.342 
CHD 5.7 (2.8 to 9.1) 292 6.4 (3.5 to 10.1) 45 0.523 
Stroke 1.5 (0.7 to 2.8) 292 2.1 (0.9 to 3.3) 45 0.168 
MI 1.9 (0.7 to 3.7) 292 2.0 (0.8 to 3.9) 45 0.648 
CHD death  0.5 (0.2 to 1.6) 292 0.8 (0.3 to 2.2) 45 0.298 
CVD death 1.0 (0.4 to 2.9) 292 1.3 (0.5 to 4.5) 45 0.163 
Table ‎4-19: Cardiovascular risk scores for subjects without established cardiovascular 
diseases or risks stratified by level of albuminuria (normoalbuminuria (n=299) versus 
microalbuminuria by the combined definition (n=48)). Missing information precluded the 
calculation in 10 subjects. Variables are expressed as median (interquartile range). Groups 
were compared using the Mann–Whitney test. 
 
Risk (%) Normoalbuminuria N Microalbuminuria N P-value 
CVD 9.0 (5.1 to 14) 253 9.2 ( 6.6 to 15) 34 0.592 
CVD (JBS) 7.5 (4.3 to 11.2) 253 8.2 (5.2 to 12.6) 34 0.497 
CHD 5.9 (3.4 to 8.9) 253 6.5 (3.6 to 10) 34 0.555 
Stroke 1.4 (0.7 to 2.4) 253 1.4 (0.8 to 2.5) 34 0.506 
MI 1.9 (0.8 to 3.5) 253 2 (1.0 to 3.7) 34 0.68 
CHD death  0.4 (0.1 to 1.4) 253 0.7 (0.2 to 1.4) 34 0.687 
CVD death 0.9 (0.3 to 2.3) 253 1.0 (0.4 to 2.9) 34 0.640 
Table ‎4-20: Cardiovascular risk scores for subjects without established cardiovascular 
diseases or risks stratified by level of albuminuria (normoalbuminuria (n=299) versus 
microalbuminuria by the combined definition (n=48)). Subjects younger than 30 years or 
older than 74 years were excluded (n=50). Variables are expressed as median (interquartile 
range). Groups were compared using the Mann–Whitney test. 
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4.4 Summary/ discussion 
The population was characterised by increased cardiovascular co-morbidities and 
complications. The percentages of diabetic subjects and current smokers were quite low 
but prescription of cardiovascular drugs such as statins and antiplatelet agents was fairly 
high, reflecting the complexity of the population. This was supported by the score for 
cardiovascular disease calculated in the population. Diabetic subjects had a prevalence of 
cardiovascular morbidities and risk scores higher than that in non-diabetic.  
When comparing the clinical characteristics according to UAE, there were obvious trends 
of increased risks, co-morbidities and proportions of drugs used in subjects with 
microalbuminuria.  Target organ damage (LVH) and CVD were strongly associated with 
microalbuminuria. There were trends for continuous relationships with UAE levels. 
Differences were not significant in diabetic patients, possibly because of number of 
individuals in each group. The trend was also observed in subjects without established 
diseases or risk factors although again the differences were not significant possibly because 
of the limited number of patients in the microalbuminuric group. 
The use of cardiovascular risk calculators revealed that the probability of developing 
global cardiovascular disease and cause-specific outcomes over ten years were higher in 
subjects with microalbuminuria.  Increased cardiovascular risk was also observed in 
subjects with microalbuminuria by the new definition although the difference was not 
significant and confidence intervals were wide. It is likely that the number of subjects in 
the new definition group was too small to provide clear differentiation. The increased risk 
in this group of patient is clinically important and may indicate that the current definition 
underestimate risk in subjects with low levels of albuminuria.  
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5. Chapter five: testing the association of 
microalbuminuria with clinical and laboratory 
characteristics by multivariate analysis 
5.1 Introduction 
Several factors influence microalbuminuria. For instance, microalbuminuria is highly 
prevalent in subjects with diabetes and an association with blood glucose level has been 
shown previously (Vupputuri et al., 2011). Also, deterioration of kidney function may lead 
to alteration of glomerular filtration and increase excretion of albumin in the urine and thus 
higher serum creatinine may have a strong influence (Comper et al., 2008). Therefore, the 
purpose of this analysis was to investigate the association of microalbuminuria with 
different laboratory and clinical characteristics in hypertensive subjects without severe 
renal impairment using regression models that adjust any potential confounders. Also, I 
sought to evaluate the usefulness of microalbuminuria as an independent predictor of 
different cardiovascular outcomes. 
5.2 Method 
The predictive values of laboratory and clinical characteristics of the studied subjects were 
analysed using binary logistic regression method.  Selection of variables was based on two 
methods; backward elimination which starts by evaluating all variables and then 
eliminating any variable that has no significant effect to the model; the other method for 
selection was carried out by adding variables that have possible effect on the association 
from prior knowledge.  
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5.3 Results 
5.3.1 Factors associated with different definitions of 
microalbuminuria  
Table ‎5-1 shows the results of logistic regression models for patients with 
microalbuminuria grouped into three categories; the conventional definition, the new 
definition, and a composite of both definitions (the combined definition) versus 
normoalbuminuria. Covariates were included in each model using a stepwise backward 
elimination procedure.  
Six hundred and fifteen cases out of 786 where included when the conventional definition 
was selected as an outcome as data for some covariates were missing. SBP, eosinophil 
count and LVH were associated with the conventional definition of microalbuminuria; 
odds ratio 1.04 (95% CI, 1.02 - 1.05), 9.63 (95% CI, 1.78 - 52.03) and 2.83 (95%, 1.59 - 
5.07), respectively. Anticoagulants were highly related to the conventional definition of 
microalbuminuria; odds ratio 9.98 (95% CI, 3.14 - 31.74). 
When the new definition group was selected as an outcome, data from 492 patients were 
included in the model. Microalbuminuria as categorized by the new definition was related 
significantly to age, serum creatinine and fasting triglycerides; odds ratios 1.03 (95% CI, 
1.00 - 1.06), 1.02 (95% CI, 1.01 - 1.04) and 1.67 (95% CI, 1.27 - 2.20), respectively. CCBs 
and anticoagulants were associated with the new definition of microalbuminuria. The odds 
ratio of CCBs in this model was 2.10 (95% CI, 1.07 - 4.13). The highest odds ratio of all 
covariates that were associated with the new definition of microalbuminuria was again 
found with anticoagulants; 5.88 (95% CI, 1.45 - 23.77). 
The combined definition of microalbuminuria was significantly associated with SBP, 
serum creatinine, LVH, fasting triglycerides, CCBs and anticoagulants. The highest odds 
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ratio was reported with anticoagulant use; 9.48 (95% CI, 2.98 - 30.20) followed by LVH; 
1.91 (95% CI, 1.11 - 3.28), CCBs; 1.65 (95% CI, 1.01 - 2.70) and fasting triglycerides; 
1.32 (95% CI, 1.05 - 1.66).  Both SBP and serum creatinine had odds ratios close to one; 
1.02 (95% CI, 1.01 - 1.04) and 1.02 (95% CI, 1.00 - 1.03), respectively. 
 
Outcome N Predictors (unit) O.R (95% CI) P-value 
Conventional 
definition 
615 
SBP (mm Hg) 1.04 (1.02-1.05) <0.001 
Eosinophil count 9.63 (1.78-52.03) 0.009 
LVH 2.83 (1.59-5.07) <0.001 
Anticoagulants 9.98 (3.14-31.74) <0.001 
New  
definition 
492 
Age (years) 1.03 (1.00-1.06) 0.026 
Serum creatinine (µmol/L) 1.02 (1.01-1.04) 0.010 
Fasting triglycerides (mmol/L) 1.67 (1.27-2.20) <0.001 
CCBs 2.10 (1.07-4.13) 0.032 
Anticoagulants 5.88 (1.45-23.77) 0.013 
Combined 
definition 
512 
SBP (mm Hg) 1.02 (1.01-1.04) <0.001 
Serum creatinine (µmol/L) 1.02 (1.00-1.03) 0.012 
LVH 1.91 (1.11-3.28) 0.020 
Fasting triglycerides (mmol/L) 1.32 (1.05-1.66) 0.016 
CCB 1.65 (1.01-2.70) 0.045 
Anticoagulants 9.48 (2.98-30.20) <0.001 
Table ‎5-1: Results of multivariate logistic regression (using backward elimination method) 
testing the association of different variables with the three definitions of microalbuminuria 
versus normoalbuminuria. N represents the number of cases included in each model. O.R.: 
odds ratio. 
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5.3.2 The Association of Microalbuminuria and end-organ damage 
The results of multivariate logistic regression analyses evaluating the influence of three 
definitions of microalbuminuria (the new, conventional and combined definitions) on LVH 
and ST-T changes on ECG (as outcomes) are listed on table ‎5-2. After adjustment for age 
and gender (model I), both conventional and combined definitions were significantly 
associated with LVH;  odds ratio 1.90 (95% CI, 1.09 - 3.33) and 1.70 (95% CI, 1.11 - 
2.61), respectively. In model I, ST-T changes on ECG were not associated with any of the 
three definitions, although the conventional and combined definitions were close to the 
threshold for significance with wide confidence intervals; odds ratio 1.96 (95% CI, 0.97 - 
3.97) and 1.71 (0.97 - 3.01), respectively. 
When logistic regression analysis was adjusted for cardiovascular risk factors such as SBP, 
DBP, BMI, total cholesterol, HDL-cholesterol, fasting glucose and triglycerides in addition 
to age and gender (model II), the combined definition remained significantly related to 
LVH with an odds ratio of 1.91 (95% CI, 1.08 - 3.39). The new and the conventional 
definitions of microalbuminuria were not individually associated with LVH (model II). ST-
T changes on ECG were associated significantly with the conventional definition (odds 
ratio; 2.36 (95% CI, 1.05 - 5.31)), while the combined definitions just failed to achieve 
significance (P=0.052,  odds ratio, 1.92 (95% CI, 0.99 - 3.72)). 
Variables that showed significant association with microalbuminuria from model II were 
included in model III (age and gender). In addition, the model was adjusted for the use 
RAS blockers (ACEIs and ARBs). As in model I, LVH was significantly related to the 
conventional and combined definitions; odds ratio 1.85 (95% CI, 1.05 - 3.24) and 1.64 
(95% CI, 1.07 - 2.52), respectively. Similarly, ST-T changes were associated with the 
conventional and combined definitions after adjustment for RAS blockers only; odds ratio 
2.20 (95% CI, 1.10 - 4.39) and 1.92 (95% CI, 1.10 - 3.36), respectively. 
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In model IV, all available variables were included and a stepwise backward elimination 
logistic regression was carried out. The number of the cases included in the model was 
small as information in some variables included in the model was not available. 
Microalbuminuria by the new definition was independently associated with LVH after 
adjusting for age, gender , RAS blockers and ST-T changes on ECG; odds ratio of 2.12 
(95% CI, 1.06 - 4.25). While the combined definition of microalbuminuria was still 
significantly related to LVH; odds ratio 1.87 (95% CI, 1.12 - 3.12), the conventional 
definition of microalbuminuria was no longer significantly associated with LVH; odds 
ratio 1.66 (95% C, 0.85 - 3.23). The small sample size may limit the reliability of the 
model as there was strong trend for all microalbuminuria measurements. 
In model IV, the association between the two definitions of microalbuminuria and ST-T 
changes on ECG was not significant after adjusting LVH, CVD and RAS blockers. 
However, the odds ratio for the conventional and the combined definitions of 
microalbuminuria was greater than unity with relatively wide confidence interval, 
suggesting that the sample size might not be sufficient to detect significant differences. 
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            LVH        ST-T changes 
 N O.R 95% CI P-value N O.R 95%-CI P-value 
Model I         
New def. 658 1.55 0.89 - 2.71 0.121 530 1.50 0.68 - 3.33 0.316 
Conventional 653 1.90 1.09 - 3.33 0.024 538 1.96 0.97 - 3.97 0.061 
Combined 727 1.70 1.11 - 2.61 0.014 584 1.71 0.97 - 3.01 0.065 
Model II         
New def. 449 1.79 0.82 - 3.91 0.145 443 1.51 0.59 - 3.86 0.389 
Conventional 456 1.90 0.91 – 3.95 0.088 450 2.36 1.05 - 5.31 0.038 
Combined 496 1.91 1.08 - 3.39 0.026 490 1.92 0.99 - 3.72 0.052 
Model III         
New def. 650 1.49 0.85 - 2.61 0.169 522 1.66 0.75 - 3.65 0.209 
Conventional 645 1.85 1.05 - 3.24 0.033 530 2.20 1.10 - 4.39 0.025 
Combined 718 1.64 1.07 - 2.52 0.024 575 1.92 1.10 - 3.36 0.021 
Model IV         
New def. 521 2.12 1.06 - 4.25 0.033 520 0.97 0.40 - 2.36 0.955 
Conventional 529 1.66 0.85 - 3.23 0.136 519 1.59 0.75 - 3.39 0.230 
Combined 574 1.87 1.12 - 3.12 0.017 572 1.30 0.70 - 2.42 0.398 
Table ‎5-2: Mutlivariate binary logistic regression testing the association of LVH and ST-T 
changes on ECG (outcomes) with different definitions of microalbuminuria. 
Normoalbuminuria was used as a reference group. Covariates added in models I, II and III 
were based on the possible effect of known risk factors on the association. In model IV, 
backward stepwise elimination method was used. N represents number of cases used in 
each model. Covartiates included in each model were as follow: 
Model I: adjusted for age and gender. 
Model II: adjusted for age, gender and cardiovascular risk factors (SBP, DBP, BMI, total 
cholesterol, HDL-cholesterol, fasting blood glucose and fasting triglycerides).  
Model III: adjusted for variables that showed significant association in model II in 
addition to RAS blockers: 
1. LVH: adjusted for age, gender and RAS blockers.  
2. ST-T changes on ECG: adjusted for RAS blockers. 
Model IV:  
1. LVH: adjusted for age, gender, RAS blockers and ST-T changes on ECG.  
2. ST-T changes on ECG: adjusted for LVH, CVD and RAS blockers. 
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5.3.3 The Association of Microalbuminuria and Cardiovascular 
diseases 
An evaluation of the association of different definitions of microalbuminuria with 
established cardiovascular diseases is presented in table ‎5-3. After adjustment for age and 
gender (model I), the combined definition was marginally significant, with an odds ratio of 
1.61 (95% CI, 1.0 - 2.60). Model II was adjusted for age, gender and cardiovascular risk 
factors (SBP, DBP, BMI, total cholesterol, HDL-cholesterol, fasting glucose and 
triglycerides). No significant association was found with all three microalbuminuria 
definitions. However, odds ratios were above unity with wide 95% confidence intervals. 
In model III, the relation between CVD risk and microalbuminuria was adjusted for RAS 
blockers in addition to age, HDL-cholesterol as they were the only significant variables 
from model II. The association between CVD risk and the three definitions of 
microalbuminuria was not significant, although the lower boundaries were again close to 
unity, especially with the combined definition; odds ratio 1.48 (95% CI, 0.91 - 2.42) P= 
0.113. 
Model IV was carried out using stepwise backward elimination. Only age and antiplatelet 
agents use were added as covariates. In this model, the combined definition was 
significantly related to CVD risk, with an odds ratio of 1.72 (95% CI, 1.05 - 2.80). Neither 
the new nor the conventional definitions of microalbuminuria alone was significantly 
associated with CVD; odds ratio 1.77 (95% CI, 0.94 - 3.34) and 1.76 (95% CI, 0.93 - 3.33) 
although again the lower 95% confidence interval was close to unity. 
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 CVD 
 N O.R 95% CI P-value 
Model I     
New def. 673 1.66 0.90 – 3.06 0.101 
Conventional 669 1.57 0.83 – 2.95 0.162 
Combined  745 1.61 1.00 - 2.60 0.050 
Model II     
New def. 458 1.71 0.76 – 3.87 0.194 
Conventional 464 1.49 0.66 – 3.37 0.343 
Combined  506 1.60 0.86 – 2.97 0.140 
Model III     
New def. 651 1.53 0.82 - 2.86 0.180 
Conventional 646 1.48 0.77 - 2.84 0.237 
Combined  720 1.48 0.91 - 2.42 0.113 
Model IV     
New def. 666 1.77 0.94 – 3.34 0.079 
Conventional 662 1.76 0.93 – 3.33 0.084 
Combined  737 1.72 1.05 - 2.80 0.030 
Table ‎5-3: Mutlivariate binary logistic regression testing the association between CVD risk 
and different definitions of microalbuminuria.Normoalbuminuria was used as reference 
group. Covariates added in models I, II and III were based on the possible effect of known 
risk factors on the association. In model IV, backward stepwise elimination method was 
used. N represents number of cases used in each model. Covartiates included in each 
model were as follow: 
Model I: adjusted for age and gender. 
Model II: adjusted for age, cardiovascular risk (SBP, DBP, BMI, total cholesterol, HDL-
cholesterol, fasting blood glucose and fasting triglycerides). 
Model III: adjusted for variables with significant association from model II (age and 
HDL-cholesterol) and RAS blockers.  
Model IV: adjusted for age and antiplatelet agents. 
 
5.3.4 Association of microalbuminuria with uncontrolled blood 
pressure  
The results presented in table ‎5-4 examine the association of microalbuminuria with 
uncontrolled hypertension. In models I and II, subjects were grouped according to their 
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blood pressure (obtained when microalbuminuria was measured) into two groups; those 
with uncontrolled hypertension (defined as SBP ≥140 or DBP ≥90 mm Hg) and those with 
lower blood pressure. After adjustment for age and use of antihypertensive agents (model 
I), uncontrolled hypertension was a significant predictor of microalbuminuria by the 
conventional and combined definitions; odds ratio 1.98 (95% CI, 1.14 - 3.43) and 1.56 
(95% CI, 1.05 - 2.30), respectively.  
In model II a stepwise backward elimination method was used. The association between 
uncontrolled hypertension and different definitions of microalbuminuria was examined 
after adjusting for any variables that showed significant association with each definition. 
Microalbuminuria by the conventional definition was significantly associated with the 
uncontrolled group; odds ratio 1.81 (95% CI, 1.01 - 3.22) after adjusting for eosinophil 
count, LVH and anticoagulants. Likewise, uncontrolled blood pressure was a significant 
predictor for the combined definition after adjustment for serum creatinine, LVH, fasting 
triglycerides, CCBs and anticoagulants; odds ratio 1.75 (95% CI, 1.04 - 2.95). 
In order to check the pattern of the association between microalbuminuria and uncontrolled 
hypertension, subjects were divided into three groups according to their treated SBP and 
DBP records. A treated SBP to levels between 140 - 159 and/or DBP between 90 - 99 mm 
Hg was considered as moderately controlled hypertension. Poorly controlled hypertension 
was defined as SBP between 160 - 179 mm Hg and/or DBP between 100 - 109 mm Hg 
while very poorly controlled hypertension was defined as SBP ≥180 mm Hg and/or 
SBP≥110 mm Hg. When SBP or DBP fell into different classes, the higher record was 
used in the classification.  
Model III was adjusted for age and antihypertensive drug use.  The new definition of 
microalbuminuria was not significantly associated with any group of uncontrolled blood 
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pressure. On the contrary, the conventional definition was highly associated with very 
poorly controlled hypertension; odds ratio 7.01 (95% CI, 3.10 – 15.88). Both poorly and 
very poorly controlled hypertension were significant predictor of the combined definition 
of microalbuminuria; odds ratio 1.86 (95% CI, 1.05 - 3.29) and 2.88 (95% CI, 1.41 - 5.91), 
respectively (figure ‎5-1).  
In model IV, a stepwise regression was used. After adjusting for age, serum creatinine 
fasting triglycerides, CCBs and anticoagulants use, there were no association with the new 
definition of microalbuminuria. Very poorly controlled blood pressure was significant 
predictor of the conventional definition of microalbuminuria and the odds ratio was 9.58 
(95% CI: 3.93 - 23.33) (figure ‎5-2). Very poorly controlled hypertension was also 
associated significantly with the combined definition of microalbuminuria; odds ratio 4.91 
(95% CI, 1.88 – 12.83). The relation between the combined definition of microalbuminuria 
and poorly controlled blood pressure control was just above the significant level; odds ratio 
2.03 (95% CI, 0.97 – 4.25). Odds ratio plots (Forest plots) of the associations between 
different groups of uncontrolled hypertension suggest trends of stepwise increases in the 
risk of microalbuminuria as the blood pressure increase (figures ‎5-1 and ‎5-2). 
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Predictors New definition only Conventional definition only  Combined  
Model I OR (95%-CI) P-value OR (95%-CI) P-value OR (95%-CI) P-value 
Uncontrolled 1.23 (0.74-2.03) 0.429 1.98 (1.14-3.43) 0.015 1.56 (1.05-2.30) 0.027 
Model II    
Uncontrolled 1.48 (0.73-3.01) 0.277 1.81 (1.01-3.22) 0.045 1.75 (1.04-2.95) 0.036 
Model III    
Moderate 1.25 (0.72-2.17) 0.428 1.41 (0.77-2.62) 0.266 1.31 (0.85-2.02) 0.221 
Poor  1.76 (0.86-3.60) 0.121 1.93 (0.87-4.29) 0.108 1.86 (1.05-3.29) 0.033 
Very poor  0.25 (0.03-1.97) 0.188 7.01 (3.10-15.88) <0.001 2.88 (1.41-5.91) 0.004 
Model IV    
Moderate 1.44 (0.67-3.09) 0.353 1.31 (0.69-2.50) 0.403 1.42 (0.80-2.51) 0.233 
Poor  1.99 (0.77-5.18) 0.158 1.55 (0.63-3.82) 0.341 2.03 (0.97-4.25) 0.060 
Very poor              --     -- 9.58 (3.93-23.33) <0.001 4.91 (1.88-12.83) 0.001 
Table ‎5-4: Model I and II represents the results of multivariate logistic regression testing the association of microalbuminuria with uncontrolled blood pressure (SBP 
≥140 or DBP ≥90 mm Hg). Model III and IV tests the association of three uncontrolled blood pressure groups (defined as moderately control: SBP 140-159 or DBP 90-
99, poor: SBP 160-179 or DBP 100-109 and very poor: SBP ≥180 or DBP ≥110) with microalbuminuria definitions (versus normoalbuminuria). Covariates adjusted in 
the models were as follow:  
 Model I and III: age and antihypertensive agents. (n= 695,692 and n=769 for new, conventional and combined definitions, respectively). 
 Model II and IV:  (a) New definition only (n=491): age, serum creatinine, fasting triglycerides, CCBs and anticoagulants. (b) Conventional 
definition only (n=615): eosinophil count, LVH and anticoagulants.  (c) Combined definition (n= 512): serum creatinine, LVH, fasting 
triglycerides, CCBs and anticoagulants  
n represents number of cases used in each model (out of 786 subjects). Low number of cases were used in model II and IV because of missing 
information for some adjusted covariate. 
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Figure ‎5-1: Forest plots showing the odds ratio with 95% confidence interval (on the 
logarithm of the base 10 scale) of three blood pressure stages as predictors of the 
conventional (A) and the combined (B) definitions of microalbuminuria after adjustment 
for age and antihypertensive agents.  
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Figure ‎5-2: Forest plots showing the odds ratio with 95% confidence interval (on the 
logarithm of the base 10 scale) of three blood pressure stages as predictors of the 
conventional (A) and the combined (B) definitions of microalbuminuria after adjustment 
for: 
 Age, serum creatinine and anticoagulants with the new definition group 
 Age and fasting glucose with the conventional definition group. 
 LVH, fasting triglycerides and CBBs with the combined definition group. 
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5.4 Summary/discussion 
Microalbuminuria by the three definitions (new, conventional and combined) was strongly 
related to several laboratory and clinical characteristics. Also, microalbuminuria was 
associated with LVH, ST-T changes on ECG and cardiovascular disease. Blood pressure 
(especially SBP) was independently associated with microalbuminuria. This was also 
evident in models that involved a group of patients with poorly controlled blood pressure 
where those with very poor blood pressure were strongly associated with 
microalbuminuria.  
Association of microalbuminuria by the new and the conventional definitions with fasting 
triglycerides and eosinophil count, respectively, may reflect the presence of inflammatory 
component of the vascular system caused by dyslipidemia. Serum creatinine was 
significantly related to microalbuminuria by the new and combined definitions, reflecting 
deterioration in kidney function in subjects with microalbuminuria. Anticoagulants were 
strongly associated with all three definitions of microalbuminuria. This might be explained 
since in subjects with hypertension, these drugs are usually utilised by those with atrial 
fibrillation and such patients usually suffer from complex risk factors such as LVH, 
increased age, higher blood pressure and vascular abnormalities. Microalbuminuria was a 
powerful predictor of LVH, CVD and ECG abnormalities and combining the two 
definitions has provided a clearer figure of the association. Although some of the 
associations with CVD in model IV were not significant, the confidence intervals were 
wide with borderline lower boundaries and odds ratio estimates were higher than one, 
indicating that the association might to be clinically relevant. 
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6. Chapter six: microalbuminuria calculated by 
different methods 
6.1 Introduction 
The gold standard method for the diagnosis of microalbuminuria is by 24-hour urine 
collection to account for any intra-individual variability over time (Witte et al., 2009). 
Several therapeutic guidelines recommend three early morning urine specimens to confirm 
the presence of microalbuminuria (National Collaborating Centre for Chronic Conditions, 
2008). However, this method is cumbersome. Recent finding in diabetic subjects suggests 
that a single specimen might be sufficient to allow the diagnosis of microalbuminuria 
(Pugliese et al., 2011).  The purpose of the analysis presented in this chapter was to test the 
reproducibility of microalbuminuria in cohorts of hypertensive subjects attending 
secondary/tertiary referral centres.  
6.2 Methods 
Microalbuminuria was initially detected by laboratory quantification at the GBPC and by 
semi-quantitative dipstick method in the Aberdeen Hypertension clinic. The prevalence of 
microalbuminuria was compared in the two cohorts. Reproducibility was evaluated by 
comparing the presence of microalbuminuria in the first sample and in subsequent 
measurements. Patient characteristics were explored in an exploratory analysis. 
A subcohort from the GBPC population had positive result in their first sample but the 
collection of further samples was not possible (n=116). The characteristics of those 
subjects were also compared with microalbuminuric subjects defined by repeated 
measurement. Groups were compared using a 2-sample t test, Mann-Whitney test or 
Fisher’s exact test, as appropriate. 
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6.3 Results 
6.3.1 Demographic characteristics of subjects attending the 
GBPC versus the Aberdeen Hypertension Clinic 
Table ‎6-1 compares the demographic characteristics of the GBPC and Aberdeen 
Hypertension Clinic cohorts. Subjects attending the GBPC were older than those attending 
the Aberdeen Hypertension Clinic; mean 58.4 ± 14.9 years versus  55.4 ± 14.8 years 
(P=0.014). There was no significant difference between the two cohorts in terms of SBP 
(140.1 ± 19.2 mm Hg for Glasgow cohort versus 142.8+21.2 mm Hg for Aberdeen cohort). 
However, subjects from the GBPC had a mean DBP of 87.4 ±11.2 mm Hg, which is 
statistically higher than in the Aberdeen Hypertension Clinic; 84.5 ± 12.4 mm Hg 
(P=0.004). The pulse pressure was higher in subjects attending the Aberdeen Hypertension 
Clinic; 58.3 ± 20.6 mm Hg versus 52.6 ± 16.3 mm Hg (<0.001) than in those attending the 
GBPC.  
Subjects attending the Aberdeen Hypertension clinic had median serum creatinine level 
higher than in the GBPC cohort; 94 µmol/L (interquartile range 84 to 106) versus 79 
µmol/L (interquartile range, 69 to 91), P<0.001. Correspondingly, the mean eGFR was 
lower in the Aberdeen Hypertension Clinic cohort than in the GBPC subjects, 67.3 ± 15.5 
mL/min/1.73 m
2
 and 80.3 ± 19.6 mL/min/1.73 m2, respectively (P<0.001). 
Random blood glucose was statistically higher in the GBPC (n=88) than in the Aberdeen 
clinic (n=165). Both cohorts had mean BMI of about 30 kg/m2. There was no difference 
between the two cohorts in the total cholesterol level, with a mean value of about 5 
mmol/L. Similarly, there was no significant difference between the two cohorts in the 
median level of HDL-cholesterol; 1.3 (interquartile range, 1.1 to 1.6) for the GBPC cohort 
versus 1.4 (interquartile range, 1.2 to 1.7) for the Aberdeen Hypertension Clinic cohort. 
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Eosinophil count was significantly higher in the Aberdeen cohort than in the GBPC cohort; 
0.15 ×10
9
/L (0.09 to 0.24) versus 0.20 ×10
9
/L (0.13 to 0.28) (P <0.001), respectively.  
The clinical characteristics of the two populations were similar (table ‎6-2). The number of 
cardiovascular and metabolic medicines used in both cohort were not different, with a 
median of 3 (interquartile range, 1 to 5). Overall, the frequency of pharmacological agents 
used was not statistically different between the two cohorts, except for ACEIs and ARBs. 
While individuals from the Aberdeen Hypertension Clinic used ACEIs more frequently 
than in the GBPC cohort (58% versus 38%, P<0.001), ARBs were prescribed to more than 
one third of the GBPC subjects compared with one-fifth of attendance at the Aberdeen 
Hypertension Clinic (P<0.001).  
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 Variable (unit) Glasgow N Aberdeen N P-value 
Age  (years) 58.4 ± 14.9 884 55.4 ± 14.8 174 0.014 
SBP  (mm Hg) 140.1 ± 19.2 880 142.8 ± 21.2 174 0.110 
DBP (mm Hg) 87.4 ± 11.2 880 84.5 ± 12.4 174 0.004 
Pulse pressure (mm Hg) 52.6 ± 16.3 880 58.3 ± 20.6 174 <0.001 
BMI (kg/m
2
) 30.0 ± 6.2 856 30.4 ± 5.4 173 0.393 
Serum creatinine (µmol/L) 79 (69 to 91) 884 94 (84 to 106) 163 <0.001 
eGFR (mL/min/1.73m
2
) 80.3 ± 19.6 884 67.3 ± 15.5 162 <0.001 
Random glucose (mmol/L) 6.6 (5.3 to 8.1) 88 5.2 (4.8 to 5.6) 165 <0.001 
Total cholesterol (mmol/L) 5.1 ± 1.1 862 5.0 ± 1.1 171 0.176 
HDL-cholesterol (mmol/L) 1.3 (1.1 to 1.6) 848 1.4 (1.2 to 1.7) 174 0.063 
Eosinophil count (×10
9
/L) 0.15 (0.09 to 0.24) 808 0.20 (0.13 to 0.28) 172 <0.001 
Number of drugs  3 (1 to 5) 860 3 (1 to 5) 175 0.117 
Table ‎6-1: A comparison of the demographic characteristics of subjects attending the 
GBPC (n=844) or the Aberdeen Hypertension Clinic (n=175).  Data are summarised as 
mean (±S.D) or median (interquartile range), as appropriate. 
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Variable (total available) Glasgow N Aberdeen N P value 
Male (1059) 45.4% 401 50.3% 88 0.246 
Co-morbidities/risk: 
Type II diabetes (1048) 13.1% 114 13.1% 23 1.000 
LVH  (954) 24.0% 187 25.9% 45 0.625 
CVD (990) 16.8% 137 21.1% 37 0.189 
Pharmacotherapy: (1040) 
Diuretics  48.4% 419 50.9% 89 0.563 
CCBs 42.9% 371 45.1% 79 0.616 
ACEIs 37.8% 327 57.7% 101 <0.001 
ARBs 35.3% 305 21.1% 37 <0.001 
Beta blockers 30.3% 262 33.7% 59 0.419 
Alpha blockers 14.8% 128 17.7% 31 0.357 
Aldosterone antagonists 9.1% 79 9.1% 16 1.000 
Imidazoline receptor agonists 1.7% 15 4.0% 7 0.078 
Statins 37.1% 321 41.1% 72 0.347 
Other lipid lowering agents 3.7% 32 2.9% 5 0.663 
Anti-platelet agents 25.4% 220 28.6% 50 0.396 
Anticoagulants 2.5% 22 3.4% 6 0.607 
Vasodilators 2.2% 19 2.9% 5 0.784 
Table ‎6-2: The clinical characteristics of subjects attending the GBPC (n=884) and the 
Aberdeen Hypertension Clinic (n=175). Variables are expressed as percentage of cohort. 
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6.3.2 Prevalence of albuminuria stratified by the study’s centres 
(GBPC versus Aberdeen Hypertension Clinic) 
After excluding 116 patients who had only one positive sample, the prevalence of 
microalbuminuria in all subjects attending the GBPC (n=768) or the Aberdeen 
Hypertension Clinic (n=175) is shown in figure ‎6-1 (A). Gross proteinuria was found in 
3.1% of subjects attending the GBPC compared with 1.7% in the Aberdeen Hypertension 
Clinic. The percentage of microalbuminuria by the conventional definition was similar in 
the two cohorts (11%). In contrast, the percentage of individuals with the new definition of 
microalbuminuria was higher in Aberdeen Hypertension Clinic than in the GBPC (21% 
versus 9%, P<0.001). 
Figure ‎6-1 (B) illustrates the prevalence of microalbuminuria in non-diabetic hypertensive 
subjects without stage 4 or 5 CKD or gross proteinuria attending the GBPC (n = 650) or 
Aberdeen Hypertension Clinic (n=136). The conventional definition of microalbuminuria 
was found in 9.2% and 11% patients attending the GBPC or the Aberdeen Hypertension 
Clinic, respectively. Approximately one-fifth of the Aberdeen Hypertension Clinic cohort 
had microalbuminuria by the new definition compared with only 8% of the GPBC cohort 
(P=0.001). 
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A.  
Glagow BP Clinic Aberdeen BP Clinic
Normal UAE
MAU by new definition
MAU by conventional definition
Gross proteinuria
Categories:
3.1%
10.9%
9.0%
77.0%
1.7%
11.4%
20.6%
66.3%
 
 
 
 
 
 
 
 
B.  
Glasgow BP Clinic Aberdeen BP Clinic
Normal UAE
MAU by new definition
MAU by conventional definition
Categories:
9.2%
7.8%
82.9%
11.0%
19.9%
69.1%
 
Figure ‎6-1: (A) The prevalence of albuminuria (microalbuminuria by the new and the 
conventional definitions and gross proteinuria) in all subjects attending the GBPC (n=768) 
versus the Aberdeen Hypertension Clinic (n=175). (B) Prevalence of microalbuminuria in 
non-diabetic hypertensive subjects without evidence of CKD stage 4, 5 or proteinuria (n= 
650 in the GBPC and 136 in the Aberdeen Hypertension Clinic). MAU: microalbuminuria. 
BP: blood pressure. 
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6.3.3 Reproducibility of microalbuminuria in hypertensive 
subjects attending the GBPC or the Aberdeen Hypertension 
Clinic 
In the GBPC population, 292 patients out of 744 patients (39%), after excluding the data of 
24 proteinuric patients, had positive microalbuminuria on first sample using laboratory 
quantification. When repeated samples were considered, the number of positive subjects 
dropped to 153 patients (52% out of 242 patients). This means that 48% of the subjects 
became negative when repeated samples were considered (figure ‎6-2 a).  
As mentioned earlier, in Aberdeen cohort, the detection of microalbuminuria was carried 
out using dipstick method and this was followed by laboratory quantification.  Ninety five 
subjects (55%) out of 172 patients had positive results on their first sample, after excluding 
the data of 3 patients with gross proteinuria. Out of those 95 subjects, 56 (59%) were 
positive on repeated samples using lab analysis (figure ‎6-2 b). This means that 41% of 
those positive on their first sample using dipstick method became negative when repeated 
samples were used in the classification. 
The prevalence of microalbuminuria on first sample detected by urine dipstick in the 
Aberdeen Hypertension Clinic was significantly higher than in the GBPC (55% versus 
39%, P<0.001). Also, the prevalence of microalbuminuria by repeated samples detected by 
laboratory method was significantly higher in the Aberdeen Hypertension Clinic (34% 
versus 23%, P=0.001). However, the difference between the two cohorts in terms of the 
proportion of subjects who became negative when repeated samples were considered was 
not significantly different (P = 0.288). 
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(a) 
 
 
(b) 
 
Figure ‎6-2: Proportion of subjects with positive UAE (by the combined definition) on their 
first sample versus those with positive result on repeated samples in: (a) the GBPC; (b) 
The Aberdeen Hypertension Clinic. In the GBPC, the first sample was estimated by 
laboratory quantification while semi-quantitative dipstick method was used in the 
Aberdeen Hypertension Clinic. 
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6.3.4 A comparison between those with positive 
microalbuminuria on repeated samples versus those who 
became negative on repeated samples 
Table ‎6-3 shows a comparison between first-sample only positive individuals and those 
who showed persistently increased UAE on the further samples for both cohorts combined, 
after excluding patients with gross proteinuria and those with type II diabetes. Overall, 
positive subjects on repeated samples were characterised by increased age, serum 
creatinine, fasting glucose, fasting triglycerides and eosinophil count which were higher 
than in those with positive microalbuminuria on their first sample only (P<0.05). eGFR 
values were significantly lower in positive subjects on repeated samples. SBP, BMI and 
ESR were higher in positive subjects by repeated samples but the differences between the 
two groups were not significant. 
While the gender distribution on subjects with positive UAE on repeated samples was 
almost equal, subjects with negative UAE on further samples were mainly female (60%) 
but the differences between the two group was not significant  (table ‎6-4). The prevalence 
of LVH, ST-T changes on ECG and CVD was higher in subjects with persisted UAE than 
in those who showed regressed albuminuria on the further samples, although the difference 
in CVD prevalence failed to achieve statistical significance. 
Positive subjects on repeated samples were treated with cardiovascular and metabolic 
medicines more often than in those with only one positive result. The use of anticoagulants 
and lipid lowering agents were higher in repeated samples positive subjects than those who 
had negative albuminuria on the further samples. 
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Variable (unit) Positive group N Negative group N P-value 
Age (years)  61.4 ± 16.2 153 56.8 ± 14.6 161 0.008 
BMI (Kg/m2)  29.8 ± 6.0 151 28.9 ± 5.3 159 0.136 
SBP (mm Hg)  144.7 ± 21.0 153 141.0 ± 17.3 161 0.076 
DBP (mm Hg)  86.7 ± 12.6 153 87.4 ± 10.3 161 0.613 
Serum creatinine (µmol/L)  90.2 ± 23.4 153 80.9 ± 18.5 161 <0.001 
eGFR (mL/min/1.73 m2)  74.4 ± 21.0 153 80.7 ± 17.9 161 0.005 
Fasting glucose (mmol/L)  5.3 ± 0.6 98 5.1 ± 0.6 121 0.048 
Total cholesterol (mmol/L)  5.0 ± 1.0 149 5.2  ± 1.0 160 0.031 
HDL-cholesterol (mmol/L)   1.4 ± 0.5 149 1.5 ± 0.5 157 0.163 
F. triglycerides (mmol/L)  1.3 (0.9 to 2.1) 97 1.2(0.9 to 1.6) 121 0.023 
Eosinophil count  (×109/L)  0.17 (0.11 to 0.26) 145 0.15 (0.09 to 0.23) 153 0.034 
ESR  (mm in 1 hr)  10 (5.0 to 19.0) 81 9 (4.0 to 15.7) 96 0.171 
Number of drugs* 3 (2 to 5) 151 2 (1 to 4) 153 <0.001 
Table ‎6-3: A comparison between subjects with positive UAE by the combined definition 
in repeated samples (Positive group, n=153) versus those who became negative based on 
multiple samples (Negative group, n=161). Subjects with diabetes mellitus and those with 
proteinuria were excluded. Contineous variables are expressed as mean ± SD or median 
(interquartile range) for non-parametric comparisons. F.: fasting. *Cariovascular/metabolic 
drugs.  
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Variable (%) Positive group N Negative group N P value 
Male  51.6% 79 40.4% 65 0.054 
Co-morbidities/ risk: 
Diabetes family history 16.0% 15 8.2% 8 0.121 
Stroke family history 16.2% 16 6.5% 7 0.044 
CHD  family history 22.7% 22 19.4% 21 0.609 
Current smoker  9.6% 10 12.2% 14 0.666 
LVH 32.2% 46 18.5% 28 0.007 
ST-T changes  22.0% 22 11.0.% 13 0.041 
CVD  23.6% 35 15.0% 23 0.079 
Pharmacotherapy: 
Diuretics  48.3% 73 42.6% 66 0.358 
CCBs 52.3% 79 40.6% 63 0.051 
ACEIs 45.0% 68 38.7% 60 0.297 
ARBs  35.8% 54 29.0% 45 0.223 
Beta blockers 36.4% 55 27.7% 43 0.112 
Alpha blockers 17.2% 26 11.0% 17 0.139 
Aldosterone antagonists 7.3% 11 5.8% 9 0.649 
Imidazoline agonists 1.3% 2 2.6% 4 0.685 
Statins  39.7% 60 31.0% 48 0.121 
Other lipid lowering 6.6% 10 1.9% 3 0.050 
Anti-platelet agents 23.2% 35 18.7% 29 0.399 
Anticoagulants 8.6% 13 1.9% 3 0.010 
Vasodilators 4.0% 6 1.9% 3 0.331 
Table ‎6-4: The clinical characteristics of subjects with positive UAE by both definitions in 
repeated samples (Positive group, n=153) versus those who became negative based on 
multiple samples (Negative group, n=161). Variables are expressed as percentage of 
cohort. N represnts number of cases of releavant variable. 
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6.3.5 Characteristics of those with only one-positive UAE sample 
versus those with positive result on single or multiple 
samples 
Tables ‎6-5 and ‎6-6 show comparisons of the demographic characteristics of subjects who 
had one positive microalbuminuria result but in whom further samples were not possible 
versus the characteristics of subjects with microalbuminuria on repeated measurements or 
those who became negative in repeated samples. The combined definition was used in each 
group. Data of patients with diabetes and those with gross proteinuria were not included in 
the comparison.  
With the exception of SBP, DBP and total cholesterol, microalbuminuric subjects by 
repeated measurement had cardiovascular risk factors higher than in those positive on one 
sample and those who became negative on repeated samples. Subjects with 
microalbuminuria on repeated samples had higher values for inflammatory markers, less 
good renal function, increased fasting glucose level and were treated with higher number 
of drugs. The proportion of those with ECG abnormalities and established CVD was also 
higher in microalbuminuric subjects by repeated samples. Subjects with only one positive 
sample had cardiovascular risk parameters higher than those who became negative such as 
age, BMI, SBP, DBP, total cholesterol, fasting triglycerides, ESR and LVH. 
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Variable (unit) Group 1 N Group 2  N Group 3  N P-value 
Age (years) 56.8 ± 14.6 161 58.2 ± 15.7 97 61.4 ± 16.2 153 0.027 
BMI (Kg/m
2
) 28.9 ± 5.3 159 30.5 ± 7.0 92 29.9 ± 6.0 151 0.117 
SBP (mm Hg) 141.0 ± 17.3 161 146.6 ± 20.8 97 144.7 ± 21.0 153 0.054 
DBP (mm Hg) 87.4 ± 10.3 161 92.1 ± 13.0 97 86.7 ± 12.6 153 0.001 
Serum creatinine (µmol/L) 80.9 ± 18.5 161 79.7 ± 15.7 97 90.2 ± 23.4 153 <0.001 
eGFR (mL/min/1.73 m
2
) 80.7 ± 17.9 161 82.2 ± 17.6 97 74.4 ± 21.0 153 0.002 
Fasting glucose (mmol/L) 5.1 ± 0.6 121 5.1 ± 0.7 62 5.3 ± 0.6 98 0.033 
Total cholesterol (mmol/L) 5.2  ± 1.0 160 5.3 ± 1.2 91 5.0 ± 1.0 149 0.046 
HDL-cholesterol (mmol/L) 1.5 ± 0.5 157 1.4 ± 0.4 86 1.4 ± 0.5 149 0.137 
Fasting triglycerides (mmol/L) 1.2 (0.9 to 1.6) 121 1.4 (0.8 to 2.1) 60 1.3 (0.9 to 2.1) 97 0.074 
Eosinophil count (×10
9
/L) 0.15 (0.09 to 0.23) 153 0.12 (0.07 to 0.22) 87 0.17 (0.11 to 0.26) 145 0.004 
ESR (mm in 1 hr) 9 (4.0 to 15.7) 96 9.5 (5 to 18) 70 10 (5.0 to 19.0) 81 0.313 
Number of drugs* 2 (1 to 4) 153 3 (1 to 4) 94 3 (2 to 5) 151 0.001 
Table ‎6-5: A comparison of the demographic characteristics of those who became negative on repeated measurements (group 1, n=161), 
microalbuminuria on one sample but further samples were not available (group 2, n=97) and microalbuminuric subjects on repeated samples by the 
combined definition (group 3, n=153). Data are expressed as mean ± (S.D) or median (interquartile range), as appropriate. N represnts number of cases of 
releavant variable.   * Cardiovascular/meatblic drug
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Variable Group1 N Group2 N Group3 N P value 
Male  40.4% 65 45.4% 44 51.6% 79 0.137 
Comorbidities/risk: 
Diabetes family history 8.2% 8 17.9% 15 16% 15 0.133 
Stroke family history 6.5% 7 11.1% 10 16.2% 16 0.089 
CHD  family history 19.4% 21 22.2% 20 22.7% 22 0.847 
Current smokers 12.2% 14 11.7% 11 9.6% 10 0.833 
LVH 18.5% 28 28.9% 24 32.2% 46 0.022 
ST-T changes on ECG 11.0.% 13 9.1% 7 22.0% 22 0.022 
CVD  15.0% 23 12.2% 11 23.6% 35 0.046 
Pharmacotherapy: 
Diuretics  42.6% 66 46.3% 44 48.3% 73 0.603 
CCBs 40.6% 63 42.1% 40 52.3% 79 0.096 
ACEIs 38.7% 60 36.8% 35 45.0% 68 0.366 
ARBs  29.0% 45 32.6% 31 35.8% 54 0.464 
Beta blockers 27.7% 43 30.5% 29 36.4% 55 0.252 
Alpha blockers 11.0% 17 13.7% 13 17.2% 26 0.291 
Aldosterone blockers 5.8% 9 10.5% 10 7.3% 11 0.415 
Imidazoline agonists 2.6% 4 2.1% 2 1.3% 2 0.743 
Statins  31.0% 48 29.5% 28 39.7% 60 0.157 
Other lipid lowering 1.9% 3 2.1% 2 6.6% 10 0.084 
Anti-platelet agents 18.7% 29 24.2% 23 23.2% 35 0.502 
Anticoagulants 1.9% 3 2.1% 2 8.6% 13 0.012 
Vasodilators 1.9% 3 3.2% 3 4% 6 0.610 
Table ‎6-6:  A comparison of the categorical variables of those who became negative on 
repeated measurements (group 1, n=161), microalbuminurics on one sample but further 
samples were not available (group 2, n=97) and microalbuminuric subjects on repeated 
samples by the combined definition (group 3, n=153). Data are expressed as percentage of 
cohort. N represnts number of cases of releavant variable. 
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6.4 Summary/discussion  
There were minor differences between the GBPC and The Aberdeen clinic populations. 
The use of semi-quantitative urine dipsticks resulted in a higher prevalence of 
microalbuminuria in the Aberdeen Hypertension Clinic. This may indicate that detecting 
microalbuminuria by semi-quantitative urine strips may overestimate the prevalence and 
give false-positive results. However, subjects attending the Aberdeen Hypertension Clinic 
had poorer renal function compared with the GBPC population, a finding which may 
explain the higher prevalence of microalbuminuria. This was supported by the observation 
that the prevalence of microalbuminuria on repeated sample was also higher in the 
Aberdeen population. Whether laboratory analysis is more accurate than urine strips in 
detecting microalbuminuria cannot be confirmed using my data.  
There were marked reductions in the prevalence of microalbuminuria on repeated samples 
compared with the first sample in both cohorts. Patients with microalbuminuria only on 
first urine sample tended to have cardiovascular risk lower than in those with repeated 
positive samples but higher than in those who became negative on repeated samples. 
Together, these finding suggest that diagnosing microalbuminuria based on single 
measurement of albuminuria is not reliable and may overestimate the prevalence of 
clinically relevant microalbuminuria. 
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7. Chapter seven: blood pressure and proteinuria 
over time in subjects attending the GBPC 
 
7.1 Introduction 
Microalbuminuria is strongly associated with high blood pressure and is prevalent in 
subjects with uncontrolled hypertension (Ravera et al., 2006). However, little is known 
about the pattern of blood pressure changes with relation to urinary albumin excretion in 
treated hypertensive subjects attending specialist clinics. The main goal of this analysis 
was to study, longitudinally, the blood pressure changes in subjects with normal urinary 
albumin excretion and those with microalbuminuria. In a secondary analysis, the results of 
proteinuria as assessed by dipsticks at entry to the clinic (baseline) were related to the 
results of laboratory analysis for microalbuminuria.  
7.2 Methods 
Anonymised patient information was extracted from the database of the GBPC. This 
database stores the demographic and clinical characteristics of more than 15,000 patients, 
including blood pressure records from each visit. At first visit, protein excretion in the 
urine is routinely investigated using Multistix 10 SG Reagent Strips. Proteinuria was 
diagnosed when the result of the dipstick showed trace or more of protein in urine (≥15 
mg/dL). The results of proteinuria examination were found in 558 subjects participated in 
the microalbuminuria analysis and linked to the results of laboratory analysis of 
albuminuria.  
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7.3 Results 
7.3.1 Blood pressure changes 
7.3.1.1 Cross-sectional analysis of blood pressure at baseline, 6 months, 1 
year and 2 years  
Table ‎7-1 shows a comparison of blood pressure changes from baseline (first-ever reading 
at the GBPC) to 6 months (±2 months), first year (± 3 months), second year (± 3 months) 
and readings obtained during the screening of microalbuminuria in all available data of 
subjects attending the GBPC. Patients with proteinuria (n=24) and those with only one 
positive sample (n=116) were excluded from this analysis making the final sample size n= 
744 (the original GBPC sample size was 884). Patients were assigned to three groups, 
according to the result of repeated measurements of UAE (i.e. normoalbuminuria, the new 
definition and the conventional definition of microalbuminuria). 
At baseline, subjects with increased UAE had SBP significantly higher than in 
normoalbuminuric individuals;  163.9 ± 23.5 mm Hg in the conventional definition group, 
161.4 ± 23.1 mm Hg in the new definition group  and 152.5 ± 20.0 mm Hg in 
normoalbuminuric individuals, P<0.001 using ANOVA test. The SBP in both definitions 
of microalbuminuria were statistically higher than that in normoalbuminuric individuals, 
P<0.05. On the other hand, DBP was not significantly different in the three groups at 
baseline (94.6 ± 10.4 mm Hg, 95.0 ± 12.0 mm Hg and 92.8 ± 12.0 mm Hg for 
normoalbuminuric subjects, the new definition and the conventional definition of 
microalbuminuria, respectively. Subjects with microalbuminuria had higher pulse pressure; 
57.9 ± 17.6 mm Hg, 66.4 ± 22.1 mm Hg and 71.1 ± 22.5 mm Hg for normoalbuminurics, 
the new definition and the conventional definition of microalbuminuria, respectively. 
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Four hundred twenty four subjects had blood pressure records after 6 months from their 
first visit. Normoalbuminuric individuals achieved 8% reduction in SBP, with a mean 
reduction of -14.7 ± 19.3 mm Hg. The SBP of subjects with microalbuminuria by the new 
and the conventional definitions was reduced by approximately 11%; mean reduction -17.5 
± 22.3 mm Hg and -16.2 ± 20.3 mm Hg, respectively. Although the reduction was 
relatively higher in microalbuminuric subjects by the two definitions, the mean SBPs were 
still significantly higher than in individuals with microalbuminuria (P=010). The mean 
SBP in the two microalbuminuric groups was above the therapeutic target for SBP (<140 
mm Hg) while normoalbuminuric individuals were just below the threshold. All the three 
groups achieved reductions in the DBP of about 5% after six months follow-up. The pulse 
pressure was again higher in individuals with microalbuminuria. 
After one year, data of 492 subjects were available. There were slight reductions in both 
SBP and DBP in all three groups. The SBP was higher in microalbuminuric subjects by the 
two definitions, although the differences between the groups were just above the 
significance threshold (p=0.052). The mean DBPs of the three groups were not different 
and below the therapeutic target (< 90 mm Hg). Microalbuminuric subjects continued to 
have greater pulse pressure than normoalbuminuric subjects. 
In their 2
nd
 year of follow-up at the GBPC, there were slight further reductions in the SBP 
of microalbuminuric subjects but not in those with normal UAE. There were no differences 
between the three groups in terms of mean SBP. Likewise, there were no apparent 
differences between the levels of DBP in the 2
nd
 year versus 1
st
 year. However, the pulse 
pressure was statistically higher in microalbuminuric patients.  The mean value of SBP in 
subjects with the conventional definition microalbuminuria was just above the therapeutic 
target (141.0 ± 19.4 mm Hg).  
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The difference between the baseline SBP and the SBP that was obtained when 
microalbuminuria was measured was highest in subjects with the new definition of 
microalbuminuria followed by the conventional definition and normoalbuminuria; - 23.2 ± 
25.1 mm Hg, - 17.8 ± 27.3 mm Hg and -14.2 ± 21 mm Hg, respectively. However, a 
comparison between normoalbuminuric and the conventional definition subjects revealed 
no statistical significance (data are not shown). Also, individuals with the new definition of 
microalbuminuria achieved the greatest reduction of DBP but the overall difference 
between the groups was not significant. Subjects with microalbuminuria by the 
conventional definition had the highest pulse pressure, followed by the new definition 
group and those with normal UAE. 
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Variables 
(mm Hg) 
Normal 
UAE 
N New 
definition 
N Conventional 
definition 
N P-value 
A. Blood pressure:       
Baseline SBP 152.5 ± 20.0 593 161.4 ±23.1 69 163.9 ± 23.5 82 <0.001 
6 months SBP: 139.6 ± 14.7 324 144.8 ± 18.9 44 145.1 ± 17.8 56 0.010 
 reduction -14.7 ± 19.3 324 -17.5 ± 22.3 44 -16.2 ± 20.3 56 0.610 
1
st
 year SBP: 139.0 ± 17.4 375 143.4 ± 20.2 53 144.2 ± 22.5 64 0.052 
 reduction -15.2 ± 22.1 375 -17.6 ± 20.3 53 - 20.1 ± 24.9 64 0.238 
2
nd
 year SBP: 138.7 ± 16.2 323 139.6 ± 18.8 50 141.0 ± 19.4 47 0.680 
reduction -16.0 ± 23.4 323 -20.7 ± 25.0 50 -25.0 ± 26.0 47 0.035 
SBP (MAU)* 138.2 ± 17.9 593 138.2 ± 16.5 69 146.1 ± 21.8 82 0.001 
reduction  -14.2 ± 21.0 593 - 23.2 ± 25.1 69 - 17.8 ± 27.3 82 0.003 
        
Baseline DBP 94.6 ± 10.4 593 95.0 ± 12.0 69 92.8 ± 12.0 82 0.306 
6 months DBP: 88.9 ± 9.1 324 90.8 ± 10.1 44 88.5 ± 9.5 56 0.395 
reduction -6.3 ± 10.6 324 -5.5 ± 9.4 44 -5.0 ± 8.6 56 0.657 
1
st
 year DBP: 87.6 ± 9.1 369 87.6 ± 10.7 52 87.1 ± 11.9 64 0.904 
reduction -7.7 ± 10.3 369 -7.0 ± 9.9 52 - 6.1 ± 11.5 64 0.525 
2
nd
 year DBP: 87.8 ± 9.0 290 86.0 ± 10.1 47 85.0 ± 8.7 46 0.087 
reduction -8.6 ± 11.3 290 -9.7 ± 12.0 47 -8.4 ± 9.0 46 0.810 
DBP (MAU)* 87.2 ± 10.0 593 85.0 ± 11.0 69 86.3 ± 13.8 82 0.217 
reduction -7.3 ± 10.6 593 -10.0 ± 13.3 69 -6.4 ± 13.2 82 0.118 
B. Pulse pressure:              
Baseline 57.9 ± 17.6 593 66.4 ± 22.1 69 71.1 ± 22.5 82 <0.001 
6 months 50.6 ± 13.4 324 54.0 ± 16.2 44 56.5 ± 16.8 56 0.009 
1 year 51.8 ± 16.2 355 55.8 ± 19.3 49 57.6 ± 20.8 62 0.025 
2 years 51.0 ± 15.1 238 55.1 ± 16.7 46 57.7 ± 18.8 43 0.015 
MAU screening 50.9 ± 15.4 593 53.2 ± 14.2 69 59.7 ± 18.9 82 <0.001 
Table ‎7-1: Blood pressure and pulse pressure over time in normoalbuminuric (n=593) and 
microalbuminuric by the new definition (n=69) and the conventional definition (n=82).  
Blood pressure reduction was calculated by subtracting the corresponding reading from 
baseline record. Data are expressed as mean ± standard deviation. * SBP (MAU) and DBP 
(MAU) refer to the blood pressure readings obtained during microalbuminuria screening.  
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7.3.1.2 Longitudinal analysis at baseline, 1 year and 2 years 
Table ‎7-2 summarises the blood pressure changes from baseline to first and second years 
of follow-up in those with information at all time points (n= 314). In this table, patients 
were divided into normoalbuminurics and microalbuminurics (by the combined definition) 
because of insufficient sample size in each microalbuminuria definition alone. As in the 
analysis that was carried out on all the available data, microalbuminuric subjects had SBP 
at baseline greater than in normoalbuminuric individuals while DBP did not differ in the 
two groups. SBP was always higher in microalbuminuric subjects at all measurement 
periods. There were no differences between the groups in term of DBP except after two 
years where DBP in individuals with normoalbuminuria was higher than in those with 
microalbuminuria. Microalbuminuric patients had the highest pulse pressure at all 
measurement periods. 
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Variables (mm Hg) Normoalbuminuria Microalbuminuria P-value 
A. Blood Pressure:    
Baseline SBP 153.8 ± 10.7 164.7 ± 14.7 0.001 
1
st
 year SBP: 139.2 ± 17.3 144.0 ± 22.0 0.089 
reduction -14.6 ± 21.9 20.7 ± 25.1 0.044 
2
nd
 year SBP: 138.4 ± 16.2 142.5 ± 20.0 0.104 
reduction -15.5 ± 23.6 -22.2 ± 25.8 0.038 
SBP (MAU)* 135.4 ± 17.6 139.8 ± 19.0 0.068 
reduction  -18.4 ± 23.2 -24.9 ± 26.0 0.042 
    
Baseline DBP 96.2 ± 10.8 94.0 ± 12.4 0.140 
1
st
 year DBP: 88.5 ± 9.1 87.0 ± 12.7 0.306 
reduction -7.6 ± 11.0 -7.1 ± 10.3 0.691 
2
nd
 year DBP: 87.6 ± 9.1 85.0 ± 9.6 0.035 
reduction -8.6 ± 11.7 -8.9 ± 10.7 0.800 
DBP (MAU)* 86.2 ± 9.1 84.0 ± 12.5 0.148 
reduction -10.0 ± 11.8 -10.0 ± 13.4 0.960 
B. Pulse pressure:    
Baseline 57.6 ± 17.7 70.7 ± 23.8 <0.001 
1 year 50.6 ± 15.2 57.1 ± 20.1 0.013 
2 years  50.8 ± 15.0 57.5 ± 18.5 0.005 
During MAU screening 49.1 ± 14.8 55.8 ± 17.0 0.001 
Table ‎7-2: Blood pressure and pulse pressure in subjects with normoalbuminuria (n=240) 
and microalbuminuria (by the combined definition, n=74) from baseline to 12 months, 24 
months and blood pressure taken during microalbuminuria study in those with records at 
all previously mentioned points. Data are expressed as mean ± standard deviation. * SBP 
(MAU) and DBP (MAU) refer to the blood pressure readings obtained during 
microalbuminuria screening.  
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7.3.2 Proteinuria changes 
After excluding those with only one positive result of microalbuminuria screening, results 
of dipstick examination at entry (first visit) to the clinic were available in 558 patients. 
Four hundred thirty subjects were normoalbuminurics at microalbuminuria screening and 
the remainder had albuminuria (gross proteinuria or microalbuminuria by both definitions).  
The results of urine dipstick analysis were evaluated with the microalbuminuria laboratory 
results. In those who had normal UAE, nearly 79% had negative proteinuria results on 
dipsticks. However, 21% of normoalbuminuric individuals had a trace of more of protein 
in urine when they first attended the clinic. About 72% of patients with gross proteinuria 
had positive baseline dipsticks but in subjects with microalbuminuria (the combined 
definition), 65% had negative baseline dipstick (figure ‎7-1).  
7.3.2.1 Patient characteristics stratified by the results of baseline dipstick 
and laboratory analysis  
Tables ‎7-3 and ‎7-4 show the demographic and clinical characteristics of the 558 patients 
stratified by the results of dipstick examination and laboratory assessment of albuminuria. 
Patients were categorised into four groups; patients with negative results in both dipstick 
and laboratory analysis (group 1), those with positive dipstick result but subsequent 
laboratory analysis showed negative result (group 2), those with negative dipstick but lab 
analysis showed positive result ( group 3) and a group of patients with positive results in 
both dipstick and lab analysis (group 4). 
Overall, the highest values for cardiovascular risk factors were found in patients belonging 
to group 4. They were older than other groups, had highest values for BMI, serum 
creatinine (and lowest eGFR), fasting glucose, ESR, eosinophils count, fasting 
triglycerides and cardiovascular/metabolic drugs.  Moreover, group 4 patients had higher 
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proportions for co-morbidities (type II diabetes, LVH, ST-T changes on ECG) and 
established CVD. 
The highest risk score for CVD over 10 years using the Framingham equation was found in 
subjects from group 3. They were also characterised by increased values for cardiovascular 
risk factors such as SBP, pulse pressure and frequent co-morbidities.  On the other hand, 
subjects from either group 1 or 2 had lowest CVD risk scores and cardiovascular 
parameters (except DBP in group 1). 
 
 
Figure ‎7-1: Dipstick examination in all albuminuria categories. 
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Variable Group 1 N Group 2 N Group 3 N Group 4 N P-value 
Age (years) 57.8 ± 12.3 339 53.9 ± 13.0 91 65.1 ± 15.1 77 65.3 ±13.8 51 <0.001 
BMI  (Kg/m
2
) 29.3 ± 6.0 331 31.4 ± 5.8 86 29.8 ± 6.1 74 33.3 ± 6.4 51 <0.001 
SBP (mm Hg) 136 ( 126 to 150) 337 130 (120 to 140) 91 138 (126 to 159) 76 138 (128 to 147) 51 <0.001 
DBP (mm Hg) 90 (80 to 94) 337 84 ( 78 to 92) 91 88 (74 to 94) 76 84 (76 to 92) 51 0.166 
Pulse pressure (mm Hg) 48 (42 to 58) 337 42 (38 to 52) 91 55 (44 to 66) 76 52 (44 to 66) 51 <0.001 
Serum creatinine (µmol/L) 78 (70 to 89) 339 78 (66 to 93) 91 84 (71 to 110) 77 87 (77  to 131) 51 <0.001 
eGFR (mL/min/1.73 m
2
) 80.6 ± 17.9 339 82.1 ± 15.6 91 74.9 ± 23.0 77 66.3 ± 27.0 51 <0.001 
Fasting glucose (mmol/L) 5.1 ( 4.7 to 5.6) 290 5.1 (4.8 to 5.5) 79 5.4 ( 5.1 to 6.0) 68 5.4 (4.9 to 7.9) 46 <0.001 
ESR (mm in 1 hour) 7 (4 to 14) 266 7 (4 to 18) 65 13 (5 to 19) 59 19 (5 to 40) 33 0.001 
Eosinophil count (×10
9
/L) 0.14 (0.08 to 0.23) 316 0.16 (0.12 to 0.25) 87 0.16 (0.11 to 0.27) 74 0.22 (0.15 to 0.34) 46 <0.001 
Total cholesterol (mmol/L) 5.1 ± 1.0 333 5.1 ± 1.1 91 4.6 ±1.1 76 4.7 ± 1.2 51 <0.001 
HDL-cholesterol (mmol/L) 1.5 ± 0.6 329 1.3 ± 0.4 91 1.3 ± 0.5 73 1.3 ± 0.5 51 0.016 
Fasting triglycerides (mmol/L) 1.5 ± 0.8 287 1.4 ± 0.8 79 1.7 ± 1.2 68 1.8 ± 0.8 46 0.022 
Number of drugs* 2.7 ±1.9 330 3.1 ± 2.1 90 4.2 ± 2.0 77 4.8 ± 2.3 48 <0.001 
CVD risk score 11.9 (7.5 to 20) 250 12.7 (7.7 to 18.5) 66 18.7 (12.1 to 27.2) 49 16.1 (9.3 to 26.5) 36 <0.001 
Table ‎7-3: Demographic characteristics stratified by the result of baseline dipstick and albuminuria laboratory analysis; group 1:  negative baseline 
dipstick and lab analysis (n=339), group 2: positive baseline dipstick but negative lab analysis (n=91), group 3: negative baseline dipstick but positive lab 
analysis (n=77) and group 4: positive dipstick and lab analysis (n=51). Data are expressed as mean ± standard deviation or median (interquartile range), 
as appropriate. * Cardiovascular/metabolic drugs.
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Variable (%) Group 1 N Group 2 N Group 3 N Group 4 N P-value 
Male 41.9% 142 44.0% 40 58.4% 45 41.2% 21 0.065 
Smokers 8.4% 27 9.1% 8 12.2% 9 9.3% 4 0.811 
Family history: 
Diabetes 12.8% 36 17.1% 14 12.5% 8 17.1% 7 0.704 
Stroke 10.4% 32 9.4% 8 11.8% 8 9.3% 4 0.959 
CHD 17.2% 53 20.2% 17 19.1% 13 27.9% 12 0.391 
Co-morbidities / risks: 
Type II diabetes 7.8% 26 14.3% 13 23.4% 18 40.0% 20 <0.001 
LVH 18.6% 57 23.3% 20 34.8% 24 42.5% 17 <0.001 
ST-T changes 12.1% 37 9.5% 8 22.1% 15 26.3% 10 0.014 
CVD (%) 12.8% 40 16.3% 14 28.8% 21 25.6% 11 0.004 
Pharmacotherapy: 
Diuretics 45.3% 150 58.2% 53 58.4% 45 64.6% 31 0.009 
CCBs 36.0% 119 46.2% 42 59.7% 46 64.6% 31 <0.001 
ACEIs 34.7% 115 38.5% 35 49.4% 38 50.0% 24 0.037 
ARBs 33.5% 111 37.4% 34 39.0% 30 54.2% 26 0.047 
Beta blockers 26.3% 87 27.5% 25 46.8% 36 45.8% 22 0.001 
Alpha blockers 13.3% 44 12.1% 11 20.8% 16 25.0% 12 0.068 
Aldosterone blockers 7.6% 25 14.3% 13 5.2% 4 12.5% 6 0.106 
Imidazoline agonists 1.2% 4 2.2% 2 1.3% 1 2.1% 1 0.739 
Antidiabetic agents 4.2% 14 6.6% 6 15.6% 12 29.2% 14 <0.001 
Antiplatelet agents 21.1% 70 28.6% 26 33.8% 26 41.7% 20 0.005 
Statins 34.4% 114 39.6% 36 49.4% 38 58.3% 28 0.003 
Lipid lowering 3.6% 12 3.3% 3 10.4% 8 6.3% 3 0.083 
Anticoagulants 1.2% 4 1.1% 1 10.4% 8 4.2% 2 0.001 
Vasodilators 1.2% 4 1.1% 1 6.5% 5 6.3% 3 0.010 
Table ‎7-4: Clinical characteristics stratified by the result of baseline dipstick and albuminuria 
laboratory analysis; group 1:  negative baseline dipstick and laboratory analysis (n=339), 
group 2: positive baseline dipstick but negative laboratory analysis (n=91), group 3: negative 
baseline dipstick but positive laboratory analysis (n=77) and group 4: Positive dipstick and 
laboratory analysis (n=51). Data are expressed as percentage of the cohort. 
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7.4 Summary/ discussion 
Microalbuminuria is associated with higher blood pressure at first visit and subsequently. 
Although blood pressure fall was greater in those with microalbuminuria, blood pressure 
remained higher in microalbuminuric subjects. On the other hand, DBP was not different 
between microalbuminuric and normoalbuminuric subjects. The pulse pressure was greater in 
microalbuminuric subjects in all measurements indicating that these subjects might be at high 
risk of vascular diseases. 
Subjects with persistence increase in the urinary albumin excretion from baseline were 
associated with complex co-morbidities and increased cardiovascular risk. Similarly those 
with negative baseline dipstick but later UAE laboratory analysis showed positive result were 
also at high risk of cardiovascular diseases compared with normoalbuminuric subjects with 
either negative or positive baseline dipstick. These finding reinforce the importance of 
screening of increased UAE as a tool of identifying subjects with increased risk for 
cardiovascular morbidities. 
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8. Chapter eight: General discussion 
8.1 General overview 
The current series of studies investigated the prevalence of microalbuminuria and the 
association with predictive factors for worse outcomes in people attending hypertension 
clinics. Most of previous attempts to examine the significance of microalbuminuria in 
hypertension population have limitations such as the selection criteria and small sample sizes. 
Also, many of these studies were confounded by possible misdiagnosis of microalbuminuria 
as the diagnosis was based on single measurement using either urine strips or laboratory 
analysis. This has led to uncertainty about the prevalence of microalbuminuria in hypertension 
and probable underestimation of its clinical significance. 
Microalbuminuria by the currently accepted threshold was found in 11% of subjects attending 
specialist blood pressure clinics (9.5% in those without diabetes). This study also 
demonstrated, for the first time, that microalbuminuria by the new definition was present in 
11% of the cohort (10% in non-diabetic). High prevalence of microalbuminuria was noted in 
people with hypertension and different co-morbidities such as diabetes, CKD and LVH. 
Microalbuminuria was also found in some people without apparent co-morbidities and with 
good blood pressure control.  
This study revealed that microalbuminuria by both definitions was an independent predictor of 
target organ damage manifested by left ventricular hypertrophy. Microalbuminuria was also a 
strong predictor for cardiovascular disease and risk factors such as ECG abnormalities. The 
use of cardiovascular risk score equations suggested that subjects with microalbuminuria had 
higher chances of developing cardiovascular disease and mortality over 10 years.  
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Although it has been argued that single screening for microalbuminuria is enough for the 
diagnosis, I found that a large proportion of participants who had increased UAE on first 
sample was categorised as normoalbuminuric when the diagnosis was based on multiple 
samples. Subjects with persistent microalbuminuria had increased values for laboratory 
parameters associated with cardiovascular risk and higher prevalence of co-morbidities and 
high-risk clinical characteristics. 
High blood pressure was a powerful predictor of microalbuminuria after adjusting for 
antihypertensive drugs and other potential confounders. The risk of microalbuminuria 
increased in those with poor or very poor blood pressure control. This was also evident in 
cross-sectional and longitudinal analysis of the blood pressure of participants from the GBPC 
where individuals with microalbuminuria had higher blood pressure at presentation and 
subsequently.  
Eosinophil count was also a significant independent predictor of the conventional definition of 
microalbuminuria. Moreover, levels of ESR were greater in people with microalbuminuria, 
supporting the involvement of inflammation in the progress.  
8.2 Interpretation of the findings  
My results suggest that microalbuminuria is a useful tool for identifying hypertensive subjects 
at increased risk for future cardiovascular events. It is extremely important to determine the 
prevalence of microalbuminuria in hypertension in order to evaluate whether screening for this 
condition provides additional information that will help in planning therapeutic strategies. In 
diabetes mellitus, for example, it is well recognised that microalbuminuria helps in identifying 
patients at higher risk for developing diabetic nephropathy; periodic screening for 
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microalbuminuria is recommended (American Diabetes Association, 2011). This 
recommendation is driven by the evidence reported from many studies that investigated the 
prevalence and the clinical usefulness of microalbuminuria screening in diabetes.  
Microalbuminuria is not uncommon in hypertension. Screening for microalbuminuria offers 
potential for identifying almost one-fifth of hypertensive subjects at increased cardiovascular 
risk. My findings showed a close association between microalbuminuria and several 
abnormalities. This association seems to start at levels below the current definition. By relying 
on the conventional definition of microalbuminuria, the clinician may miss an opportunity of 
identifying those with early vascular changes.  
The association of microalbuminuria with increased laboratory parameters and cardiovascular 
risk score in people without co-morbidities or risk may reflect that those subjects are at greater 
risk for future cardiovascular events. Microalbuminuria offers additional information beyond 
that provided by conventional risk factors. Therefore, screening for microalbuminuria in 
apparently healthy subjects with hypertension may detect early changes that require more 
rigorous treatment. This needs to be confirmed on a prospective study with larger sample size. 
The observation that large proportion of individuals with microalbuminuria at first screening 
became negative when multiple samples were considered indicates that single screening is not 
enough for reliable diagnosis of microalbuminuria in hypertension. This also means that any 
future study investigating microalbuminuria and outcomes in hypertension should be based on 
multiple samples for better correlation. 
My findings also emphasise on the importance of blood pressure as one of the most important 
determinant of microalbuminuria. Thus, better control of blood pressure using 
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pharmacological approaches should be the main strategy for attenuating microalbuminuria in 
hypertension.  
8.3 Study population 
The individuals who participated in my studies had the typical characteristics of those 
attending hypertension clinics in the UK; relatively high age, a high proportion of obese and 
overweight subjects, sub-optimal control of blood pressure, mildly elevated serum cholesterol 
and relatively normal glucose level and renal function (Cuspidi et al., 1999, Cuspidi et al., 
2006, Eguchi et al., 2010). The cohort was also characterised by increased co-morbidities. The 
prevalence of LVH was lower than that reported in several studies which have used 
echocardiography for the diagnosis (Mancia et al., 2002, Martinez et al., 2003, Cuspidi et al., 
2012). Difference can be attributed to variability in the definitions and methods used for the 
identification of LVH and the population tested (high risk, untreated hypertension, etc).  Also, 
the percentage of people with diabetes was relatively low (Lonati et al., 2008). This is because 
subjects with diabetes mellitus in Glasgow are usually referred to diabetologists, even if they 
suffer from high blood pressure.   
8.4 Prevalence of microalbuminuria 
The prevalence of microalbuminuria by the conventional definition was 11%. When the data 
of patients with diabetes and those with impaired renal function were excluded, 
microalbuminuria was found in 9.5% of the subjects.  
This prevalence is relatively low compared with that reported in a number of studies (Böhm et 
al., 2007).  This might be because repeated measurement were made in this study to minimise 
the effect of confounding factors such as requesting multiple samples and the exclusion of 
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UTI-positive samples. Furthermore, the prevalence of microalbuminuria was based on 
laboratory quantification of albumin levels in the urine.  
This is the first study to report the prevalence of microalbuminuria based on multiple samples 
in treated hypertensive subjects attending secondary/tertiary blood pressure clinics. The 
MAGIC trial reported lower prevalence of microalbuminuria (6.7%) in non-diabetic subjects 
with hypertension (n=787) using repeated measurements. However, there were some 
restrictions on the population tested such as exclusion of those older than 72 years, those with 
liver disease, heart failure, kidney disease, severe hypertension, severe obesity and patients 
with hypokalemia (Pontremoli et al., 1997). The limits for defining microalbuminuria in the 
MAGIC study were also more restricted than that used in the current study and those of most 
therapeutic guidelines (ACR 2.38 – 19 mg/mmol in males and 2.96 – 20 mg/mmol in females). 
The i-SEARCH global study also reported the prevalence of microalbuminuria in the setting 
of blood pressure clinics (Böhm et al., 2007). The overall prevalence of microalbuminuria in 
more than 20,000 individuals from 26 countries was 58%. This high prevalence could be due 
to several factors. Microalbuminuria was detected on single occasion using urine strips. In 
addition to the limited ability of urine strips to quantify albumin levels, strips also carry the 
risk of overestimation or underestimation due to concentration or dilution of the urine (Lin et 
al., 2011). This is because urine dipsticks detect urinary albumin concentrations which are 
affected by urine volume. In my analysis, I used the albumin-to-creatinine ratio that adjusts for 
any possible volume differences. 
The authors of the i-SEARCH study did not mention whether spot or early morning samples 
were used. Spot urine samples are subject to confounding influences and  have been shown to 
overestimate the prevalence of microalbuminuria (Witte et al., 2009). In a study that used 24-
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hour urine collection as a reference method, the ACR from early morning urine samples was 
compared with the ACR from spot urine samples (Witte et al., 2009). The investigators found 
that the prevalence of microalbuminuria using 24-hour urine collection, early morning and 
spot urine samples were 10%, 7.5% and 22.4%, respectively.  
The other factor that might lead to the increased prevalence of microalbuminuria reported in 
the i-SEARCH study is that the population studied had complex co-morbidities. For instance, 
the prevalence of diabetes and established cardiovascular disease were higher than that 
observed in the current analysis; 27.5% versus 13.1% and 36% versus 18%, respectively. Such 
conditions are usually associated with a higher prevalence of microalbuminuria and therefore 
affect the overall prevalence in the study population.  
Microalbuminuria by the conventional definition was found in 20% of patients with diabetes. 
This prevalence was less than that reported in the literature. For example, among patients with 
diabetes who participated in the HOPE and Micro-HOPE studies, about one-third had 
microalbuminuria (ACR ≥ 2 mg/mmol in both genders) (Heart Outcomes Prevention 
Evaluation Study Investigators, 2000b). The prevalence of microalbuminuria, measured as 
ACR 30 to 300 mg/g, in patients with diabetes (n= 10,640) who participated in the 
ADVANCE study, was 27% (Ninomiya et al., 2009). In the I-DEMAND (Italy Developing 
Education and awareness on MicroAlbuminuria in patients with hyperteNsive Disease) study, 
52% and 44% of diabetic hypertensive subjects with normal eGFR or reduced eGFR, 
respectively, were microalbuminurics (Leoncini et al., 2010).  In the HOPE, ADVANCE and 
I-DEMAND studies, all prevalence estimates was based on single measurement of albumin 
excretion. The ADVANCE and HOPE studies, the selection criteria of patients enrolled 
involved the presence of cardiovascular disease in addition to diabetes mellitus. The 
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prevalence of microalbuminuria tends to be high in patients with concomitant cardiovascular 
disease (Mlačak et al., 1999). 
The low percentage of patients with diabetes in the current study undoubtedly affects the 
microalbuminuria prevalence. In the I-DEMAND study (n=3534), 37% of the participants in 
the cohort had diabetes mellitus compared with 13% in my study. Also, the definition of 
microalbuminuria in the I-DEMAND study was ACR ≥2.5 mg/ mmol in males or ≥3.5 mg/ 
mmol in females, but it was not clear whether or not subjects with gross proteinuria were 
included. The present study allows a clearer estimate of the prevalence of microalbuminuria in 
hypertension, without the confounding influence of diabetes. 
Albuminuria below the conventional definition has been shown to be associated with 
increased cardiovascular risk (Klausen et al., 2004). The current threshold of defining 
microalbuminuria is arbitrary. Therefore, I sought to investigate the prevalence of lower levels 
of microalbuminuria (the new definition) and its association with co-morbidities. The use of 
the new definition increased the prevalence of microalbuminuria by 11.1% in the overall 
population, and 10% in non-diabetic non-CKD (stage 4 or 5) subjects.  
I am not aware of any study based on clinical settings of blood pressure clinic that has studied 
the prevalence of microalbuminuria using the new definition. In the PREVEND study, the 
prevalence of high-normal albuminuria defined as UAC of 10–20 mg/l was about 6% (de 
Jong et al., 2003). Nevertheless, the PREVEND study was population-based and measurement 
of microalbuminuria was carried out at single occasion without correcting any variations in 
urine volume. In a Japanese study, high normal albuminuria, defined as ACR >20 - <30 
μg/mg, was found in 20% of untreated subjects with essential hypertension (Ohmaru et al., 
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2011). However, the sample size was small (n=332) and there were many exclusions (e.g. 
those with CHD, arrhythmia, cardiomyopathy and cerebrovascular diseases). 
Microalbuminuria was estimated from single random urine specimen, a method that has been 
shown to overestimate microalbuminuria prevalence, as mentioned earlier.  
8.5 Association of microalbuminuria with the 
characteristics of non-diabetic hypertensive subjects 
without severe kidney dysfunction 
Subjects with microalbuminuria by the new and the conventional definitions were older than 
those with normal albumin excretion. This finding is in agreement with previous studies where 
advanced age was shown to be among the clinical characteristics of microalbuminuric subjects 
(Hillege et al., 2001, Klausen et al., 2005, Romundstad et al., 2003b). In a recent community-
based study of approximately 11,000 subjects, there was a clear trend of a linear relationship 
between age and albumin excretion in the urine (classified into five groups; optimal, 
intermediate, high-normal, microalbuminuria and gross proteinuria) (Blecker et al., 2011). 
Microalbuminuria based on both definitions was not associated with increased BMI. The 
available data of the association between microalbuminuria and obesity is conflicting. While 
some studies report a stepwise relationship between BMI and UAE in the general population 
(Kramer et al., 2005, Ferris et al., 2007), hypertension (Pontremoli et al., 1997, Martínez et al., 
2001, Bello et al., 2010) and diabetes (Kramer et al., 2009), others suggest a relationship with 
central obesity measured by waist circumference (Bonnet et al., 2006, Böhm et al., 2007, 
Chandie et al., 2007, Rossi et al., 2010). However, many previous studies reported no 
association between BMI and microalbuminuria (Leoncini et al., 2010, Oliveras et al., 2011).  
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There is no specific explanation of the conflicting findings about the association between BMI 
and UAE. Both microalbuminuria and obesity are risk factors for cardiovascular diseases. The 
studied population may have an impact on the association between obesity and 
microalbuminuria. For instance, increased BMI and central obesity are frequent observations 
in advanced type II diabetes mellitus, which is also characterised by nephropathy. In this 
study, diabetic subjects with gross proteinuria had statistically significant higher BMI than 
those with lower levels of albuminuria, although the small number of diabetic patients makes 
it difficult to provide conclusions. In hypertension, the association is not very well established. 
In the study by Leoncini et al. (Leoncini et al., 2010), subjects with morbid obesity (>150% 
ideal weight) were excluded, which may affect the association. The finding by Martínez et al. 
(Martínez et al., 2001) is limited by the small number of subjects with microalbuminuria 
(n=16). The sample size in this study is larger, and selection was not influenced by BMI. 
Unfortunately, waist circumference was not measured, precluding investigation of any 
association with microalbuminuria. 
Gender distribution was not significantly different in subjects with and without 
microalbuminuria. The available data on the association of microalbuminuria with specific 
gender is also contradictory. Among subjects who participated in the PREVEND study, 
microalbuminuria was more prevalent in men, almost twofold greater than in women (Verhave 
et al., 2003). Several studies have reported similar findings (Viazzi et al., 2010, Böhm et al., 
2007, Tada et al., 2008, Jauregui et al., 2009). On the other hand, data from the third National 
Health and Nutrition Examination Survey revealed that microalbuminuria was more likely to 
be prevalent in females (Jones et al., 2002). The EPIC-Norfolk study also reported a higher 
prevalence of microalbuminuria in females than in males (14% versus 8%, P<0.05) (Yuyun et 
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al., 2004b). Other studies reported no gender differences between those with and without 
microalbuminuria (Jager et al., 1999, Calviño et al., 1999).  
The inconsistency in gender prevalence of microalbuminuria might be attributed to the 
variability of albumin excretion. Most studies were based on a single random urine specimen. 
Such a collection method is more prone to bias caused by confounders such as UTI, exercise 
and menstruation. Therefore, gender differences in prevalence of microalbuminuria are not 
well supported. Also, a plausible pathophysiological basis for such an association is lacking. 
Microalbuminuria was strongly associated with increased blood pressure, a finding that agrees 
with most reported studies on hypertensive subjects (Moran et al., 2006, Lurbe et al., 2002, 
Dell'omo et al., 2003). There was a stepwise relationship between SBP and UAE. Similar 
finding have been reported with both office and ambulatory blood pressure measurements in 
individuals with hypertension, and even in those with high-normal blood pressure (Moran et 
al., 2006). A causal relationship is supported by the observation that strict control of blood 
pressure prevents the development of microalbuminuria and that blood pressure control 
reduces albuminuria (Philipp et al., 2009, Menne et al., 2012).  
Subjects with the new definition of microalbuminuria had SBP higher than that in people with 
normal urinary albumin excretion, although the difference was not significant. Reffelmann et 
al. (Reffelmann et al., 2010) demonstrated that similar association between SBP and high 
normal albuminuria. This study was based on general population with albumin excretion being 
measured only once and with inclusion based on the availability of baseline echocardiographic 
analysis. My finding on the association of SBP with low albumin excretion is important since 
most of people were under fairly extensive hypertension management in a specialist clinic 
setting. 
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DBP was not significantly different in the three albuminuria groups. However, pulse pressure 
was significantly higher in patients with microalbuminuria. One of the possible explanations is 
that subjects with microalbuminuria might suffer from stiffness of large arteries. The 
importance of this finding arises from the observation that high pulse pressure is associated 
with increased cardiovascular risk and is a frequent observation in  several co-morbidities such 
as atherosclerosis (van Popele et al., 2001, Assmann et al., 2005, Tada et al., 2008). In my 
study, those with microalbuminuria by the new definition had high triglycerides and used a 
significantly greater proportion of lipid lowering agents, possibly reflecting a higher 
prevalence of hyperlipidemia and atherosclerosis. These subjects also had higher pulse 
pressure, with a trend towards a significant difference, than in individuals with 
normoalbuminuria. All these findings support the notion that subjects with microalbuminuria 
are at greater risk for subsequent cardiovascular events. 
The association between microalbuminuria and increased pulse pressure has been previously 
reported (Viazzi et al., 2002, Verhave et al., 2005). In a population-based longitudinal study 
investigating the association of several blood pressure parameters (pulse pressure, SBP, DBP 
and mean blood pressure) with UAE, the study revealed that pulse pressure was the best 
predictor for microalbuminuria (Farasat et al., 2010). The small sample size of that study (n= 
450) and the small percentage of subjects with hypertension (34%) make it difficult to extend 
the observation to general hypertension population. Blecker et al. (Blecker et al., 2011) also 
demonstrated a graded increase of pulse pressure with increasing urinary albumin levels 
(measured on single occasion) in general population. The ROADMAP study reported a close 
relationship between UAE and pulse pressure in those with type II diabetes (Januszewicz et 
al., 2011). But the restrictions in the population involved in the ROADMAP to diabetic 
patients limit the generalisability of the findings. In the current study, I have shown the 
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association in general hypertension population and at even lower levels of albuminuria which 
has not been previously reported. 
Subjects with microalbuminuria by both definitions had poor renal function, manifested by 
high serum creatinine level and low eGFR. I have demonstrated that subjects with 
microalbuminuria by the new definition had the lowest grade of eGFR and the highest level of 
serum creatinine. The importance of this finding comes from recent evidence that showed that 
a combination of eGFR and albuminuria is a powerful predictor for progression to ESRD and 
mortality in the general population (Hallan et al., 2009) and in American Indians with diabetes 
(Berhane et al., 2011).  Moreover, it has also been shown that microalbuminuria itself is a 
strong predictor of advanced renal impairment in non-diabetic hypertensive subjects (Viazzi et 
al., 2010). Therefore, microalbuminuria provides clinical utility for identifying subjects at high 
risk of worse renal outcomes. This potential needs to be confirmed in prospective studies in 
general hypertension population involving people with low grade albuminuria.  
Fasting glucose levels in non-diabetic subjects with microalbuminuria were higher than in 
those with normoalbuminuria. Also, random glucose was higher in those with 
microalbuminuria by the conventional definition. The relationship was stronger in subjects 
with hypertension and diabetes mellitus. The association of albuminuria and increased blood 
glucose levels is firmly established in patients with diabetes mellitus (Tapp et al., 2004). On 
the other hand, the interpretation of such a relationship in subjects with hypertension is 
difficult, since the results of the majority of studies are confounded by the inclusion of patients 
with diabetes mellitus. One study in non-diabetic subjects with hypertension suggested no 
difference in glucose level between those with normal UAE and microalbuminuria (Viazzi et 
al., 2010).  
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Impaired glucose tolerance has been found in subjects with hypertension and 
microalbuminuria (Bianchi et al., 1995). In addition, an association of insulin resistance with 
microalbuminuria was reported in a non-diabetic population (Hoehner et al., 2002). A defect 
in insulin signalling has been suggested to play a role in the pathogenesis of microalbuminuria 
(Jauregui et al., 2009). Increased level of fasting glucose in non-diabetic subjects with 
microalbuminuria may reflect changes in the insulin-glucose pathway. Such a finding raises a 
question as to whether or not non-diabetic subjects with hypertension and microalbuminuria 
might be at higher risk of developing diabetes than those with normoalbuminuria. 
Longitudinal follow-up of such a group of patients may clarify possible aetiological relevance.  
The threshold used for the diagnosis of diabetes mellitus is arbitrary (American Diabetes 
Association., 2010). The relationship between blood glucose levels and cardiovascular risk is 
likely to be continuous (Coutinho et al., 1999, Kay-Tee et al., 2001, Brunner et al., 2006). 
Therefore, the relation between blood glucose levels in non-diabetic subjects in the current 
study supports the suggestion that microalbuminuria is a risk predictor for cardiovascular 
disease. 
With the exception of the triglycerides level, there were no significant differences in the lipid 
profile between microalbuminuric and normoalbuminuric individuals. Those with 
microalbuminuria by the new definition had a higher triglycerides level than in both 
normoalbuminuric and microalbuminuric subjects by the conventional definition. My findings 
are in contrast with those reported in several epidemiological studies where the prevalence of 
hyperlipidemia was frequent in subjects with microalbuminuria (Cirillo et al., 1998, Campese 
et al., 1999, Salles et al., 2011a). One possible explanation is that the use of lipid lowering 
agents is fairly high in the current study (more than 38% used statins and other lipid lowering 
199 
 
agents). The treatment of referred patients is based on overall cardiovascular risk, and hence 
rigorous control of serum cholesterol is of particular importance. The initiation of a lipid 
lowering regimen might have confounded the findings. Subjects with microalbuminuria by the 
new definition had a high level of fasting triglycerides. The use of statins was also highest in 
these subjects was also the highest. 
The association of triglycerides with cardiovascular disease is ambiguous. Whether 
triglycerides provide additive information on cardiovascular risk beyond other lipid 
parameters is not well established. The Emerging Risk Factor Collaboration showed that the 
relationship between vascular disease and increased triglycerides levels is weak after adjusting 
for other potential risk factors (Di Angelantonio  et al., 2009). Nevertheless, a relationship 
between CHD and triglycerides was reported recently, where a 16% increase in triglycerides’ 
concentration was associated with a 10% higher risk of CHD (Sarwar  et al., 2010). Two 
recent meta-analyses suggested a relationship between triglycerides and vascular 
cerebrovascular complications after adjusting for potential confounders (Labreuche et al., 
2010, de Caterina et al., 2010).  In view to these findings, it seems that subjects with 
microalbuminuria by the new definition might be at risk of vascular complication. As a result, 
rigours control of blood pressure and other risk factors, including serum lipids, is of particular 
importance. 
Levels of inflammatory markers used in my study (eosinophil count and ESR) were higher in 
those with microalbuminuria. Although the association between microalbuminuria and 
inflammation has been previously reported with more sensitive markers of inflammation such 
as CRP (Kshirsagar et al., 2008, Festa et al., 2000), in my analysis I found that frequently 
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requested tests such as complete blood count (eosinophils) and ESR could serve as a useful 
tool for alerting the clinician about subclinical inflammation in those with microalbuminuria.  
Several inflammatory markers that have been linked to cardiovascular morbidity and mortality 
(such as interleukin-18) were strongly correlated with microalbuminuria in patients with 
diabetes mellitus (Blankenberg et al., 2002, Nakamura et al., 2005). In a small cohort of non-
diabetic subjects with untreated hypertension, albumin excretion was correlated with hs-CRP, 
interleukin-18 and soluble CD40 ligand ( an atherogenic mediator) (Tsioufis et al., 2006). 
ACR was significantly correlated with hs-CRP, while interleukin-18 and CD40 ligand were 
not. However, the study is limited by the small sample size (n=118) and the selection criteria 
(only males, smokers and those with obesity were excluded). Another study showed a strong 
association between microalbuminuria and asymmetric dimethylarginine (another atherogenic 
mediator) in subjects with hypertension, but without diabetes and other cardiovascular 
diseases, limiting the generalisability of the results (Tsioufis et al., 2010). 
The prevalence of a family history of cardiovascular or metabolic diseases was more often 
found in subjects with microalbuminuria, although the association was not significant. There 
was no difference between the groups in terms of the proportion of current smokers. This 
finding differs from earlier findings that reported a positive association between cigarette 
smoking and the prevalence of microalbuminuria (Ukena et al., 2010, Pinto-Sietsma et al., 
2000). The low number of current smokers in my cohort might limit the ability to detect the 
association between UAE and smoking. In addition, it is possible that a proportion of the 
participating subjects had stopped smoking recently, and therefore any association would be 
weakened. 
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Target end-organ damage manifested by LVH was strongly prevalent in those with 
microalbuminuria. Even those with low grade albuminuria had higher prevalence of LVH than 
in individuals with normal UAE. A close association between albuminuria (microalbuminuria 
and gross proteinuria) and LVH on ECG was reported in the LIFE study (Wachtell et al., 
2002). In that study, 8,029 subjects with hypertension and LVH evident on ECG were 
included. After 14 days of treatment with a placebo, another ECG was obtained, along with 
morning urine specimens for ACR measurement. Based on the second ECG, 78% of the 
cohort had persisting LVH. Microalbuminuria was strongly associated with LVH in those with 
LVH on the second ECG, more so than those who became negative. The association was 
evident even after controlling for possible confounders such as blood pressure, age, gender, 
serum creatinine and diabetes. Despite this, the LIFE study had a number of limitations. For 
instance, microalbuminuria was detected by a single sample without investigating for evidence 
of UTI in the specimen. This might overestimate the microalbuminuria prevalence. Selection 
bias also affected the magnitude of the association, as patients were selected based on the 
presence of LVH in the first ECG, and only 22% had no evidence on the second ECG. In other 
words, it would be better if the association had been reported in a cohort of general 
hypertension subjects with a normal cardiovascular disease distribution. In my analysis, the 
association was seen in general population with limited inclusion/exclusion criteria and after 
confirming the presence of microalbuminuria. 
Subjects with microalbuminuria by the new definition had a high prevalence of LVH. 
Reffelmann et al. (Reffelmann et al., 2010) investigated the clinical utility of 
microalbuminuria in predicting future changes in left ventricular mass in a cohort of 1,086 
subjects from the general population. They found that levels of UAE starting from 0.5 
mg/mmol were a strong predictor of increased left ventricular mass over the next 5 years. The 
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association was stronger in sub-groups with hypertension than in those without hypertension. 
As mentioned earlier, single urine specimen was used for diagnosing albuminuria in the study 
by Reffelmann et al. (2010) which may limit their finding. Also, they investigated the 
predictive value of low albuminuria for subsequent ventricular changes while I reported 
increased LVH in those with the new definition of microalbuminuria.  The finding presented 
in this study along with other studies emphasise the importance of early identification of 
people with low albumin levels in their urine, in order to implement more rigorous control of 
blood pressure to prevent target organ damage. 
The presence of ST-T segment changes on ECG was greater in subjects with 
microalbuminuria than in those with normal UAE. Again, a graded increased prevalence of 
ST-T changes was noted. Few studies have addressed the association between 
microalbuminuria and ECG abnormalities (Jafar et al., 2009, Sciarretta et al., 2009) and these 
are confounded by selection criteria of studied population and albuminuria measurement. 
More importantly, the association between albuminuria and ECG abnormalities seems to 
predict increased risk for all-cause and cardiovascular mortality (Diercks et al., 2002). In 
addition, the association of ECG strain patterns with heart failure was reported in the LIFE 
study were combination of ECG strain patterns and albuminuria was associated with a 10% 
increased risk of developing heart failure, compared with 8% and 5% in those with an ECG 
strain alone or albuminuria, respectively (Okin et al., 2008). It should be noted that an ECG 
strain pattern itself is known to be a powerful risk factor for cardiovascular morbidity and 
mortality (Okin et al., 2004). Therefore, subjects with a combination of hypertension, 
microalbuminuria and ECG strain patterns should be considered as a very high risk 
population, and strict medical care should be followed. 
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In my study, minor nonspecific ST-T changes were not excluded. This is because there is 
evidence that this type of ECG abnormalities may predict future cardiovascular morbidities 
(Kumar and Lloyd-Jones, 2007, Kumar et al., 2008). For instance, a study involving 1,970 
patients with hypertension who were followed for 9 years, demonstrated that minor ST-T 
changes on ECG were independent predictors of future CHD (Schillaci et al., 2004).  
Subjects with microalbuminuria had a higher prevalence of established cardiovascular disease 
than those with normal UAE. The prevalence in subjects with the new definition of 
microalbuminuria is also high. Several epidemiological studies suggested links between 
microalbuminuria and cardiovascular diseases but rarely excluded those with diabetes mellitus 
or focused on high risk population (Wachtell et al., 2003, Cao et al., 2006, Jackson et al., 
2011). Microalbuminuria has been also shown to predict future cardiovascular events (Lee et 
al., 2010, Ärnlöv et al., 2005). The presence of increased UAE in those with established 
cardiovascular disease suggests continuous vascular dysfunction. This could be translated into 
future cardiovascular events. Therefore, microalbuminuria might be used as a therapeutic 
target in those subjects. 
The use of cardiovascular and metabolic drugs in subjects with microalbuminuria by both 
definitions was higher than in those with normoalbuminuria. This finding suggests that more 
drugs were required for controlling risk factors, especially blood pressure. This was supported 
by the observation that drugs that are usually prescribed in the management of resistant 
hypertension (such as alpha blockers) were more common in subjects with microalbuminuria 
than in those with normoalbuminuria. Microalbuminuria was common finding in high risk 
group who were taking multiple drugs. Many of drugs that are usually used in cardiovascular 
complications such as lipid lowering drugs, anticoagulants and vasodilator were taken by large 
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proportion of subjects with microalbuminuria even at lower levels reinforcing increased 
prevalence of cardiovascular disease. 
 
8.6 Cardiovascular risk scores 
I have shown that people with microalbuminuria by the two definitions are associated with 
complex co-morbidities and risk factors. However, whether such an association could be 
translated into future events can only be confirmed by following up those patients for several 
years, and comparing new events in microalbuminuric and normoalbuminuric individuals.  As 
this approach is time-consuming and not feasible in the short term, I have utilised the 
Framingham equation and the modified equation applied by the JBS for estimating 10-year 
risk based on the available parameters. The Framingham equation is among the most 
commonly used equations in clinical practice for risk stratification, and has been shown to be 
valid in northern European populations (Haq et al., 1999). 
The risk of overall cardiovascular and cause-specific outcomes tended to be higher in subjects 
with microalbuminuria. The same trend was observed using the JBS calculation of overall 
cardiovascular risk. However, the trend was not significant in the age-restricted group (30-74 
years), probably because of the small number of patients included in the calculations. Two 
studies reported similar increase of risk scores with microalbuminuria but were limited by the 
small sample size (Asselbergs et al., 2004) and both involved the general population (Ärnlöv 
et al., 2005). The median risk score for overall cardiovascular disease in both definitions of 
microalbuminuria using the Framingham equation is intermediate. This indicates that the 
current conventional risk factors used in the Framingham equation might not completely 
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identify people at increased risk for subsequent cardiovascular events. Screening for 
microalbuminuria could offer additional information beyond that provided by traditional risk 
factors. This needs to be confirmed prospective studies with long follow up duration. 
 
8.7  Multivariate analyses 
Several classical risk factors for increased UAE were independent predictors, including 
increasing age, SBP, eosinophil count, serum creatinine and LVH. Two parameters were 
highly correlated with microalbuminuria; fasting triglycerides and anticoagulants. The 
probability of microalbuminuria by the new definition increases by 67% for every unit 
increase in fasting triglycerides (mmol/l). Such an independent association has been reported 
in a few studies involving patients with diabetes (Franciosi et al., 2007, Smulders et al., 1997). 
An Asian study reported similar finding in subjects with hypertension but without diabetes 
mellitus (Nishijo et al., 1999). However, participants were restricted to men and sample size 
was small (n=245). 
There is no clear explanation of the strong association between triglycerides and 
microalbuminuria by the new and the combined definition. A high level of triglycerides is one 
of the components of the metabolic / insulin resistance syndrome (Bulhões and Araújo, 2007). 
This syndrome has been demonstrated to precede the onset of albuminuria in non-diabetic 
individuals (Fujikawa et al., 2001). Such changes could be more prevalent in those with 
microalbuminuria by the new definition. The other possible mechanism that may contribute to 
the high level of triglycerides is related to poor kidney function. The prevalence of high 
triglycerides levels in patients with CKD is about 50% (Miller et al., 2011). It has been 
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postulated that decreased renal function is associated with impaired catabolism of 
triglycerides, mediated by an incompletely understood mechanism (Attman and Samuelsson, 
2009). In my study, those with microalbuminuria by the new definition were characterised by 
increased serum creatinine and low eGFR, and therefore hypertriglyceridaemia mediated by 
renal deterioration cannot be ruled out. 
Anticoagulant (mainly warfarin) was strongly associated with microalbuminuria by the 
conventional and the new definitions. In a hypertension population, these agents are usually 
prescribed to subjects suffering from atrial fibrillation. A strong association between 
microalbuminuria has been reported in subjects with atrial fibrillation and hypertension (Böhm 
et al., 2009) and in other high atrial fibrillation risk populations (McManus et al., 2009). Thus 
anticoagulant use in this study is probably a marker for atrial fibrillation. The strength of the 
association may be overestimated since numbers were small but the lower confidence limit 
support a clinically significant relationship. 
The use of calcium channel blockers was also significant predictor of microalbuminuria. It has 
been postulated that dihydropyridine CCBs may worsen albuminuria if used as monotherapy 
(Monster et al., 2002, Ruggenenti et al., 1998). My observations cannot confirm a causal 
relationship. The relationship may reflect risk which led to CCBs being used but equally could 
be result of CCBs use. 
Results from multivariate analysis demonstrated that microalbuminuria is an independent 
predictor for cardiovascular diseases and risk factors (LVH and ECG abnormalities). Although 
some of the associations were not significant, the odds ratios were close to unity with wide 
confidence intervals, suggesting that the number of cases included in the models was too 
small. In addition to the LIFE study that reported a close relationship between 
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microalbuminuria and LVH (Wachtell et al., 2002), Dell'omo et al. (Dell'omo et al., 2003) also 
reported an independent association between microalbuminuria and LVH in untreated subjects 
with hypertension but without diabetes mellitus, although the sample size was small (n=330) 
and population selected had many restrictions (e.g. Absence of cardiovascular diseases, males, 
and availability of some biochemical parameters). Data from the HyperGEN study reported 
such an association in normotensive subjects who were selected based on the availability of 
echocardiographic information (Djoussé et al., 2008). I have reported such an association in 
subjects who were under fairly extensive control of cardiovascular risk factors. Again, 
classifying subjects with increased albumin excretion as a high risk population, and 
introducing early intervention might be translated into overall cardiovascular risk reduction. 
Increased blood pressure is among the most frequently reported pathologic risk factors for 
microalbuminuria. In the current study, I found that uncontrolled blood pressure was 
associated with high probability of microalbuminuria. I also observed a clear trend of 
increased risk of microalbuminuria associated with the severity of blood pressure. A 
relationship between office and ambulatory blood pressure (especially SBP) with albuminuria 
has been suggested in a population-based study (Cirillo et al., 1998) and in subjects with 
hypertension but without cardiovascular disease (Cerasola et al., 2010).  
 Recently, a sub-analysis of the ROADMAP study showed that tight control of blood pressure 
was associated with a lower incidence of microalbuminuria in patients with hypertension and 
diabetes mellitus (Menne et al., 2012). A reduction of blood pressure was associated with the 
regression of microalbuminuria in 1,657 patients with uncontrolled hypertension (defined as 
blood pressure >130/85 mm Hg in those diabetes and > 140/90 mm Hg in non-diabetic 
subjects) (de Alvaro et al., 2005). However, 105 hypertension clinics participated in this study 
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and microalbuminuria screening was performed according to the practice of each clinic.  This 
means that the detection of microalbuminuria in this particular study was prone to 
measurement bias. This is supported by the observation that microalbuminuria was present in 
62% of the participants, indicating overestimation of the condition.  
 
8.8 Methodology comparison 
Clinical guidelines recommend multiple urine samples for the diagnosis of microalbuminuria 
in order to avoid overestimation caused by confounders (National Collaborating Centre for 
Chronic Conditions, 2008). As mentioned earlier, the diagnosis of microalbuminuria in most 
of the studies involving subjects with hypertension and microalbuminuria has been based on a 
single measurement. Diagnosis based on a single measurement of microalbuminuria may lead 
to an overestimation of microalbuminuria prevalence which, in turn, leads to unnecessary 
intervention. On the other hand, if the performance of a single screening of microalbuminuria 
is as good as multiple testing, the current recommendation should be changed, as the present 
approach might delay appropriate intervention.  
Over 40% of subjects who were positive at a first screening had normal UAE on subsequent 
measurements. Such a reduction occurred even after minimising confounders of urinary 
albumin excretion, such as excluding any sample with evidence of UTI. Moreover, those with 
normal UAE in subsequent samples had risk factors lower than those of individuals with 
persistent microalbuminuria. 
The Third National Health and Nutrition Examination Survey that investigated the prevalence 
of reduced renal function in the US general population demonstrated that about 63% of 
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participating subjects had persistent albuminuria at the second measurement (Coresh et al., 
2003). However, urine was randomly collected in this study and was based on general 
population. Very few studies have addressed the reproducibility of microalbuminuria 
screening in hypertension. James et al. (James et al., 1994) examined the reproducibility of 
two consecutive urine specimens in 64 elderly subjects with untreated hypertension (mean age 
74 years). The study reported a high variability of albumin excretion. The importance of this 
study is that the variability occurred in a cohort of elderly people where the effect of potential 
confounders such as rigorous exercise, high protein intake and postural changes is unlikely to 
relevant. The study did not mention whether urine samples were tested for evidence of UTI, 
although the potential effect of this on variability is unlikely as the assessment of 
microalbuminuria was performed on two consecutive samples. Again the small sample size 
was a major limitation of this study. 
Pugliese et al. (Pugliese et al., 2011) recently reported a good performance of single samples in 
identifying persistence microalbuminuria during 3-6 months follow-up in a cohort of patients with 
type II diabetes mellitus. However, this observation might not be applicable to individuals with 
hypertension due to the higher prevalence of albuminuria in patients with diabetes. My findings 
suggest that the current approach of recommending multiple samples should continue to minimise 
false-positive microalbuminuria especially in subjects with hypertension. 
8.9 Blood pressure and albuminuria over time 
I investigated the blood pressure changes over time and correlated these with definitions of 
microalbuminuria. A strong association between SBP (and pulse pressure) with 
microalbuminuria was reported in cross-sectional and longitudinal analyses. Those with 
microalbuminuria had higher blood pressure at first visit to the clinic and subsequently. 
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Although those subjects had a greater blood pressure reduction, the blood pressure was always 
higher than that in individuals with normal UAE. These finding indicate that subjects with 
microalbuminuria require more aggressive treatment in order to attain recommended blood 
pressure targets. Furthermore, the high pulse pressure in those subjects could reflect vascular 
stiffness and therefore, appropriate intervention should be implemented.  
Isles et al. (Isles et al., 1986) examined the mortality rate in 3783 subjects with hypertension 
attending the GBPC. They reported that mortality was better correlated with achieved blood 
pressure rather than baseline blood pressure. Subsequent evidence showed a beneficial effect 
of optimal control of eventual blood pressure on cardiovascular outcomes (Estacio and 
Schrier, 1998, Hansson et al., 1998, Berl et al., 2005). This indicates that people with 
microalbuminuria may be at high risk for cardiovascular disease as the eventual blood 
pressure was higher than that in subjects with normoalbuminuria.  
Baseline dipstick examination (at first visit) was correlated with the result of laboratory 
analysis of microalbuminuria. The use of urine strips might not be sensitive to detect low 
levels of albuminuria at baseline. However, a population-based study of 2321 subjects showed 
that a trace of proteinuria might be a useful tool of identifying individuals with 
microalbuminuria (Konta et al., 2007). Therefore, I examined whether changes in albumin 
excretion were associated with increased or decreased cardiovascular risk factors.  
There was a clear trend for increased risk depending on the result of the two measurements of 
microalbuminuria. For example, those with positive result in the two measurements showed 
the highest values for cardiovascular risk while those with negative results in both analyses 
had the least risk. Also, regression from positive proteinuria was associated with risk factors 
lower than in those who developed microalbuminuria. These findings support the notion that 
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reduction in urinary protein excretion are associated with reduction in cardiovascular 
morbidities and mortalities (Zeeuw et al., 2004). My results are consistent with those of Ibsen 
et al. (Ibsen et al., 2005) who investigated the effect on albuminuria changes in subjects with 
hypertension and LVH. During 4.8 years follow-up, the use of antihypertensive agents was 
associated with significant reduction in primary end point (myocardial infarction, stroke and 
cardiovascular mortality). 
8.10 Study strengths and limitations 
A major strength of the current studies is that it involved people representing a typical 
hypertension population being followed up in secondary/ tertiary hypertension clinics. There 
were minimum restrictions in terms of population examined. They represented a wide range of 
age, hypertension severity and were mainly non-diabetics. The majority of studies that have 
tested the association between microalbuminuria and hypertension were mainly part of clinical 
trials or involved population at high risk or with many restrictions. Another strength of my 
study is that several measurements were obtained to minimise the variability of urinary 
albumin excretion such as using repeated urine samples and minimising the effect of 
confounders. Also the sample size is fairly large compared with that in previous studies. 
My studies have also some limitations. First, the cross-sectional design of the study precludes 
confirmation of causal relationship. For example, CCBs use was a strong predictor of 
microalbuminuria but whether these agents cause microalbuminuria cannot be answered by 
the current analysis. Second, screening for microalbuminuria in the Aberdeen Hypertension 
Clinic was carried out using semi-quantitative urine strips. However, it has been shown that 
the use  of semi-quantitative dipsticks in general population and in diabetes for detecting 
microalbuminuria resulted in correct classification of  albuminuria groups compared with 
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laboratory analysis (Graziani et al., 2009). Moreover, data from the Aberdeen Hypertension 
clinic represented only 17% of the total sample size. Also, the classification of participants in 
my study was based on the mean of last two samples which were analysed using laboratory 
instruments in both centres.  
8.11 Future work 
The current series of studies could be a basis of a more comprehensive analysis. After 
classifying the participant to the different albuminuric groups, prospective follow up of each 
group is the logical approach. For instance, a follow up of people with normal UAE to 
determine the rate of new onset microalbuminuria and associated factors is one of the possible 
approaches. Similarly, the rate of progression to gross proteinuria or regression to 
normoalbuminuria would be of great interest. The predictive value of each definition of 
microalbuminuria for future cardiovascular events is another plausible analysis. Recording 
mortality rates in each group is achievable since the GBPC database is linked with the 
Registrar General of Scotland. Linkage of the records of the patients who participated in this 
series of studies with national morbidity and mortality statistics offers one approach with the 
potential to test the clinical relevance of my findings. 
A second phase of this study would include evaluation of the influence of rigorous 
cardiovascular risk management including different anti-hypertensive drugs on 
microalbuminuria, blood pressure and other risk factors. Such a study could be the basis of in-
depth analysis of antihypertensive agents.  As I have explained earlier, there is an ongoing 
debate about whether certain pharmacological groups confer additional anti-proteinuric effects 
beyond that provided by blood pressure lowering. This could be addressed via a randomised 
trial involving individuals with microalbuminuria where drugs that have putative additional 
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anti-proteinuric effect (as claimed for RAAS blockers) should be compared with another 
pharmacological group. The trial might be designed so that the group with putative anti-
proteinuria might achieve less good blood pressure in order to evaluate whether they could 
provide better control of albuminuria. Earlier attempts have yielded unreliable results because 
of failure to allow for blood pressure differences. 
With a larger sample size and additional information, it would be informative to investigate 
whether the incorporation of microalbuminuria enhances the risk the cardiovascular risk 
assessment compared with classical risk factors.  
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9. Conclusion 
Microalbuminuria is present in almost one-fifth of subjects with essential hypertension 
attending secondary/tertiary referral centres. Microalbuminuria serves as a tool for identifying 
individual at risk for cardiovascular complications. Even levels of albumin excretion in the 
urine lower than the conventional thresholds are associated with complex co-morbidities and 
risk factors. Therefore, there is a need for a new definition of microalbuminuria that takes into 
the account early increase in the albumin level. Screening of microalbuminuria should be 
confirmed in multiple samples and the diagnosis should continue to rely on the results of these 
samples rather. Several factors are associated with microalbuminuria risk. However, it seems 
that increased blood pressure is the predominant risk factors associated with 
microalbuminuria.  
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